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Abstract
The work of this thesis aimed to investigate dietary strategies for the 
amelioration of the lipid abnormalities found in an atherogenic lipoprotein 
phenotype/metabolic syndrome. The strategies involved the manipulation of the 
quantity and quality of dietary fat and carbohydrate, and the quantity of protein. 
This led to three different dietary interventions that included:
(I) The OPTILIP study, a randomly controlled, parallel study designed 
to determine the optimal intake of dietary n-6/n-3 fatty acids with 
respect to blood lipids and lipoproteins. This was achieved by 
comparing four diets with varying n-6/n-3 ratios (3:1-5:1); one 
containing additional long chain polyunsaturated fatty acid n-3 (from 
fish, notably salmon, and a long chain n-3 enriched spread), two with 
additional linolenate (from a rapeseed oil based spread and cooking 
oil) and one with a combination of long chain polyunsaturated fatty 
acid n-3 and linolenate, with a control based on a estimated UK diet 
(10:1). Healthy male and postmenopausal females aged 45-70 were 
randomly allocated to one of the five diets for six months.
(II) The effects of low-fat, high and low glycaemic index diets. This 
study was designed to test the effects of high and low glycaemic 
index (GI) low-fat diets. Fourteen normal, healthy men (aged 35-55 
years) characterised with an atherogenic lipoprotein phenotype, were 
randomly assigned to one of two prescribed diets containing either a 
high proportion of foods with a high glycaemic index (> 80) or a low 
glycaemic index (< 60). Dietary prescriptions were achieved by 
instructing volunteers to follow two cycles of a 7-day menu that 
provided a choice of foods and mixed meals appropriate to either their 
high or low glycaemic index status. The study was free-living, with a 
crossover design.
(III) The effect of low and high-carbohydrate hypoenergetic diets.
This study was designed to test both low and high-carbohydrate
II
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weight-reducing diets against a control for 6 -months. Subjects were 
overweight/obese subjects (180) randomised to 1 of the 3 diets, a low- 
fat, high-carbohydrate diet, a high-protein, high-fat diet or a control..
The main results for the OPTILIP study were reductions in pre and postprandial 
plasma triacylglycerol, small, dense low density lipoprotein and increases in the 
larger, lipid-rich high density lipoprotein two subfraction that was more 
pronounced in males on the two long chain polyunsaturated n-3 (fish-rich) diets. 
The low glycaemic index diet was accompanied by decreases in plasma 
cholesterol, triacylglycerol, high density lipoprotein-cholesterol and low density 
lipoprotein-cholesterol, body mass and body mass index, there were no 
significant differences in any of these variables after the high glycaemic index 
diet. There was no change in the distribution of low density lipoprotein 
subclasses as measured by its peak density or in waist circumference for either 
group. The low and high-carbohydrate hypoenergetic diets were similar with 
respect to weight loss (-9%), although the low-carbohydrate group increased 
lean body mass. Plasma triacylglycerol, low density lipoprotein peak density, 
triacylglycerol:high density lipoprotein-cholesterol, insulin, and Homeostasis 
model assessment decreased on both diets but to a greater magnitude on the low- 
carbohydrate diet; whereas plasma total cholesterol, low density lipoprotein- 
cholesterol, and high density lipoprotein-cholesterol were reduced to a greater 
extent on the high-carbohydrate diet relative to the low-carbohydrate diet. In 
conclusion, the results of the three dietary interventions described in this thesis 
all show, to varying degrees, favourable effects on markers of an atherogenic 
lipoprotein phenotype/metabolic syndrome and on traditional risk factors for 
cardiovascular disease, plasma total cholesterol and low density lipoprotein- 
cholesterol. The next obvious step would be to investigate the combined effects 
of a diet low in the ratio of n-6/n-3 fatty acids, high in protein with the source of 
carbohydrate derived from low glycaemic index foods. The precise proportions 
of macronutrients would need further work and may even depend on genotype 
and or phenotype and therefore warrant an individual approach to nutrition with 
prospective selection of subjects.
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1Chapter 1 General Introduction 
Summary
An atherogenic lipoprotein phenotype gives rise to abnormal lipoprotein 
structure and metabolism and is associated with in excess o f  a 3-fold risk o f  
cardiovascular disease. This introductory chapter describes lipoprotein 
structure and metabolism and the pathology o f atherosclerosis; the history and 
role o f plasma cholesterol and low density lipoprotein cholesterol in the 
aetiology o f cardiovascular disease is reviewed and the evidence for high density 
lipoprotein cholesterol and plasma triacyglycerol as more informative predictors 
o f cardiovascular disease is discussed. Finally, the elevation o f  plasma 
triacylglycerols in the generation o f  an atherogenic lipoprotein phenotype and 
how dietary therapy can potentially reverse this abnormality is introduced.
1.1 Lipoprotein structure
Lipoproteins are a dynamic group of polydisperse particles synthesised in the 
liver and the intestine. They are constantly undergoing transfer and 
transformation. There are four major categories of lipoproteins (Goldstein and 
Brown, 1977) that are classified in terms of their density and flotation constant 
(Hinton et al, 1974), electrophoretic mobility (Noble, 1968), and size (Bautovich 
et al, 1973). The main lipoproteins are: chylomicrons; very low-density 
lipoprotein (VLDL); low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) (Table 1.1). There are also subcategories of lipoproteins namely, the 
LDL and VLDL subclasses that range from a small, dense variety to a larger, 
more buoyant species (Griffin et al, 1999); intermediate-density lipoprotein 
(IDL); Lp(a) (Couderc and Maachi, 1998); and two classes of HDL - HDL2 and 
HDL3 (von Eckardstein et al, 1994; Tailleux & Fruchart, 1996).
Lipoprotein Density (Kg/L) Particle Diameter 
(nm)
Electrophoretic
mobility
Chylomicrons <0.95 80-1200 Origin
VLDL 0.95-1.006 30-80 Pre-beta
LDL 1.006-1.063 18-35 Beta
HDL 1.063-1.21 5-12 Alpha
Table 1.1 Physical characteristics of the major lipoprotein classes
2Although the major classes of lipoproteins differ in many respects, they also 
share some common features. Their conformation is globular (Goldstein and 
Brown, 1977) and at the surface of the lipoprotein is a monolayer of amphipathic 
lipids (phospholipid and cholesterol) and apolipoproteins. The non-polar parts of 
these lipids and the apolar amino acid residues of the apolipoprotein are adjacent 
to the core of non-polar esterified cholesterol and triacylglycerols (TAG). Thus, 
the outer, hydrophilic part contains the charged molecules: the phospholipids, 
free cholesterol, and the apolipoproteins, while the core of the lipoprotein carries 
the hydrophobic molecules, namely the esterified cholesterol, TAG, and the 
apolar amino acid residues of the apolipoproteins (Goldstein and Brown, 1977). 
Table 1.2 shows data on the distribution of the above molecules for each 
lipoprotein class and Figure 1.1 the structure of a lipoprotein.
Composition (% mass 
Lipoprotein Protein FC CEs PLs Ta
>)
(G
Chylomicrons 1-2 1-3 2-4 3-8 90-95
VLDL 10.4 5.8 13.9 15.2 53.4
LDL 21.4 7.6 32.2 21.3 17.5
HDL 53.3 2.7 13.2 27.7 27.0
Table 1.2 Composition of the major lipoprotein classes. Note: IDL and LDL have been 
classed as a single category (LDL). FC = free cholesterol, CEs = cholesteryl esters, PLs = 
phospholipids, and TAG = triacylglycerol.
3A. Surface view
Fig, * Structure of a lipoprotein.
Apolipoprotcin 
Free
cholesterol 
Phospholipid
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B. Transverse section
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\
Cholesterol esters 
or
triacylglycerols
Figure 1.1 Lipoprotein Structure. A surface (A) and transverse section view (B) o f a 
lipoprotein molecule. The TAG, cholesteryl esters, and the apolar region of the apolipoproteins 
form the inner core. The outer core consists of a phospholipid bilayer, with free cholesterol and 
the polar amino acid residues of the apolipoproteins.
4There are eleven different types of apolipoprotein and they have extensive 
structural diversity. Each of the different apolipoproteins has a different role to 
play, the major functions are: structural, metabolic regulators, immunological, 
and haemostatic (Mahley et al, 1984). Some apolipoproteins are associated with 
the activation of enzymes, for example, apolipoprotein CII is involved with TAG 
hydrolysis and the enzyme lecithin cholesterol acyltransferase (LCAT) is 
activated by apo Al (Jonas, 1991). Table 1.3 gives data about the major 
apolipoproteins.
Apolipoprotein Molecular mass 
(Da)
Plasma 
concentration 
(mg/100ml) 3 rd- 
97th percentile
Function Lipoprotein
distribution
Al 28016 80-160 Activation of 
LCAT.
Detergent
properties
HDL
All 17414 20-55 ? Activation o f  
hepatic lipase.
HDL
AIV Activation of  
LCAT
HDL
B48 264000 0-2 Secretion o f  
chylomicrons.
Chylomicrons
B100 550000 60-160 Secretion of  
VLDL, structural 
protein o f LDL, 
receptor- 
mediated LDL 
catabolism.
VLDL, LDL
Cl 6600 3-11 LCAT and LPL 
activator.
HDL, VLDL
CII 8850 1-7 Activation of  
LPL.
Chylomicrons, 
VLDL, HDL.
CIII 8800 3-23 Inhibition o f  
hepatic uptake of 
chylomicrons 
and VLDL.
Chylomicrons, 
VLDL, HDL.
D 32500 9 ? HDL
E 34100 2-6 Hepatic
clearance o f  
chylomicron 
remnants and 
IDL.
Chylomicrons, 
VLDL, HDL.
(a) 300000-700000 1-100 Inhibitor o f  
fibrinolysis
Lp(a)
Table 1.3 Properties of the apolipoproteins.
51.2 Lipid metabolism
1.2.1 Exogenous pathway
The partial or total hydrolysis of TAG during digestion gives rise to free fatty 
acids (NEFA), glycerol, diacylglycerols and monoacyglycerols. Fatty acids, in 
the presence of bile salts, enter the intestinal mucosa where, amongst other 
metabolic transformations, they are resynthesised to TAG. The TAG and other 
molecules such as cholesterol, cholesteryl esters and phospholipids associate 
with small quantities of apolipoproteins, Al, All, AIV and B48 (apo B48 is the 
N-terminal part of the apolipoprotein B100, the protein associated with LDL) to 
form chylomicrons (Hultin & Olivecrona, 1998).
Chylomicrons travel through the lymphatic system and enter the blood 
circulation via the thoracic duct. They are normally only present in the 
postprandial state, and they consist of over 90% TAG and contain relatively 
small amounts of protein (Havel, 1995; Hultin & Olivecrona 1998). The nascent 
chylomicrons undergo an exchange with HDL, giving up some of their 
cholesteryl esters and apo A in return for C and E apolipoproteins.
Once chylomicrons have acquired apo CII they can activate the enzyme, 
lipoprotein lipase (LPL) (Semenkovich, 2004; Haberbosch et al, 1984). LPL is 
located on the vascular endothelium of cells with a high requirement for TAG 
(e.g. skeletal and cardiac muscle, adipose tissue, and lactating mammary glands). 
LPL hydrolyses TAG hence releasing them from the core of the chylomicron. In 
doing so, the chylomicron becomes progressively smaller and becomes relatively 
richer in cholesterol and protein and depleted in TAG. Phospholipids, free 
cholesterol, and the C apolipoproteins are transferred to HDL; apo B48 and apo 
E remain tightly bound to the chylomicron which is now known as a 
chylomicron remnant (Hultin, 1998). The remnant chylomicrons are degraded in 
the liver via the LDL (apo B/E) receptor (apo E targets chylomicron remnants 
towards the liver) or the LDL-receptor related protein (LRP) (Willnow, 1997) 
(Figure 1.1). Alternatively, they are recycled in the form of other lipoproteins.
61.2.2 Endogenous pathway
VLDL is a TAG rich lipoprotein that is predominantly synthesised in the liver 
and to a lesser extent in the intestine. VLDL provides TAG to tissues in both the 
fasting and postprandial state. Once VLDL has been secreted, it undergoes 
exactly the same sequence of events as chylomicrons, i.e. the exchange of 
apolipoproteins and lipids with HDL and the progressive removal of TAG by 
lipoprotein lipase (Haberbosch et al, 1984; Murdoch & Breckenridge, 1995). 
However, some of the metabolic transformations are somewhat different. The 
human liver secretes VLDL cholesterol in its free form and it undergoes 
esterification in the circulation. Free cholesterol is transferred to HDL, via a 
concentration gradient, and esterified by the enzyme lecithin cholesterol 
acyltransferase (LCAT) (Jonas, 1991). Once formed, the cholesteryl esters are 
transferred back to VLDL. This process cannot take place by simple diffusion as 
cholesteryl esters are highly hydrophobic and the concentration gradient is 
unfavourable therefore a protein known as cholesteryl ester transfer protein 
(CETP) (Barter et al, 2003) transports the cholesteryl esters from HDL to VLDL. 
It does this in exchange for TAG and thus contributes to the removal of TAG 
from VLDL; however, lipolysis by lipoprotein lipase is the major mechanism for 
removal of TAG.
VLDL and chylomicrons also differ in the apolipoprotein they carry; VLDL 
carries apo B100 as opposed to the apo B48 associated with chylomicrons 
(Mahley et al, 1984). As in the case for chylomicrons, apo B100 remains tightly 
associated to VLDL and its amount does not vary after secretion. It is probable 
that each molecule of VLDL contains one molecule of apo B100 (Elovson et al, 
1988) (Figure 1.2).
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81.2.3 LDL metabolism
The lipolysis of VLDL-TAG results in a progressive decrease in size; in most normal 
humans the majority of VLDL is converted to LDL via IDL, which is associated with 
apo E (Musliner et al,, 1987). LDL serves as the provider of cholesterol to all tissues 
as it is capable of crossing the endothelium and entering the tissue fluid. Cholesterol 
is required by the cell for plasma membrane repair and growth. Some cells utilise 
cholesterol to synthesise steroid hormones or bile acids whilst others store cholesterol 
in the form of cytoplasmic cholesteryl ester droplets (Brown and Goldstein, 1986).
LDL is able to enter cells by two routes: one which is regulated according to the 
cholesterol requirement of each individual cell, and one which appears to depend 
almost entirely on the extracellular levels of LDL. This cellular uptake of LDL is an 
important factor in understanding the atherogenic properties of these lipoproteins.
The first route is by a cell surface receptor that is specific for the binding of 
lipoproteins that contain apo B100 or apo E (Figure 1.3). This is the apo B 100/E 
receptor (otherwise known as the LDL receptor). The receptor is capable of binding 
to apo E carrying lipoproteins. However, it usually binds to the lipoproteins carrying 
apo B100 of which LDL is the most abundant. The LDL receptor is located on the 
surface of cells where LDL can bind and be transported into the cell by receptor- 
mediated endcytosis (Goldstein and Brown, 1977). Once in the cell LDL is delivered 
to lysosomes where they hydrolyse the cholesteryl ester (CE) and apo B100. The 
liberated free cholesterol is the signal by which the cellular cholesterol content is 
precisely regulated by three co-ordinated reactions that prevent excessive 
accumulation of cholesterol in the cell. (I) Suppression of 3-hydroxy, 3- 
methylglutaryl CoA reductase (HMG-CoA reductase) activity, the rate-limiting 
enzyme for cholesterol synthesis, thus reducing the rate of endogenous production of 
cholesterol. (II) Inhibition of the synthesis of LDL receptors, preventing uptake of 
extracellular cholesterol from LDL. (Ill) The esterification of cholesterol catalysed 
by acyl CoA:acyl cholesterol transferase (ACAT) leading to re-esterification and 
storage in ester form of any excess cholesterol (Goldstein and Brown, 1977).
9The other mechanism by which cholesterol can enter the cell is by a mechanism 
known as pinocytosis (Goldstein and Brown, 1977). LDL binds to sites on the cell 
where the LDL (apo B 100/E) receptor is not located; since the pathway is not receptor 
mediated, HDL can compete with LDL for this uptake process. Because there is an 
absence of receptor the binding is of a low affinity and at low levels of LDL this route 
may have little significance. Non-receptor-mediated LDL uptake is not saturable, 
therefore any increase in extracellular LDL levels results in an increase in uptake. 
When LDL levels are relatively high, entry of cholesterol into cells by this route may 
assume greater quantitative importance than that via the LDL (apo B 100/E) receptor, 
which will be both saturated and down-regulated. This appears to be the case in the 
human adult where LDL cholesterol is relatively high compared to most animal 
species; only one-third of LDL is catabolised by receptor-mediated uptake and two- 
thirds by non-receptor-mediated pathways. In hypercholesterolaemia, even more 
LDL is catabolised via the non-receptor-mediated pathway (Brown and Goldstein, 
1986).
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Fig. 28 The LDL receptor pathway. (Adapted from Brown & Goldstein)'.
Figurel.3. LDL (apo B/E) Receptor. Steps in the LDL receptor-mediated uptake, described in the
text above.
1.2.4 Reverse cholesterol transport
The return o f cholesterol from the tissues to the liver is termed reverse cholesterol 
transport (Figure 1.4, von Eckardstein et al, 1995; Tailleux & Fruchart, 1996). Recent 
developments on the mechanisms o f reverse cholesterol transport have come from the 
discovery o f mutations in the ATP-binding cassette A l (ABCA1) transporter in 
Tangiers disease (Brewer et al, 2004). The ABCA1 transporter was found to efflux 
excess cellular cholesterol from peripheral tissue, including macrophages, to poorly 
lipidated apoA-I and hence playing a role in reverse cholesterol transport. The poorly 
lipidated apo A l or nascent HDL are disc shaped and secreted by the intestine and 
liver. Free cholesterol on the surface o f HDL is esterified by lecithin cholesterol 
acyltransferase (LCAT, Jonas, 1991) and the cholesteryl ester (CE) is transferred to 
the core to form mature and spherical HDL 3 . HDL 3 removes cholesterol via the 
scavenger receptor class B, type 1 (SR-B1) pathway, accumulation o f cholesterol and
11
further activity of LCAT converts HDL3 to HDL2 which can exchange cholesteryl 
esters for TAG from TAG-rich lipoproteins (TGRL) through the action of cholesteryl 
ester transfer protein (CETP, de Grooth et al, 2004). The HDL2 can return to the liver 
were it is catabolised or can be converted back to HDL3 by hepatic lipase (HL). 
Therefore, reverse cholesterol transport can work in two ways, through the direct 
removal of cholesterol from peripheral tissue and catabolism by the liver or through 
exchange of CE for TAG and then removal of the CE via remnant lipoproteins and the 
LDL receptor related protein (LRP).
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1.3 Cardiovascular disease
1.3.1 LDL oxidation and atherosclerosis
Atherosclerosis is characterised by the accumulation of lipids within the arterial 
wall. This can lead to a proliferation of certain cells that can eventually obstruct 
blood flow and cause thrombosis, thus causing loss of oxygen to the brain and 
heart and leading to a heart attack or stroke referred to as coronary heart disease 
(CHD) and cerebrovascluar disease respectively, which together are known as 
cardiovascular disease (CVD).
There are three main hypotheses to explain the aetiology of atherosclerosis: the 
response to injury, the response to retention, and oxidative modification of LDL 
(reviewed by Stocker & Keaney, 2004). The response to injury hypotheses 
begins with an injury to the endothelium of the artery that renders it more 
permeable to LDL and other atherogenic lipoproteins that deposit in the 
subendothelium space. In response, leukocytes and platelets adhere to the 
endothelium followed by transmigration across the endothelium; this causes a 
procoagulant environment. The leukoctyes and platelets secrete cytokines, 
vasoactive agents, and growth factors that promote an inflammatory response, 
with smooth muscle cells migrating to the intima of the artery and creating an 
intermediate lesion. The response to retention hypothesis implicates 
hyperlipidaemia causing retention of lipoproteins (both apoB 100 and B 48) to 
proteoglycans on the arterial wall as the initial step in atherosclerosis. Whereas 
the oxidative modification hypothesis involves LDL crossing the subendothelial 
space of lesion-prone arterial sites. During this process, LDL lipids are subject to 
oxidation and, as a consequence, apolipoproteinB-1 0 0  is modified so that the net 
negative charge increases. This modification of apolipoprotein B-100 renders 
LDL susceptible to macrophage uptake via a number of scavenger receptor 
pathways producing cholesterol ester-laden foam cells. It is this accumulation of 
foam cells that forms the atherosclerotic lesion.
14
1.3.2 Total and LDL cholesterol
Cholesterol was discovered by Poulletier de la Salle in 1769, but it was Michel 
Chevreul in 1815 who named it cholesterine and he believed it to be a “fat-like” 
substance (reviewed by Olson, 1998). It was later renamed cholesterol and its 
chemical structure and biosynthetic pathway were elucidated by 1932 and 1956 
respectively (reviewed by Quiney & Watts, 1989). Since then a plethora of 
studies investigating cholesterol’s role in atherosclerosis and CVD have been 
conducted. CVD is a multifactoral condition and methods of prevention have 
focussed mainly on the lowering of plasma/serum total cholesterol (TC) and low 
density lipoprotein cholesterol (LDL-C). This has involved the use of both 
dietary and pharmaceutical therapy.
The work of Keys and co-workers in the late 1950s, which led to the Seven 
Countries Study (SCS, Anonymous, 1970), provided evidence that differences in 
dietary fat contributed to the frequency of coronary heart disease (CHD) in 
different countries. It is now well accepted that dietary fat and especially the 
type of fat can produce changes in circulating plasma TC and LDL-C, with 
saturated fat increasing plasma TC and LDL-C and polyunsaturated fats having a 
hypocholesterolaemic effect (Hu et al, 2001). At about the same time Keys was 
conducting the SCS, the Framingham study, an observational cohort study, 
examined men and women who were free of CHD at the start of the study 
(Kannel et al, 1971). After 14 years of follow-up a positive relationship between 
cholesterol and the risk of CHD with an additional gender difference for prebeta 
lipoprotein (VLDL) was found. The study revealed that women were at greater 
risk from prebeta lipoprotein than TC, with men being at greater risk from TC 
but there was no evidence for prebeta lipoprotein. Even greater insight into this 
relationship between elevated cholesterol and cardiovascular (CV) risk is due to 
the numerous studies on the cholesterol lowering drugs, “statins”. The statins 
work by inhibiting the rate limiting enzyme for cholesterol synthesis, HMG coA 
reductase.
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Before the emergence of the statins numerous drugs including: cholestyramine, 
equine oestrogens, clofibrate, dextrothyroxine and nicotinic acid in The Coronary 
Drug Project, (Anonymous, 1973) and gemfibrozil as part of the Helsinki Heart 
Study (HHS, Frick et al, 1987) were investigated for their effect on CVD. 
Furthermore, cholestyramine was further investigated in the Lipid Research 
Clinics Coronary Primary Prevention Trial (LRCCPPT, anonymous, 1984). The 
results of these early studies showed that the oestrogens had to be discontinued 
due to malignancies; clofibrate showed no benefit in overall mortality or non- 
fatal CVD; nicotinic acid showed a reduction in non-fatal myocardial infarction 
(MI) but not in all cause mortality and was poorly tolerated. The results of the 
Helsinki Heart Study showed no difference between the placebo group and the 
gemfibrozil group in terms of all cause mortality, yet both non-fatal and fatal MI 
and cardiac deaths were reduced in the gembribrozil group. The authors 
attributed this to both a reduction in LDL-C and an increase in HDL-C (Frick et 
al, 1987).
The three major lipid-lowering randomised trials involving statins in the mid 
1990’s were the Scandinavian Simvastatin Survival Study Group (4S) 
(Anonymous, 1994), the West of Scotland Coronary Prevention Study 
(WOSCOPS) (Sheperd et al, 1995), and the Cholesterol and Recurrent Events 
(CARE) (Sacks et al, 1996) (Table 1.4). Both the 4S and the CARE study were 
secondary prevention trials and showed that in patients with prior myocardial 
infarction (MI) and a wide range of TC levels responded to statin therapy. The 
4S study investigated patients with an initial higher plasma TC and after a 5 yr 
follow-up reductions of 25% and 38% were observed for plasma TC and LDL-C 
respectively; with end-point reductions in all-cause mortality (30%), and major 
coronary events (34%). This was the first statin trial to observe a link with 
reduction in LDL-C to a reduction in coronary events. The CARE study 
compared provastatin versus placebo in subjects with normal levels of plasma 
TC, this trial also showed a reduction in coronary death or nonfatal MI of 24%. 
Both plasma TC and LDL-C were reduced (20% and 28% respectively), albeit to 
a lesser extent than the 4S trial. However, a subgroup analysis of patients with 
higher initial LDL-C (>3.88 mmol/L) had a greater reduction (35%) in coronary 
events compared to a 26% reduction in patients with LDL-C from 3 .2 3 -3 .8 8
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mmol/L. The WO SCOPS investigated subjects with initial high levels of TC and 
LDL-C (7.03 ± 0.57 and >4.00 mmol/L respectively) on pravastatin or placebo. 
After 5 yrs of follow-up coronary events were decreased 31%, revascularisation 
37%, and CV mortality 32%, with no difference in non-CV mortality; TC and 
LDL-C were reduced by 20% and 26% respectively. This was the first primary 
prevention study with a statin to show a reduction in CV events in high-risk 
subjects with high BMIs and a high proportion of smokers. The 
AFCAPS/TexCAPS study was another primary prevention trial with subjects 
who were considered healthy with a 0.5 -  1% risk of CHD events, although with 
a high TC/HDL-C ratio (Downs et al, 1998). The results were comparable to 
WOSCOPS with a 37% reduction in coronary events. However, the reductions 
in non CV deaths were similar in both treatment and placebo groups, with 2/3 of 
the deaths occurring from non CV events, thus emphasizing that subjects who are 
not at risk of CHD are more likely to die of non-CV events. The largest trial of 
its kind was the Heart Protection Study (HPS) (Anonymous, 2002), this found a 
reduction in total and coronary mortality across a full spectrum of plasma TC and 
LDL-C ranges (Table 1.4).
The results of the HPS (Anonymous, 2002) and some more recent trials: the 
Pravastatin in elderly individuals at risk of vascular disease study (PROSPER, 
Shepherd et al, 2002); Atorvastatin for primary prevention of cardiovascular 
events study (ASCOT-LLA, Sever et al, 2003); and the Pravastatin or 
Atorvastatin Evaluation and Infection Therapy study (PROVE IT, Cannon et al, 
2004) provided the necessary evidence for the strategy to take for the secondary 
prevention of CHD i.e., statin therapy with LDL-C lowering as the primary target 
(Grundy et al, 2004). However, for primary prevention the procedure to take is 
less clear. According to the National Cholesterol Education Program Adult 
Treatment Program III (NCEP ATP III, Grundy et al, 2002) for the elderly 
without established CVD it is usually down to clinical judgement whether to 
initiate LDL-C lowering drug therapy; for people with 2+ risk factors and a 10 
yr, 10 -  2 0 % risk (moderately high risk) drug therapy is considered after an 
unsuccessful lowering of LDL-C to < 3.36 mmol/L with therapeutic lifestyle 
changes. Risk factors are: cigarette smoking, hypertension, low HDL-C, family 
history of CHD, and age. People at moderate risk (10 yr, < 10% risk) with 2+
17
risk factors are candidates for drug therapy if therapeutic life style changes did 
not lower LDL-C to < 4.14 mmol/L. People with low risk ( 0 - 1  risk factors) 
drug therapy are considered if LDL-C is > 4.91 mmol/L and drug therapy is 
discretionary if LDL-C is between 4.14-4.91 mmol/L.
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Simvastatin 
vs. placebo
4S (Anonymous, 
1994)
Secondary
prevention
N = 4444 angina or prior ML TC 5.5 -  
8.0 mmol/L. Follow-up 5 yrs. TC 
reduced 25%, LDL-C 35%. Reduced 
major coronary events
Pravastatin
vs.placebo
WOSCOPS (Shepard 
et a\, 1995)
Primary 
prevention 
with at risk 
subjects: high 
TC, high BMI 
and high level 
of smokers.
N = 6595 hypercholesterolaemic men 
(TC 7.03 ± 0.57), no prior MI. Follow- 
up 5 yrs. Reduced coronary events 
31%, revascularisation 37%, CV 
mortality 32%, TC 20%, LDL-C 26%, 
no difference in non-cardiovascular 
mortality, total mortality borderline 
(22%, P = 0.051).
Pravastatin
vs.placebo
CARE (Sacks et al, 
1996)
Secondary
prevention
N = 4159 prior MI with 
normocholesterolaemia (5.4 ± 0.4 
mmol/L). Follow-up 5 yrs. TC and 
LDL-C reduced 20% & 28% 
respectively. Reduced coronary death 
or nonfatal MI by 24%. No significant 
difference in CV, non-CV, or total 
mortality. Only MI was reduced
Pravastatin
vs.placebo
LIPID (Anonymous, 
1998)
Secondary
prevention
N = 9014 MI or unstable angina. TC 
(4.0 -  7.0 mmol/L). Follow-up 6 yrs. 
Coronary mortality reduced 24%, total 
mortality reduced 22%, coronary death 
and nonfatal MI reduced 24%, 
coronary revascularisation 20%, and 
strokes 19%. TC and LDL-C reduced 
18% and 24% respectively.
Lovastatin 
vs. placebo
AFCAPS/TexCAPS 
(Downs et al, 1998)
Primary
prevention
N = 5608 men 997 women healthy 
population, TC (5.71 ± 0.54 mmol/L). 
Follow-up 5 yrs coronary event 
reduced 37%, no difference in total 
mortality. Non-cardiovascular deaths 
attributed to 2/3 from both groups.
Atorvastatin
vs.
angioplasty
AVERT (Waters, 
2000)
Secondary
prevention
N = 341 stable angina patients. Follow- 
up 18 mo. Drug treatment reduced 
time to ischaemic event
Simvastatin 
vs. placebo
HPS (Anonymous, 
2002)
Secondary
prevention
N = 20 536 high risk patients, prior 
coronary disease, atheromatous 
disease, or diabetes. Follow-up 5.5 
yrs. Simvastatin reduced coronary 
mortality 18%, no effect on noncardiac 
mortality, reduced total mortality.
Both high and low TC and LDL-C 
patients benefited to the same 
proportion.
Table 1.4 The major statin trials. Shows the results o f the major HMG CoA inhibitor trials 
from the mid 1990’s to the early 2000’s. The results show the effectiveness o f statins across a 
broad range o f TC and LDL-C levels with “at risk” and healthy subjects.
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1.3.3 HDL-C
Current guidelines have largely focussed on the lowering of plasma TC and 
LDL-C and state there is insufficient evidence for a therapeutic goal for HDL-C, 
yet they indicate that increasing HDL-C with fibrates reduces the risk of CHD in 
patients with initially high plasma TAG levels (Grundy et al, 2004). In fact the 
early study of gemfibrozil, mentioned above, as part of the Helsinki Heart Study 
(Frick et al, 1987) concluded that the reduction in coronary events was not only 
due to the lowering of LDL-C but also the increase in HDL-C achieved. The 
problem with plasma TC and LDL-C as risk factors are they do not discriminate 
between CHD and non-CHD states (Figure 1.5) and the benefits of LDL-C 
lowering by statins only account for ~ 30% reduction in CHD events thus still 
leaving many patients vulnerable to CHD (Kreisberg & Oberman, 2002). 
Moreover, plasma TC as a risk factor represents a paradox due to the distinction 
between “absolute risk” and “attributable risk” (Griffin, 1999). To quote 
Griffin’s interpretation of data from the Framingham study (Fruchart & Packard, 
1997), “The absolute risk associated with a raised cholesterol of 7.5 mmol/L, as 
calculated from mortality curves, is about 90%. This would be impressive if it 
were not for the fact that only 3% of individuals with CHD have a serum 
cholesterol at or above this level. On the other hand, the risk associated with 
cholesterol of 5.2 mmol/L is only about 20%, but approximately 45% of CHD 
patients fall into this category”. Thus plasma TC is a poor discriminator between 
disease and healthy states.
HDL-C is considered a negative risk factor for CVD (Brewer, 2004; Gotto et al, 
2004), perhaps because of its role in reverse cholesterol transport and antioxidant 
properties (Kreisberg & Oberman, 2002; Gotto & Brinton, 2004; Brewer, 2004). 
In addition, HDL-C is a better discriminator of CHD than LDL-C (Figure 1.5) 
and for every 0.026 mmol/L increase in HDL-C CHD is reduced by 3% (Castelli, 
1988; Anonymous, 2002). Current drug therapies have shown varying responses 
with the raising of HDL-C, with niacin exerting a percentage increase between 
15 - 30%, fibrates between 10 - 15%, and statins ranging from 5 -  12% 
(reviewed by Brewer, 2004) with ruvastatin and fluvastatin more potent than the 
other statins (Edwards & Moore, 2003). Moreover, some of the statin trials
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discussed above (Table 1.1) have shown that low levels of HDL-C on either 
statin treatment or placebo show the same regression curve (Pedersen et al, 1998; 
Sacks et al, 2000; Gotto et al, 2000; Simes et al, 2002). In other words, sub­
group analysis of the major statin trials showed strong negative correlations with 
coronary events and HDL-C in both treatment and placebo groups. Therefore, 
even treatment with a statin does not provide protection against a coronary event 
if HDL-C levels remain low. Table 1.5 compares the effects of some major and 
minor drug studies aiming to raise HDL-C and/or the effects on CVD, and all 
cause mortality. The table provides evidence that the raising of HDL-C can be as 
effective as the lowering of LDL-C (Manninen et al, 1988; Bloomfield et al,
2001). The protection from coronary events afforded by HDL-C in the HHS was 
a 3% decrease in events for every 1% rise in HDL-C and this was independent of 
both LDL-C and plasma TAG (Manninen et al, 1988).
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Gemfibrozil vs. 
placebo
Manninen et 
al (1988)
HHS
Primary
prevention
HDL-C t 11% 
TAG |  35% 
LDL-C 1 11%
N = 4081men 
hypercholesterolaemics. 
Follow-up 5 yrs. 1 in 
coronary events 34%.
Gembibrozil vs. 
placebo
Bloomfield et 
al (2001)
VA-HIT
Secondary
prevention
HDL-C |  6% 
TAG 131%  
LDL-C
N = 2531 men with 
CHD, initial HDL-C (< 
1.0 mmol/L), LDL-C (< 
3.6 mmol/L). Follow- 
up 5 yrs, non-fatal MI 
or coronary death 1 
22%.
Ciprofibrate Aguilar- 
Salinas et al 
(2004)
CIPROAMLAT
Primary
prevention
HDL-C t 10% 
TAG 1 44% 
LDL-C 1 5.4%
N = 437 men and post­
menopausal women 
with HTG and low 
HDL-C. Follow-up 4 
mo
Colestipol-niacin 
vs. placebo
Blankenhom 
e ta l(  1987)
CLAS
Primary
prevention
HDL-C t 37% 
TAG 1 22% 
LDL-C 1 43%
N = 162 previous 
bypass surgery men. 
Follow-up
NIASPAN Capuzzi et al 
(1998)
HDL-C t 28% 
TAG 1 27% 
LDL-C 1 20%
N  = 517 Follow-up 2 
yrs
Simvastatin (S) 
vs. atorvastatin 
(A)
Ballantyne et 
al (2003)
CHESS 
Primary & 
secondary 
prevention
S HDL-C t 8.9% 
A HDL-C t 3.6% 
S LDL-C 1 45% 
A LDL-C 1 53%
N = 917
hypercholesterolaemic 
patients with and 
without CHD. Initial 
TAG 1 4.5 mmol/L. 
Follow-up 24 weeks.
Rosuvastatin vs. 
atorvastatin, 
simvastatin, 
pravastatin,
Jones et al 
(2003)
STELLAR R HDL-C t 9.6% 
A HDL-C t 4.4% 
S HDL-C t 5.2% 
P HDL-C t 5.6%
N = 2431
hypercholesterolaemic
Table 1.5 Drug therapy for raising HDL-C and lowering plasma TAG.
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Figure 1.5 Distribution of LDL-C and HDL-C. A. Men with and without CHD (on 
angiography) in Framingham showing LDL-C as a poor and HDL-C as a more informative 
predictor of CVD. B. Shows men with high HDL-C and high LDL-C have a lower risk o f CHD 
and even with low LDL-C CHD risk is still higher if HDL-C is low.
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1.3.4 Plasma TAG and the generation o f  an ALP
Total plasma TAGs show a negative correlation with HDL-C and a strong 
positive relationship with CHD; some studies have reported that the relationship 
with plasma TAG and CHD disappears after adjustment with HDL-C (Criqui et 
al, 1993; Manninen et al, 1992) whereas others have shown plasma TAG to be 
predictive of CHD even after adjustment for HDL-C (Stampfer et al, 1996; 
Jeppesen et al, 1997; Jeppesen et al, 1998). In a meta-analysis by Austin (1998) 
comprising 46 000 men and 11 000 women with follow-up > 8 yrs, plasma TAG 
was predictive of CVD independent of HDL-C. Thus with this evidence and that 
of others plasma TAG is now considered an independent risk factor for CVD 
(Griffin et al, 2001; Hokanson & Austin, 1996). Current US guidelines for 
plasma TAG are: normal < 1.69 mmol/L; borderline high 1.7 -  2.24 mmol/L; 
high 2.25 -  5.63 mmol/L; and very high > 5.64 (Grundy, 2002). The European 
guidelines state no specific targets to treat plasma TAG or HDL-C, but indicate 
that plasma TAG >1.7  mmol/L and HDL-C (< 1.0 mmol/L and <1.2 mmol/L 
for men and women respectively) are considered risk factors for CHD (De 
Backer et al, 2003).
Elevated levels of plasma TAG (>1.5 mmol/L) are the cornerstone feature of the 
atherogenic lipoprotein phenotype (ALP) which also consists of, low levels of 
HDL-C, unremarkable LDL-C concentration but with a predominance of small, 
dense LDL (sdLDL) (Austin, 1990). In addition to low HDL-C levels, like LDL, 
the HDL particle is smaller and denser. Other lipoprotein abnormalities include 
elevated CE-rich VLDL and chylomicron remnants (Krauss & Siri, 2004). LDL 
is a heterogeneous particle with at least seven subspecies, distinguished by size 
and density. These subspecies have been categorised into four subclasses, from 
the largest and most buoyant LDL-I to the smallest and densest LDL-IV (Krauss 
& Burke, 1982). As with both LDL and HDL, VLDL can be subcategorised into 
a range of subspecies namely, VLDLi and VLDL2 (Large and small VLDL 
respectively) (Georgiva et al, 2004). As mentioned above (Section 1.2.3) LDL is 
generated through the hydrolysis of VLDL and IDL by the action of LPL, 
whether LDL becomes the larger, more buoyant type or small and dense depends 
on the subclass of VLDL secreted from the liver. Large TAG-rich VLDLi leads
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to smaller, denser LDL through the activity of both LPL and HL; whereas large, 
buoyant LDL is derived from relatively cholesterol-rich and smaller VLDL2 
(Griffin & Packard, 1994) (Figure 1.6). The determination of which type of 
VLDL is secreted depends on the .hepatic TAG levels, with high levels leading to 
larger TAG-rich VLDL and low levels leading to the less buoyant species.
Both sdLDL and smaller, HDL3 can be generated through the action of CETP; 
TGRL can exchange TAG for CE from larger more buoyant LDL and HDL, the 
now TAG-rich LDL and HDL are hydrolysed by HL to form smaller and denser 
LDL and HDL (Packard, 2003) (Figure 1.7). The characteristics of a 
predominance of sdLDL or larger buoyant LDL is referred to as LDL subclass 
pattern B or A respectively. The pattern B atherogenic phenotype is associated 
with several disease states involving insulin resistance, including type II diabetes, 
the metabolic syndrome and obesity (Erkelens, 1998; Lamarche et al, 1999; 
Grundy, 1998; Kwiterovich, 2002; Blackburn et al, 2003). Furthermore, patients 
with familial combined hyperlipidaemia also have a predominance of sdLDL 
(Austin, 2000). Whether sdLDL is an independent risk factor for CVD is still 
being debated (Krauss & Siri, 2004) as the relationship with sdLDL and CHD is 
often weakened when adjusted for other risk factors such as plasma TAG and 
HDL-C. This is not surprising due to the strong positive relationship with 
sdLDL and plasma TAG, and an inverse relationship with HDL-C (Bemeis & 
Krauss, 2002). Nevertheless, studies have shown that a relationship with sdLDL 
and CVD exists (Table 1.6).
In the Diabetes Atherosclerosis Intervention Study (DAIS, Vakkilainen et al, 
2003) subjects with sdLDL were shown to have the greatest progression of 
atherosclerosis as measured by coronary angiography. When treated with 
fenofibrate LDL size increased and was associated with the reduction in plasma 
TAG. In a study by Niemeijer-Kanters et al (2001) a subgroup of 17 subjects 
from the 50 type II diabetics recruited converted from sdLDL pattern B to 
pattern A when treated with a combination of statin, fibrate and acipimox. 
However, not all the subjects with pattern B responded to treatment even though 
plasma TAG was lowered below the 1.5 mmol/L threshold showing a varied 
response. In a cohort of the Quebec Cardiovascular Study (St-Pierre et al, 2001),
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2034 men who were free of IHD at the start of the study were followed for 5 
years. After the 5 years subjects who had IHD showed greater relative 
percentages of LDL III compared to the IHD-free subjects. In addition to particle 
size, the cholesterol concentration of LDL subclasses were measured and the 
strongest predictor of ischemic heart disease (IHD) was with the concentration of 
LDL-C in sdLDL, which was independent of total LDL-C and plasma TAG. 
Similarly in a study by Williams et al (2003), who measured the relative 
percentage of all the LDL subclasses (LDL-I -  IV) found the smallest, densest 
LDL-IV was the strongest predictor of stenosis; a known predictor of MI and 
coronary death (Azen et al, 1996). In a study that measured LDL subclasses 
quantitatively by NMR (Rosenson et al, 2002) it was shown subjects with sdLDL 
cholesterol levels of 30 mg/dL (0.78 mmol/L) were 9 times more likely to show 
coronary artery disease (CAD) progression compared to lower levels. 
Furthermore, LDL III has been associated with a 3-fold increase in CHD (Griffin 
et al, 1994; Austin et al, 1988).
Fenofibrate vs. 
placebo
Vakkilainen 
et al (2003)
DAIS LDL size f  4% 
TAG |  28% 
HDL-C t  7.5%
N = 418 type II 
diabetics. Follow-up 
40 mo. CAD 
measured by 
angiograph.
Combined 
simvastatin, 
gemfibrozil, 
and acipimox
Niemeijer- 
Kanters et al 
(2001)
LDL size f 5.1% 
TAG I 59% 
HDL-C t 37%
N = 50 type II 
diabetics. Subgroup 
o f responders = 17 . 
Follow-up 30 weeks.
No drug,
ongoing
prospective
observational
study
St-Pierre et 
al (2001)
Quebec
Cardiovascular
Study
LDL 11151% 
IHD cases.
LDL III 40% in 
IHD-free
N = 2034 IHD-free 
men. Follow-up 5 
yrs.
No drug,
ongoing
prospective
observational
study
Williams et 
al (2003)
LDL IV b% 
regression slope 
= 0.238, P = 0.01.
N =  117 CAD men. 
Follow-up 4 yrs. End­
point measure = 
stenosis.
Pravastatin vs. 
placebo
Rosenson et 
al (2002)
PLAC-1 sdLDL i  30% Post-hoc study N = 
241 CAD patients. 
Follow-up 3 yrs. End­
point = angiograph.
N/A Watts et al 
(1993)
STARS LDL III showed 
strongest -ve  
association with 
coronary luminal 
dimension
N = 74 men. Follow- 
up 38 mo. End-point 
measure = coronary 
angiograms
Table 1.6 sdLDL and CVD
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1.3.5 The role o f insulin in generating sdLDL
The characteristics of an ALP are strongly associated with the other 
abnormalities seen in insulin resistant states, such as the metabolic syndrome 
(MS) and type II diabetes (Krauss & Siri, 2004). For example, both high plasma 
TAG and sdLDL have been correlated with hyperinsulinaemia and inversely with 
measures of insulin sensitivity (Watson et al, 2004). High plasma TAG is 
generated from an increase in VLDL from an increased flux of NEFA to the 
liver. In insulin sensitive states insulin acutely inhibits VLDL secretion from the 
liver. However, in insulin resistance where hyperinsulinaemia is prevalent the 
liver becomes resistant to this inhibition (Watson et al, 2004). Furthermore, this 
hyperinsulinaemia suppresses the activity of LPL and therefore impairs the 
hydrolysis of chylomicron and VLDL TAG by skeletal muscle and adipose 
tissue. In turn, the residence time of these lipoproteins increases which can lead 
to increased levels of CM and VLDL remnants, which are considered highly 
atherogenic particles (Wilhelm & Cooper, 2003).
1.4 Dietary strategies for ameliorating an ALP
While the role of drug therapy for the treatment of lipid abnormalities is now 
beyond dispute for the secondary prevention of CHD and in high-risk states 
(Grundy et al, 2004), the first line of defence against the primary prevention of 
CVD should be therapeutic lifestyle changes that reverse a deleterious lipid 
profile. Considering that statin, fibrate, and nicotinic acid treatment (the most 
effective drug therapies) all carry the risk of side effects (Wolfe, 2004; 
Wierzbicki et al, 2003; McKenny, 2004), dietary therapy represents a safer 
alternative for primary prevention.
Although the employment of low-fat, high-CHO diets for the lowering of plasma 
TC and LDL-C have been the cornerstone of therapeutic lifestyle changes for 
primary prevention of CVD (Parks & Hellerstein, 2000) they are not necessarily 
the best strategy for the reversal of an ALP (Krauss, 2001). This is due to the 
potential plasma TAG raising and HDL-C lowering effects observed with low- 
fat, high-CHO diets (Hellerstein, 2002). Three different dietary strategies have
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shown potential for the lowering of plasma TAG and the amelioration of an ALP, 
they include: (I) the quality of dietary fat with the effects of n-3 fatty acids 
obtained primarily from marine sources to be effective in lowering plasma TAG 
and reversing an ALP (Harris, 1997; Griffin, 2001); (II) the quality of dietary 
CHO with low glycaemic index diets showing improved glycaemic control and 
lipid lowering properties (Giacco et al, 2000; Jarvi et al, 1999) and (III) the 
quantity of dietary CHO with low-CHO, high-protein, high-fat diets growing in 
interest with the recognition that they may lower plasma TAG, raise HDL-C and 
increase insulin sensitivity (Yancy et al, 2004; Foster et al, 2003). Therefore, 
both the quality and quantity of dietary CHO and fat have been investigated for 
the potential lowering of plasma TAG and the amelioration of an ALP. These 
strategies have been studied in both normal and dyslipidaemic states and are 
introduced below.
1.4.1 Fish oils and n-3 fatty acids
In the early 1970’s Bang and colleagues (1971) investigated lipid and lipoprotein 
levels in the Greenland west coast Inuits and found an association between 
consumption of fatty fish and marine mammals with a lower mortality rate from 
CVD. Since this initial finding, there has been a plethora of studies investigating 
the effects of n-3 fatty acids and CVD (reviewed by Din et al, 2004; Bucher et al,
2002) with the majority of studies finding a cardio-protective effect of n-3 fatty 
acids. Elevated plasma TAGs are now considered an independent risk factor for 
CVD (Griffin et al, 2001; Austin et al, 2000; Hokanson & Austin, 1996) which 
can lead to an ALP and increased risk of atherosclerosis (Griffin, 1999). 
Therefore the lowering of plasma TAG represents a possible mechanism for the 
reversal of an ALP and decreasing the risk of CVD. The effects of n-3 fatty 
acids for the lowering of plasma TAG have been variable (Harris, 1997) and are 
dependent on the quality and quantity of n-3 fatty acids.
Harris (1997) compared a mixture of 68 crossover and parallel studies and found 
an overall plasma TAG lowering effect of fish oil supplementation of 25% in the 
parallel studies and 34% in the crossover studies. Moreover, when the studies 
examined hypertriacylglycerolaemic (HTG) (> 2.0 mmol/L) and
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normotriacylglycerolaemic (NTG) (< 2.0 mmol/L) groups, they found the HTG 
group to be greater responders. Harris also analysed the plasma TAG lowering 
effect of plant derived n-3 fatty acids (a-linolenic acid, ALNA) and out of 3 
further studies only one showed a plasma TAG reducing effect with a mega dose 
of 38 g of ALNA (60 ml of flaxseed oil). Since Harris’ meta-analysis numerous 
studies have demonstrated the plasma TAG lowering effect of n-3 fatty acids; 
Table 1.7 shows the key studies with additional lipoprotein effects if studied.
In a recent study by Brady et al (2004) the effects of two different ratios of n-6/n- 
3 fatty acids were compared in a 2-period, parallel intervention, in a population 
of Indo-Asians resident in the UK. In the first period of the study (6 weeks) 
subjects were randomised to either moderate or high ratio n-6/n-3 diets (9:1 and 
16:1 respectively). The n-6 fatty acids were given in the form of spreads and 
oils. After 6 weeks both groups were given an additional 2.5 g of n-3 LCP (long 
chain polyunsaturates) in the form of fish oil capsules. Although the new ratio of 
n-6/n-3 fatty acids was not stated in the paper, it was possible to calculate from 
the tables provided that the moderate n-6 diet was changed to 3.5:1 and the high 
n-6 diet to 7.1:1. The overall results are shown in Table 1.7; additionally, with 
regards to plasma TAG, the authors reported a reduction in both dietary groups 
with no significant differences between the two. Furthermore, decreases in 
sdLDL were observed but with no significant changes in HDL-C. Interestingly, 
although subjects were recruited as normolipidaemic they did display moderately 
high fasting plasma TAG and a predominance of sdLDL (LDL III) which are 
both characteristic of an ALP. Another recent study compared the effects of fish 
oils between Indo-Asians and white Europeans (Lovegrove et al, 2004); there 
findings also showed a reduction in plasma TAG but with no change in sdLDL 
(Table 1.7). In contrast to the majority of the studies on n-3 fatty acids there was 
a small but significant increase in HDL-C that was consistent with the finding of 
the GISSI study (GISSI-Prevenzione, 1999).
In a study by Finnegan et al (2003) the effect of n-3 fatty acids were assessed in 
a placebo-controlled parallel study. Moderately hyperlipidaemic subjects (n = 
150) were assigned to 1 of 4 experimental treatments or a control. The
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treatments were: moderate 0.8 g EPA & DHA/d, high 1.7 g EPA & DHA/d, 
moderate 4.5 g ALNA/d, and high 9.5 g ALNA/d. The intervention was for 6 
months and results showed only moderate reductions in plasma TAG and only 
with the high dose n-3 LCP group (Table 1.7). Evidence from the studies in 
Table 1.7 and the meta-analysis by Harris (1997) show, universally, a reduction 
in plasma TAG -  the magnitude of which appears to be dependent on the design 
of the study (whether crossover or parallel) and the dose of supplementation. 
Only the study by Brady et al (2004) investigated the ratios of n-6/n-3 fatty acids 
and there appears to be a general consensus that n-3 LCP confer the greatest 
improvements with regard to ALP markers. With respect to LDL size three 
studies showed an increase and three studies showed no change (Table 1.7); only 
two studies investigated the effects of n-3 fatty acids with respect to HDL 
subclasses and only one out of two studies showed an increase in HDL size 
(Table 1.7).
N-3 LCP have been shown to have either no effect oh plasma TC or a slight 
LDL-C raising effect. Meta-analysis (Harris, 1997) revealed a 5-10% increase in 
LDL-C and the studies outlined in Table 1.7 show a varied response ranging 
from 0 -  17.6% with LDL-C and only one study resulted in an increase in plasma 
TC. The LDL-C raising effect of n-3 LCP may be due to an increase in LDL size, 
i.e., an increase in CE and possibly decrease its atherogenic potential. This rise 
in LDL-C with no subsequent change in plasma TC or HDL-C (Minihane et al, 
2000; Calabresi et al, 2000) suggests a lowering of cholesterol in VLDL/IDL or 
remnants of CM/VLDL metabolism. As mentioned above (Section 1.3.4) the 
type of VLDL produced by the liver will give rise to different LDL subclasses, 
with a decrease in VLDLi producing larger, more buoyant, less atherogenic LDL 
but not necessarily a decrease in LDL-C concentration. A study by Rivellese et 
al (2003) supports this paradigm with decreases in VLDL cholesterol and TAG 
and an increase in LDL-C with n-3 supplementation with fish oil.
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A
(%)
A
(%)
A
(%)
A
(%)
A
(%)
A (%)
Brady et al 
(2004)
-20 -9 < - > ■<—> N/A 2-period parallel (see text), 
n = 29, n-6:n-3 ratio o f 3.5 
and 7.1.
Lovegrove et 
al (2004)
-9 * - » 4 N/A Indo-asian vs. European 
grp, n = 84, parallel 
controlled study, 12 wk, 1 
g pikasol (367 mg EPA 
225 mg DHA)
Finnegan et al 
(2003)
-7.7 N/A 9.7 17.6 N/A Moderate hyperlipidaemia, 
n = 150, parallel study, 6 
mo, 5 different grps 
described in main text.
Petersen et al 
(2002) 22
•<—» < - » < - » ~ 19% Moderately hypertensive 
(HPT) type II diabetics, n 
= 42, parallel study, 2.6 g 
EPA/DHA @ 40 & 25% 
respectively
Mabile et al 
(2001)
1 N/A < - > N/A 16
Normotriacylglycerolaemic 
(NTG), 12 HTG, 1800 mg 
EPA, 1200 mg DHA, no 
control grp
Minihane et al 
(2000)
-35.3 -26 7.1 N/A Male ALP subjects, n = 50, 
crossover, 6 wk, 6 g fish 
oil (28% EPA, 22% DHA)
Calabresi et al 
(2000)
-27 <—>• 21 N/A Familial combined 
hyperlipidaemia (FCHL), n 
= 14, crossover study, 8 
weeks, Omacor 3.4 g 
EPA/DHA
GISSI (1999) -3.4 N/A 8.8 N/A n = 2403, parallel study, 
MI patients, 42 mo, 860 
mg EPA, 430 mg DHA
Tinker et al 
(1999)
1 T < - » N/A HPT subjects, n = 11, 
crossover design
Suzukawa et al 
(1995)
-24 t t <—>• Hypertensive subjects, 
crossover study, n = 20, 6 
wk, 1 g Omacor
Table 1.7 The effects of n-3 & n-6 PUFA on fasting lipids.
The two main reported adverse effects of n-3 fatty acids are an increase in 
plasma TC and LDL-C (discussed above) and an increase in LDL susceptibility 
to oxidation. It has been previously reported (Finnegan et al, 2003; Lussier- 
Cacan et al, 1993; Suzukawa et al, 1995) that fish-oil supplementation increases 
the susceptibility of ex-vivo LDL to oxidation, presumably by increased
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unsaturation of cholesteryl and phospholipid esters and therefore increased free- 
radical attack. However, it is unknown if this finding can be extrapolated to an 
in-vivo situation.
1.4.2 Low-fat diets
The debate regarding the changes in the lipid profile induced by low-fat high- 
carbohydrate (LFHC) diets continues and results of some of the most recent 
interventions are reviewed below. Pieke et al (2000) compared a high-fat, low- 
carbohydrate diet (HFLC) with a low-fat, high-CHO (LFHC) diet; the HFLC diet 
consisted of 39% total fat, with a high content of mono-unsaturated fatty acids 
and marine long-chain n-3 polyunsaturated fatty acids (MUFAs and LCP n-3); 
the LFHC consisted of total fat (28%) and CHO (54%) of total energy. The 
intervention was designed sequentially, with subjects on the HFLC part first (3- 
weeks) followed by the LFHC diet (3-weeks). The authors found favourable 
changes in lipids with the HFLC diet when compared to baseline with a decrease 
and increase in serum TAG and HDL-C respectively. During the LFHC phase, 
serum TAGs increased and HDL-C decreased, other lipids did not change 
significantly. However, the LFHC diet was not matched with respect to the 
proportions of MUFAs and n-3 PUFAs, with eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) consisting of 1.6% and 0.0% on the HFLC and 
LFHC diets respectively. It is therefore reasonable to conclude that the reduction 
in serum TAGs during the HFLC phase was as a consequence of the dietary n-3 
PUFA (Section 1.4.1). The reason for elevation in serum TAGs during the 
LFHC phase of the intervention could be due to carbohydrate induced HTG. 
Although the carbohydrate content of both diets consisted of bread, cereals, 
vegetables and fruit, the authors do not give a more detailed inventory of these 
foods regarding the complex versus simple carbohydrates or glycaemic index. 
For example, some of the food categories mentioned above have been shown to 
exhibit a high content of sucrose, and/or high glycaemic index which may have 
contributed to the rise in serum TAG and fall of HDL-C.
Saris et al (2000) investigated changes in body weight and blood lipids in a large, 
sequential dietary intervention (the CARMEN study). This long-term study (6
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months) compared two LFHC diets with a control diet plus a seasonal control 
group. The two LFHC diets consisted of a high simple and a complex 
carbohydrate (CHO) group respectively. The control group was provided with 
food products of a typical macronutrient composition (15% protein, 36% total fat 
and 44% total CHO). Both LFHC groups were provided with low-fat products 
with either a high or low ratio of complex to simple CHO. The LFHC groups 
reduced both total body mass and fat mass compared with the control group. 
There was no difference in body mass between the two LFHC groups or in the 
seasonal control group. There were no adverse or favourable changes in serum 
lipids within any of the groups (i.e., cholesterol was not reduced, as commonly 
seen with LFHC diets and weight loss). Furthermore, the unexpected lack of any 
effects on serum TAGs and HDL-C, often observed with LFHC diets, may have 
been attributed to the concomitant loss in both total and fat mass seen in both 
LFHC groups. Another long term, ad libitum, dietary intervention investigated 
the effects of two LFHC (simple CHO and complex CHO) diets on weight loss 
and serum lipids (Poppitt et al, 2002). The subjects were overweight with risk 
factors associated with the metabolic syndrome. The main effects were 
reductions in plasma TC and LDL-C in the complex CHO group and increases in 
plasma TAG in the simple CHO group (HDL-C was lowered in both groups). 
The favourable lipid changes in the complex CHO group only occurred with 
weight loss. Body mass was maintained within the simple CHO group yet an 
unfavourable lipid profile still occurred.
Vidon et al (2001) using a random crossover design compared an isoenergetic 
HFLC diet with a moderately LFHC diet with equal proportions of saturated, 
monounsaturated and polyunsaturated fatty acids with low levels of 
monosaccharides. The authors concluded that the LFHC diet was beneficial with 
regards to the lipid profile with reductions in plasma TC, LDL-C and HDL-C, 
but no change in the LDL-C:HDL-C ratio. In addition, they found no change in 
plasma TAG concentrations. Parks et al (1999) compared similar diets (i.e., 
HFLC vs. LFHC), in both normal and HTG subjects. In contrast to Vidon et al 
(2001) both normal and HTG groups showed increased plasma TAGs and 
reduced plasma TC, LDL-C and HDL-C. Although fibre was increased by 50%
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in the LFHC phase, simple sugars did increase by 38% which may account for 
the differences in TAG concentration within these two studies.
The results of the aforementioned studies are in conflict with either a consistent 
negative or positive outcome with regards to lipids during a LFHC diet. It 
appears that when this dietary regime is studied under tightly controlled 
situations, comparing isoenegetic diets, then unfavourable changes can occur to 
plasma TAG and HDL-C (Parks et al, 1999), but not always (Vidon et al, 2001). 
However, when LFHC diets are fed ad libitum and concomitant weight loss 
occurs then the changes in plasma TAG and HDL-C are negligible (Poppitt et al, 
2002; Saris et al, 2001). In addition, the level of simple CHO to complex CHO 
plays an important role with HTG being induced more readily with LFHC simple 
CHO diets when compared to LFHC complex CHO diets.
1.4.3 The glycaemic index
Although some of the studies mentioned above distinguish between complex and 
simple carbohydrates and show difference between the two diets, they do not 
relate to the specific effect of foods with regard to glycaemia, i.e. the glycaemic 
index. The metabolic response to carbohydrate rich foods can be assessed by the 
glycaemic index (the incremental area under the curve of plasma glucose to a 
given food compared to a reference food, i.e. glucose or white bread (Jenkins et 
al, 1981; Foster-Powell et al, 2002). The measurement of glycaemic index (GI) 
reveals that even complex carbohydrates can have higher glycaemic responses 
than simple sugars.
The effects of low GI diets have been variable and reviewed below and 
summarised in Table 1.8. Two studies have examined the effect of LGI diets and 
LDL subclasses (Dumesnil et al, 2001 & Luscombe et al, 1999), the former 
observed an increase in LDL size after only 6-day on a LGI diet (with a 
concomitant fall in plasma TAG), compared to an AHA phase I diet (Krauss et 
al, 1996). While subjects were healthy, albeit overweight, and showed 
characteristics of an ALP; the low glycaemic index (LGI) diet was also high in 
protein at the expense of CHO giving the diet a low glycaemic load (GL, GL =
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GI x available CHO) and GI (not reported). This is an unfair comparison 
because two parameters have been changed at the same time making it difficult 
to conclude as to which component is altering the lipid profile. The authors did 
not observe any other changes in plasma lipids during the LGI diet, though 
during the AHA phase I diet plasma TAG and TC:HDL-C increased whereas 
HDL-C fell suggesting an exacerbation of an ALP and further evidence of CHO 
induced HTG. Furthermore, the LGI diet resulted in a reduction of fasting 
insulin and an improved metabolic profile over 24 h. Luscombe et al (1999) 
compare the effects of 3 diets (high MUFA, HGI, and LGI) in NIDDMs and in 
contrast to Dumesnil et al (2001) they showed no effect on LDL subclasses, 
plasma TAG or fasting insulin. Subjects (n = 28) were free-living who received 
the diets over a four-week period for each arm in random order -  no washout 
periods were included between each arm. Only HDL-C showed a positive change 
with both the LGI and the high MUFA phases. The differences in the GI 
between the 3 groups were: HGI diet = 63 units, LGI = 43 units and the high 
MUFA diet = 59 units (glucose = 100). Compared to other studies, the HGI arms 
of the high CHO and high MUFA diets were still relatively low GI and this may 
account for the lack of difference between the HGI and LGI low fat diets, i.e. 
there may be a threshold of GI and beyond which there are no further favourable 
changes in plasma lipids.
When subjects have been pre-selected with hyperlipidaemia the response to a 
LGI diet with respect to plasma TAG appears to be more pronounced. In two 
studies by Jenkins et al (1985 & 1987a) plasma TAG was significantly reduced 
with hyperlipidaemic patients in response to a LGI diet. The 1987 study 
researched 30 hyperlipidaemic (classified to type II a & b, type III and type IV) 
patients who had been attending a lipid clinic for ~ 5 yr in a 3 month 
intervention. The study protocol was designed to reduce the GI of the diet during 
the middle month of a 3 month period; during the 1st and 3rd month patients 
adhered to their normal lipid clinic diet. During the middle intervention period, 
higher GI starch foods were exchanged with LGI foods of similar nature. Results 
showed significant reductions in plasma TAG, TC and LDL-C, with no change in 
HDL-C during the LGI phase. Moreover, greater reductions were achieved with
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the HTG dyslipidaemias (type IV). These changes were achieved with a 
reduction of only 11 GI units.
Three dietary interventions with low and high GI diets in CHD patients were 
consistent in showing no change in plasma TAG or HDL-C (Frost et al, 2004, 
1998, & 1996). In the 2004 study the authors investigated the effect of a LGI 
diet versus health education guidelines (COMA panel, Cardiovascular Review 
Group, 1994) in free-living CHD patients, there were no changes in any of the 
outcomes. It is important to note, that although a significant difference of -13% 
in GI (LGI vs. healthy eating) was achieved there was no significant difference in 
GL, indicating that the healthy eating group had reduced the overall amount of 
CHO. The other two studies focused on insulin sensitivity in adipocytes (Frost et 
al, 1996) and cytokines (Frost et al, 1998) and therefore are beyond the scope of 
this report.
Diabetes (especially type II) has been associated with dyslipidaemia, notably 
with HTG and low levels of HDL-C which may be caused by complications with 
the action of insulin (Ludwig, 2002). Considering LGI diets have been shown to 
improve the metabolic profile and increase insulin sensitivity (Dumesnil, 2001), 
then a LGI diet would be expected to improve diabetic dyslipidaemia. Dietary 
intervention studies have shown a variable response with respect to plasma TAG, 
with 3 studies favouring a LGI diet (Jarvi et al, 1999; Frost et al, 1994 & 
Wolever et al, 1992) and 4 studies showing no change (Giacco et al, 2000; 
Luscombe et al, 1999; Brand et al, 1991; and Jenkins et al, 1988), with Jenkins 
et al (1988) showing a reduction in plasma TAG on the HGI diet. Although the 
latter 4 studies showed no improvements with plasma TAG levels there were 
other beneficial effects of a LGI diet: improvement in glycaemic control (Giacco 
et al, 2000; Brand et al, 1991); increase in HDL-C (Luscombe et al, 1999); and 
improvements in blood glucose, Hbaic, and urinary c-peptide-to-creatinine ratio 
(Jenkins et al, 1988). In a recent study of IGT subjects who are at increased risk 
of developing diabetes, results of fasting TAG remained unchanged and HDL-C 
actually increased on the HGI diet, with no change after the LGI diet (Wolever & 
Mehling, 2003). However, improvements in postprandial glycaemic control 
were observed. Therefore, the evidence for prescribing LGI diets for diabetics
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for the improvement of dyslipidaemia is not overwhelming. However, favourable 
metabolic consequences can be achieved with a LGI diet.
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Source TAG sdLDL HDL-C Comments
HGI LGI HG
I
LG
I
HG
I
LG
I
Frost et al 
(2004)
<r-> <—» 4- » <-4 CHD (n = 55), 2-diet parallel design, 12-wk
Wolever &
Mehling
(2003)
T 4-4 Impaired glucose tolerance (IGT) (n = 34), 3-diet parallel 
design, 4-mo
Bouche et al 
(2002)
<—► 4-4 <—4 Moderately overweight (n = 11), 2-diet crossover, 5-wk
Giacco et al 
(2000)*
<—4 Type I diabetic (n = 46), 2-diet parallel design, 6-mo
Dumesnil et al 
(2001)**
1 4-4 <—4 Healthy, t BMI (n = 12), 3-diet parallel design, 6-d
Jarvi et al 
(1999)
I 1 1 Overweight (n = 20), 2-diet crossover, 24-d
Luscombe et al 
(1999)
4- » 4- » 1 T NIDDM (n = 21), 3-diet crossover, 12-wks
Frost et al 
(1998)
<—>• Parental history of CHD and control females (n = 61), 3- 
diet parallel, 3-wks
Frost et al 
(1996)
4-4 4-4 CHD (n = 30), 2-diet parallel design, 4-wks
Frost et al 
(1994)
<—> <—4 Type II diabetic (n = 51), 2-diet parallel design, 12-wks
Wolever et al 
(1992)
T I Type II diabetic (n = 15), 2-diet crossover, 2-wks
Brand et al 
(1991)
«—> 4- » 4-4 4-4 NIDDM (n = 16), 2-diet crossover, 12-wks
Jenkins et al 
(1988)
i <—> <—4 <—4 NIDDM (n = 8), 2-diet crossover, 2-wks
Jenkins et al 
(1987a)
<—> I <—4 4-4 Hyperlipidaemic (n = 30), 2-diet, 3-way crossover, 3-mo
Jenkins et al 
(1987b)
«—>• Healthy (n = 6), 2-diet crossover, 2-wks
Jenkins et al 
(1985)
t i 4-4 <—4 Hyperlipidaemic (n = 12), 2-diet, 3-way crossover, 3-mo
Table 1.8. Changes in markers of an ALP with HGI & LGI diets. Blank spaces = not 
measured ( |  = significant increase; I = significant decrease; <-> = no significant difference). . * 
Giacco et al (2000), included higher fibre in the LGI diet. **Dumensnil et al (2001), included
higher protein with the LGI phase.
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1.4.4 High-protein, high-fat diets
While lowering the GI of the diet is an effective method for decreasing the GL an 
alternative approach is to reduce the total CHO. High-protein, high-fat (HPHF) 
diets have been shown to be highly effective in reducing body weight and plasma 
TAG and raising HDL-C levels, but with less success in lowering plasma TC and 
LDL-C. Much of the evidence for the above has come from recent interest in 
low-CHO diets (Seshadri et al, 2004; Yancy et al, 2004; Foster et al, 2003; 
Samaha et al, 2003; Westman et al, 2002). These long-term and short-term 
studies (4 weeks -  1 year), are presented in Table 1.9 and as mentioned above 
plasma TAG show the most pronounced reductions and this is regardless of 
initial subject characteristics or whether the diets were hypo or iso-energetic. 
The response to HPHF diets with respect to plasma TC and LDL-C has been 
more variable with only one study showing a reduction with a hypoenergetic diet 
in obese subjects (Westman et al, 2002). The other hypoenergetic, HPHF diets 
showed either no change or very moderate increases in plasma TC with slightly 
higher increases in LDL-C. The only isoenergetic study showed more marked 
increases in plasma TC and LDL-C of 15 and 16%, but the increase in HDL-C 
was 32% which may offset the risk of CVD (Volek et al, 2003).
Possible mechanisms on how HPHF diets lower plasma TAG include a lowering 
of VLDL and especially VLDL size, the study by Seshadri et al (2004) showed a 
decrease in large VLDL particles with the HPHF diet with the authors 
speculating insulin to play a key role. The role of VLDL size and the production 
of sdLDL is discussed above, implicating insulin as a key player. With a HPHF 
diet the low CHO content reduces the GL of the diet and although both dietary 
protein and fat are insulinaemic, the lack of CHO and the hypoenergetic nature of 
HPHF diets may decrease total insulin levels and thus lowering VLDL 
production. In addition, the high-fat content of the diet may increase LPL 
activity and thus increase clearance of TGRL as described by Campos et al 
(1995).
41
11
A(% ) A(% ) A(% ) A(% ) A(% )
Seshadri -29 t 1.7 1.8 0.3 Obese/diabetic/MS 
subjects, n = 43, parallel 
HPHF vs. conventional 
diet hypoenergetic
Yancy
(2004)
et al -Al N/A -3 1.0 10 Hyperlipidaemic, 
overweight subjects, n = 
45, parallel study LFHC 
vs. HPHF hypoenergetic 
(24-wks).
Foster
(2003)
et al -17 N/A 0.1 0.31 11 Obese subjects, n = 33 
parallel study HPHF vs. 
LFHC hypoenergetic (12 
mo).
Samaha
(2003)
et al -20 N/A 1.1 4.4 0 Obese subjects, n = 64, 
parallel study HPHF vs. 
conventional diet 
hypoenergetic (6-mo)
Westman
(2002)
et al -43 N/A -5.1 -7.3 19.2 Overweight/obese, n = 
41, HPHF no control 
hypoenergetic (6-mo).
Volek
(2004)
et al -22.5 0.0 1.0 5.3 1.9 Overweight/obese 
female, n = 13, crossover 
design HPHF vs. LFHC 
hypoenergetic (2 x 4- 
wks)
Volek
(2003)
et al -30 0.0 16 15 32 Normal weight, 
normolipidaemic women, 
n = 10, crossover design 
HPHF vs. LFHC 
isoenergetic (2 x 4-wks).
Volek
(2000)
et al -55 N/A 1.7 10 10 Normal weight, 
normolipidaemic men, n 
= 10, HPHF high n-3 no 
control (8-wks) 
hypoenergetic.
Table 1.9 Effect of HPHF diets on surrogate markers of CVD
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1.5 Aims and objectives
The overall aim of this thesis was to investigate dietary strategies for the 
amelioration of the lipid abnormalities found in an ALP. These strategies 
involved the manipulation of the quantity and quality of dietary fat and CHO, 
and the quantity of protein. This has been examined by investigating three 
different forms of dietary intervention that included:
(I) The effects of different ratios of n-6/n-3 PUFA derived from marine 
and plant sources by designing non-supplemented, whole food diets. 
This was achieved by providing subjects with different types of tinned 
fish, spreads and oils and encouraging the consumption of oily fish 
(Chapter 4).
(II) The effect of low-fat, high-CHO diets with a low and a high 
glycaemic index respectively. This was achieved by providing 
subjects with detailed menus, recipes and presentations providing 
information regarding the quality and quantity of CHO (Chapter 5).
(III) The effect of a two hypoenergetic, commercially available diets. This 
was achieved by manipulating macronutrient proportions by reducing 
the intake of CHO or fat respectively. Subjects were provided with 
the commercially available dietary strategy and were advised by 
registered dieticians (Chapter 6).
Before undertaking the interventions in Chapters 4-6, a major objective was to 
establish a rapid, high-throughput method for the separation of LDL subclasses, 
for defining the characteristics of an ALP.
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Chapter 2 Materials and General Methods 
2.1 Materials
The NVT 65 and NVT 65.2 rotors were kindly supplied on loan from Dr John 
Graham (John Graham consultancies, Merseyside, UK). All kits for the SPACE 
autoanalyser were supplied by Randox Laboratories Ltd., County Antrim, UK. 
All other chemicals and reagents were of analytical grade and obtained from 
Sigma Chemical Co (Poole, Dorset, UK).
2.2 Preparation of plasma
Blood was taken by venepuncture both pre and postprandial from male and 
female volunteers (see individual chapters for further details) either by vacutainer 
or syringe and needle. The blood was collected into commercially available 
vacutainers or centrifuge tubes with the following anticoagulants (Table 2.1):
k 2e d t a Choi., TAG, LDL-C, HDL-C, Apo-B, NEFA, 
RBC and plasma membrane fatty acid analysis
Fluoride oxalate (FO) Glucose
Lithium heparin (LH) Insulin, LPL, HL
Table 2.1. Anticoagulants and assays
The blood was immediately centrifuged at 2000g for 20 min at 4° C in an 
Heraeus Labofuge 400R low speed centrifuge to separate the plasma from the 
blood cells. Aliquots of plasma were dispensed into appropriately labelled 
cryovials (1.8 ml) and stored at -80°C for subsequent analysis.
2.3 Analyses using a SPACE auto-analyser
Plasma samples were analysed on a SPACE auto-analyser (Alferwassermann, 
AL Woerden, Netherlands); for each assay specific quality controls (QCs) were 
measured at 2 h time intervals -  assays were performed only if the QCs were
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within the accepted parameters provided by the supplier. All assays (accept 
ApoB) were colourimetric enzymatic procedures relying on the endpoint 
production of a coloured pigment (Siedel et al, 1983; Kattermann et al, 1984; 
Trinder, 1969; Munz et al, 1974). The concentration of the dye was proportional 
to the test at a specific wavelength, within a specific concentration range. QCs, 
specific wavelength and assay ranges are given for each assay. The test for 
ApoB was an immunoturbidity procedure.
2.3.1 Total Cholesterol
Cholesterol esters were hydrolysed to free cholesterol and free fatty acids by 
pancreatic cholesterol esterase. The liberated cholesterol and any free 
cholesterol present in the plasma were both oxidized by cholesterol oxidase, 
reaction:
Cholesterol esters + H2O cholesterol esterase cholesterol + fatty acids
Cholesterol + 0 2 cholesterol oxidase > Cholestone-3-om + H20 2
2 H2O2 + 4-aminantipyrine + phenol Peroxidase ^  quinoneimine + 4 H2O
The absorbance of the quinoneimine pigment is measured bichromatically at 
505/692 nm. Intra and inter-assay precision gave CVs for high and low quality 
controls of < 5% respectively.
2.3.2 TAG
The principle of the assay is similar to the cholesterol above; however, glycerol- 
3-phosphate is the substrate to be oxidized to form peroxide, the reaction is 
described below:
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TAGs + 3 H2O  l££m ► glycerol + fatty acids
glycerol + ATP GK—► glycerol-3-phosphate + ADP
glycerol-3-phosphate + O2 GP0 ► dihydroxyacetone-phosphate + H2O2
H2O2 + 4 aminantipyrin + 4-Chorophenol — — ► quinoneimine +
4H20  + HCl
Where POD = peroxidase, GPO = glycerol-3-phosphate oxidase, GK = glycerol 
kinase, ATP = Adenosine-5’-triphosphate, ADP = Adenosine-5’-diphosphate
The absorbance was measured bichromatically at 505/692. Intra and inter-assay 
precision gave CVs for high and low quality controls of < 5% respectively.
2.3.3 HDL-C
The assay for HDL-C consists of two reaction steps; the first step eliminates 
chylomicrons, VLDL and LDL-C with the following enzyme sequence:
Step 1
Cholesterol ester cholesterol esterase— ^ Cholesterol + fatty acid
Cholesterol + 0 2 Cholesterol oxidase  ^ cholestone + H20 2
2h 2q 2 — 2H20  + 0 2 
Step 2
HDL-C was then released by detergents and measured specifically:
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Cholesterol ester Cholesterol esterase— ^ Cholesterol + fatty acid
Cholesterol + 0 2 cholesterol oxidase  ^ CkoleStOW + H20 2
2H20 2 + 4-AA + HDAOS — gs!s!s^ ------- ► Quinone pigment + 4H20
Where 4-AA = 4-Aminoantipyrine
HDAOS = N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxyaniline.
The intensity of the quinoneimine dye product is directly proportional at 600 nm 
within the linear concentration range of 0.10 -  2.4 mmol/L. Intra and inter-assay 
precision gave CVs for low, medium and high and quality controls of < 5% 
respectively.
2.3.4 LDL-C
LDL-C was measured identically to HDL-C; however, TOOS (N-Ethyl-N-(2- 
hydroxy-3-sulphopropyl)-3-methylaniline replaces HDAOS as the detergent. The 
method is linear between 0.258 - 25.8 mmol/L. Intra and inter-assay precision 
gave CVs for low, medium and high and quality controls of < 5% respectively.
2.3.5 Glucose
Glucose was determined by enzymatic oxidation in the presence of glucose 
oxidase (GOD). Peroxidase (POD) catalyses the hydrogen peroxide product with 
phenol and 4-aminophenzone to produce a red -  violet quinoneime dye. The 
absorbance of the dye is measured bichromatically at 505/692 nm.
The reaction:
Glucose + O2 + H2O — ----- ► gluconic acid + H2O2
2 H2O2 + 4-aminophenzone + phenol POD ^  quinineimine + 4 H2O
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Intra and inter-assay precision gave CVs for high and low quality controls of < 
5% respectively.
2.3.6 ApoB 
Principle
Human total apo B was measured turbidimetrically, apo B forms a precipitate 
with a specific antiserum, which is measured turbidimetrically at 340 nm. The 
antigen-antibody complex produces a turbid precipitate; the level of turbidity is 
proportional to the concentration of Apo B.
Method
A linear standard curve was constructed from an Apo B standard (Randox) using 
saline (0.9% w/v), ranging from 0.0 -  2.18 g/L. Three quality controls were 
employed a low, medium and high (0.87, 1.24, and 1.63 g/L respectively). 
Precision tests were carried out on each QC and intra-assay CVs were < 8 % for 
the low, medium and high QCs respectively (n = 5). Inter-assay precision gave 
CVs of < 9% (n = 10).
2.3.7 NEFA
NEFA was determined by the enzymatic reaction of Acyl CoA Synthetase and 
Acyl CoA Oxidase to produce peroxide; the peroxide reacts with 4- 
aminoantipyrine which results in a purple coloured adduct that absorbs at a 
wavelength of 550 nm. The intensity of the colour is proportional to the NEFA 
concentration, reaction:
NEFA + ATP + CoA Acy,CoA Syn,he,ase ( Acyl CoA + AMP + PPi 
Acyl CoA + 0 2 Acyl CoA Oxidase  ^ 2,3,-trans-Enoyl-CoA + H20 2
2H20 2 + TOOS + 4-AAP POD purple adduct +4 H2O
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Where 4-AAP = 4-aminoantipyrine, Toos = N-ethyl-N-(2-hydroxy~3- 
sulphopropyl) m-toluidine.
The assay is linear up to 2.0 mmol/L with a sensitivity of 0.10 mmol/L. Low and 
high quality controls were employed with intra-assay CVs of 3.4% and 2.3% 
respectively (low QC, n = 11 and high QC, n = 9) and inter-assay CVs of 8.9% 
and 7.4% respectively (low QC, n = 22 and high QC n = 18).
2.4 Lipoprotein analysis
2.4.1 Ultracentrifugation methods
2.4.1.1 Preparation o f total lipoproteins 
Principle
Sequential flotation (Havel et al, 1955) involves a series of centrifugation steps 
whereby the density of the plasma is raised sequentially by the addition of 
sodium or potassium bromide.
Method
Whole plasma was adjusted to density 1.21 kg/L by the addition of KBr by 
employing the following formula:
KBr (g) = Initial volume (ml) x [final density -  initial density]
1-[final density x 0.312]
The adjusted plasma (1.0 ml) was transferred to a Beckman Ultra-Clear 
centrifuge tube (12 ml) and mixed with a KBr 1.21 kg/L, 1% EDTA density 
solution. Tubes were housed in a Beckman 70.1 Ti rotor and centrifuged for 20 
h at 147 000g(av), 15°C. After centrifugation, the top yellow band (~ 400 pi) was 
aspirated and used for subsequent analysis or stored at -80°C.
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2.4.1.2 Salt-gradient ultracentrifugation fo r the analysis o f  LDL Subclasses 
Principle
The principle o f this method was based upon reverse rate zonal separation. With 
normal rate zonal separation, successive layers o f decreasing density are layered 
one on top o f the other to form a discontinuous gradient; alternatively, under­
layering can be used (Figure 2.1). The sample is over-layered on the top o f the 
gradient and the tubes are centrifuged. The density layers diffuse to form a linear 
gradient and the sample migrates until it reaches its specific density. With 
reverse rate zonal separation, the sample is adjusted to a specific density and 
more buoyant density solutions are layered over the sample. The tubes are 
centrifuged, diffusion occurs to form a linear gradient and the bands o f interest 
migrate via flotation.
Figure 2.1 Preparation of gradients. Under-layering (a) and over-layering (b) a discontinuous
gradient.
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Method
LDL subclasses were isolated using a discontinuous KBr gradient (Griffin et al, 
1990). Plasma (3 ml) was adjusted to a density of 1.090 kg/L by the addition of 
KBr and layered over a dense “cushion” of density 1.182 kg/L (0.5 ml) in 
polycarbonate Ultra-Clear centrifuge tubes (13 ml). Followed by successive 
over-layering of the subsequent densities: 1.060 kg/L (1 ml), 1.056 kg/L (1 ml), 
1.045 kg/L (1 ml), 1.034 kg/L (2 ml), 1.024 kg/L (2 ml) and 1.019 kg/L (1 ml). 
The centrifuge tubes were centrifuged in a Beckman SW40 Ti rotor at 200 
000g(av), 23 °C for 23 h (acceleration program 7 and deceleration without brake) 
in a Beckman Optima XL-100 ultracentrifuge.
2.4.1.3 Iodixanol gradient ultracentrifugation for the identification o f  
lipoproteins
Lipoproteins were separated employing iodixanol (Optiprep™, John Graham 
consultancies, Merseyside, UK), for full details of the methods see Chapter 3, 
Section 3.1.3.1.
2.4.2 Electrophoresis methods
Gel electrophoresis is commonly used to separate macromolecules according to 
their net electrostatic charge, when a macromolecule is placed under the 
influence of an electric field it will migrate towards the anode or cathode 
depending on its size and charge.
2.4.2.1 Gradient gel electrophoresis for the identification o f  LDL and HDL 
Subclasses.
Principle
51
With most polyacrylamide gel electrophoresis (PAGE) systems, the 
concentration of the gel is uniform, and separation is based entirely on the rates 
of migration of the charged particles in the electrical field. A disadvantage of this 
technique is that the macromolecules can continue to migrate off the gel if the 
electrical field exists for too long. Thus, with a uniform gel, the distance of 
migration is a function of the size of the particle, its charge, and the duration of 
the electrophoresis.
Gradient Gels: If gels are prepared with different concentrations of acrylamide, 
macromolecules can be separated with higher resolution and can be prevented 
from running off the gel. Acrylamide gel is cross-linked with N,N'-methylene 
bisacrylamide. The basic principle is that, with a higher gel-solution 
concentration, the matrix that is formed upon polymerisation will be more tightly 
meshed, and larger macromolecules will not be able to migrate past layers of 
predetermined pore size. In the gradient gels, the distance of migration is thus a 
function of the size of the macromolecule and the concentration gradient of the 
gel.
In a typical gradient gel electrophoresis (GGE) set-up, the rate of mixing of two 
gel solutions with different acrylamide concentrations will determine the gradient 
of concentrations. The two different concentrations of gel solution are allowed to 
mix in equal proportion in a linear gradient, with the highest concentration being 
layered at the bottom and the lowest concentration constituting the top layer. The 
properties of GGE have been utilised to separate both LDL (Krauss & Burke, 
1982) and HDL subclasses (Blanche et al, 1981).
Method
Both LDL and HDL subclasses were analysed using commercially available pre­
cast non-denaturing polyacrylamide gradient gels using a PGGE Pore Gradient 
Lipoprotein Electrophoresis System (C.B.S. Scientific Company, Del Mar, 
California, USA). LDL and HDL subclasses were separated using 2-16% and 4- 
30% acrylamide respectively. Total lipoprotein samples were prepared by 
ultracentrifugation as described in section 2.4.1.1. After centrifugation, the top
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fraction (400 p\ of visible yellow band) was removed; a 100 p\ aliquot of the 
band was pre-stained with bromophenol blue (final concentration 5% w/v wrt 
bromophenol blue). Samples (10 jul) and high molecular weight markers 
(Sigma-Aldrich, Dorset) (10 //l, only used for HDL subclasses) were transferred 
to the gel wells after the gels were pre-equilibrated at 70 V, 65 mA for 30 min. 
Following sample addition, gels were run at 20 V, 50 mA for 20 min., followed 
by 70 V, 65 mA, 30 min. and finally for 120 V, 100 mA for 24 h. Gels were 
removed from their casing and placed in fixing solution (sulphosalicylic acid, 
10% w/v) for 30 min. followed by protein staining for 1 h (0.1% w/v coomassie 
blue R250, Methanol: glacial acetic acid: reverse osmosis (RO) water in a 5:1:4 
ratio). Gels were de-stained with Methanol: glacial acetic acid: RO water 50: 75: 
874 (ml) overnight. Once gels were de-stained, they were photographed using a 
D1X digital camera (Nikon, Surrey, UK) and analysed using total lab software 
v2.01 (Nonlinear Dynamics, Newcastle upon Tyne, UK).
2.4.2.3 Agarose gel electrophoresis
Principle
Agarose gel electrophoresis was performed using the protocol provided by Sebia 
(YSI Clandon Ltd., Famborough, UK), which is an adaptation of the methods of 
Noble (1968). In agarose gel electrophoresis, the protein moves on a support 
made of agarose and at a defined pH lipoprotein particles will migrate towards 
the cathode.
The mobility, which is defined as the rate of movement in cm per second under a 
field of 1 volt per cm, is dependent on the charge of the protein molecule, the 
interactions of the protein with the support and the nature of the buffer. 
Lipoproteins are separated on agarose gels solely according to their charge, and 
they have been classified into four distinct types namely, the origin, p, pre-p, and 
a  (Figure 2.2). The following lipoproteins have been determined for each of the 
classification: the origin band = chylomicrons, P band = LDL, pre-P band =
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VLDL and the a  band = HDL. Lipoproteins are visualised on agarose gels by 
staining for lipid using Sudan black.
Method
Whole plasma and gradient fractions, in aliquots of 2 ju\, were electrophoresed on 
preformed Sebia hydragel lipo-Lp(a) agarose gels on a Sebia K20 electrophoresis 
chamber (YSI Clandon Ltd., Famborough, UK) for 75 minutes, 27 mAmps per 
gel. The gels were dried in an oven at 80°C for 35 minutes followed by staining 
in Sudan black stain solution (ethanol (80 ml), distilled water (70 ml), and Sudan 
black (1 ml)) for 15 minutes and destained in ethanol/water (45% v/v) for 5 
minutes. The electrophoresis buffer provided by Sebia contains: Tris (7.2 g/ml), 
barbital (1.84 g/ml), sodium barbital (10.3 g/ml) and sodium azide (0.1 g/ml).
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a
Pre-p
p
Origin
Anode
Figure 2.2. Agarose Gel Electrophoresis. Schematic o f agarose gel electrophoresis o f human 
plasma lipoproteins. Chylomicrons band at the origin, VLDL bands at P migration, LDL at pre-P
migration and HDL at a  migration.
2.5 Analysis of Lipases
2.5.1 Total and Hepatic Lipase Activity
Principle
Total and hepatic lipase activities were measured using a commercially available 
kit (Technoclone, Hampshire, UK). The assay measures lipase activity in 
postheparin plasma (PHP), heparin was intravenously injected and blood was 
drawn at 5 and 15 min 6  h after a fatty meal (see Chapter 4 for further details). A 
TAG (1 -trinitrophenyl-amino-dodecanoyl-2-pyrendecanoyl-3 -O-hexadecyl-sn-
glycerol (12-TA-10-P-6)) in which the trinitrophenyl group intramolecularly 
quenches the pyrene fluorescence is used as the substrate. In the presence of 
active lipase, hydrolysis of the quencher occurs and pyrene fluorescence can be 
detected.
Direction of 
migration
Method
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The method requires four working steps:
Stepl. Standard Curve
A linear standard curve was constructed by performing a serial dilution of a 
reconstituted standard of 12-TA-10-P-6 (unquenched% standard range: 0.30 -  20 
pmol/ml. The fluorescence of the standards was read at 342 nm excitation and 
400 nm emission with excitation and emission slit width set at 10 nm 
respectively on a Varian, Cary Eclipse, fluorescence spectrophotometer (Varian, 
Surrey, UK). The sensitivity of the instrument was adjusted to ensure there was 
no signal overflow of the photomultiplier. This was achieved by reading the 
highest standard first and setting the photomultiplier to a lower voltage than the 
arbitrary reading of the standard.
Step 2
The molar fluorescence of the pyrene group is required for the calculation of the 
concentration of the unquenched pyrene group, which accumulates over time in 
the kinetic assay. The molar fluorescence constant of the pyrene fluorescence of 
the unquenched product is the gradient of the straight line derived from the linear 
standard curve. The gradient of the curve was calculated from the straight line, 
mathematically described as y = mx + c (where m = the gradient).
Step 3
The lipase activity in the assay corresponds to the appearance of the pyrene 
fluorescence of the unquenched product over time. If the calibration range is not 
altered, the increase of fluorescence in the lipase assay over time remains linear 
and no signal overflow occurs. Substrate was transferred to a cuvette (2 ml) and 
pre-heated to 37°C; PHP sample (20 pi, diluted 1/10 with buffer A or B) was 
added to the substrate and mixed, kinetic measuring commenced after 2  min. and 
continued for a further 5 min. Fluorimeter settings were as above.
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Step 4
Calculation of lipase activity: the gradient of the standard curve is now used to 
calculate lipase activity. Cleavage of the quencher by lipase in the kinetic assay 
results in release of the pyrene group over time, which results in a straight line. 
The activity of the lipase in the kinetic assay is calculated as the ratio delta 
fluorescence/time in the assay and the molar fluorescence, calculated from the 
gradient of the standard curve:
RFU xm in ' /RFU x pmol ■'x ml = pmol/ml/min.
Where RFU = relative fluorescence.
Lipase activity, however, is normally expressed as pmol/ml/h.
For both total and hepatic lipase, the assay procedure is identical apart from the 
conditions of the buffer. For total lipase a lower pH of 8.2 and physiological salt 
concentrations are required; for HL a higher pH (8 .8) and ionic strength is 
necessary; under these conditions LPL is inhibited. The limitations of the assay 
are that LPL activity cannot be calculated from the difference between the two 
values. In addition, the test result may be influenced by competitive inhibition of 
plasma lipids.
The intra and inter-assay precision of the test were determined using one subject: 
PHP was assayed for both total and hepatic lipase on two separate occasions. 
CVs for intra-and inter-assay precision were < 10% respectively.
2.6 Analysis o f Insulin
Principle
The quantitative measurement of insulin in human samples was measured with a 
commercially available immuno-chemiluminometric assay (Molecular Light
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Technologies, Cardiff, UK). The assay was a two-site immunoassay employing 
an insulin specific solid phase antibody immobilised on microtitre wells and a 
soluble antibody labelled with a chemiluminescent acridinium ester. The plasma 
sample is incubated simultaneously with the labelled antibody solution in the 
microtitre well; a wash step is required to remove unbound labelled antibody 
before measurement. The bound luminescence is quantified by a microtitre plate 
luminometer capable of in situ reagent addition. The luminescent reaction is a 
rapid flash (> 95% complete in 1 sec.) which permits the entire plate to be read in 
~ 5 min.
Method
Kit components and samples were brought to room temperature (RT) before 
starting the assay. Standards (0-200 mU/L) were reconstituted by the addition of 
reverse osmosis (RO) water (1.0 ml) and mixed until dissolved. The labelled 
antibody concentrate (900 pi) was dispensed into the labelled antibody diluent 
and mixed. Wash buffer (1 part buffer concentrate in 9 parts RO water) was 
prepared.
Aliquots of 100 /A of labelled antibody solution were dispensed into appropriate 
microtitre wells and standards and samples (25 jul) were transferred to the wells 
in duplicate. The plates were sealed and incubated for 2 h at 37°C, following 
incubation the plates were washed 3 times with wash buffer, using an automatic 
plate washer. Finally, plates were read in a luminometer (Berthold, 
Hertfordshire, UK); results were calculated using Micro Win 2000 software. The 
software converts the unknown relative luminescence (RLU) values from a 
cublic spine fit standard curve (0 -  200 mU/L) into mU/L
Precision (CVs) of four controls over three assays were: 7.7% at 6.5 mU/L =; 
4.2% at 21.0 mU/L; 3.6% at 84 mU/L; and 4.3% at 169 mU/L. Conversion factor 
from mU/L to pmol/L = 7.5.
58
2.6.1 Calculation of the homeostasis assessment model (HOMA)
The homeostasis assessment model (HOMA) was calculated using the following 
formula: insulin (pmol/L) x glucose (mmol/L)/ 22.5.
2.7 Blood pressure
Principle
Blood pressure is a measure of the force that blood exerts outwardly against a 
large artery’s wall. Blood moves through the circulatory system because of 
pressure differences between the two sides of the heart and within the capillary 
beds. Blood is at its highest pressure when it leaves the left ventricle during 
contraction of the heart (systole). Blood pressure is at its lowest when the heart 
is in relaxation (diastole).
Method
Blood pressure was measured using an automated sphygmomanometer (Omron 
705CP, Omron).
2.8 Anthropometric measures
Height and weight were measured with a stadiometer and beam balance 
respectively. Body mass index (BMI) was calculated using the formula kg/m . 
Waist and hip were measured using a standard tape measure; waist to hip ratio 
(WHR) was calculated.
2.8.1 Body fat percentage employing Dual-Energy X-ray Absorptiometry
Principle
Dual-energy X-ray absorptiometry (DEXA) scans the body with two distinct 
levels of energy. The attenuation of the tissues for the two different levels of
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radiation depends on its chemical composition and is detected by photocells. 
The instrument’s software generates a 2D picture of the body and can calculate 
bone mineral density, lean mass and adipose tissue fat mass. The instrument is 
limited in the sense that it cannot measure different adipose tissue depots. The 
reproducibility of DEXA is very high at ~ 2% for body composition; however, 
DEXA is based upon the assumption of a steady hydration state of fat free mass 
and therefore error can be considerable (Van Der Ploeg et al, 2003; Blake & 
Fogelman, 1997).
Method
Body fat percentage was measured elsewhere.
2.9 Plasma fatty acid and red blood cell phosphoglyceride composition
Principle
Plasma and RBC fatty acids are characterized by their chain length, the degree of 
unsaturation, configuration and position of the double bonds. The fatty acid 
profiles are determined by gas chromatography of the methyl esters which are 
prepared by extracting and derivatising the fatty acids from the membranes 
respectively.
Method
Plasma and RBC fatty acids were measured elsewhere
2.10 Statistical analysis
Descriptive statistics were undertaken in order to characterise the study 
populations at each time point and assess normality of the data distribution. In 
addition the time and treatment effects of the intervention were statistically 
investigated. Paired t tests were applied for comparisons within an intervention
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Chapter 3 Method Development 
Abstract
Background: A predominance o f sdLDL confers in excess o f  a 3-fold increase in 
CHD risk. The conventional methodfor the detection o f sdLDL, salt density 
gradient ultracentrifugation has been superseded by more rapid techniques.
Hypothesis: Iodixanol has been shown to fractionate the principal lipoproteins, 
this study aims to identify LDL subclasses by a combination o f  iodixanol density 
gradient centrifugation and digital photography.
Methods: LDL subclasses were separated in 3 h from prestained plasma on a 
self-forming density gradient o f iodixanol. LDL subclass profiles were generated 
by digital photography and gel-scan software. Plasma samples from 106 normo- 
and dyslipidaemic individuals were used to optimise the gradient for the 
resolution o f LDL heterogeneity. A subgroup o f 47 LDL profiles were then 
compared with LDL subclasses separated by salt DGUC to validate the 
iodixanol gradient.
Results: The peak density o f  the predominant LDL band correlated significantly 
with the relative abundance (as a percentage) o f  sdLDL as resolved by salt 
DGUC (P <0.001). As shown previously, LDL isolated at a lighter density in 
iodixanol compared with salt gradients. A predominance o f  sdLDL 
corresponded to a peak density on iodixanol o f 1.028 kg/L. This density and the 
area under the LDL profile lying above this density were sensitive and specific 
markers for the prediction o f  a predominance o f sdLDL (P <0.001) and showed 
predictable associations with plasma TAG (r = 0.59; P <0.001) and HDL-C (r = 
0.4; P <0.001).
Conclusions: This simple method for the detection o f sdLDL can differentiate a 
predominance o f  sdLDL, is highly reproducible, and can be used preparatively 
to isolate sdLDL.
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3.1 Identification of LDL subclasses using self-generated gradients of 
iodixanol
3.1.1 Introduction
Intense clinical interest in the measurement of LDL subclasses stems from a 
strong and consistent association between a predominance of small, dense LDL 
and increased CHD risk (Bemeis & Krauss, 2002). This subtype of LDL also 
expresses relatively greater atherogenicity than its larger and lighter counterparts, 
and characterises the dyslipidaemia of an ALP (Austin et al, 1990), as found 
typically in type 2  diabetes and the metabolic syndrome and other situations 
where hypertriacylglycerolaemia exists (Grundy, 1998).
Heterogeneity in LDL was first identified in the late 1940s in the analytical 
ultracentrifuge (Gofman et al, 1949) and later by density gradient
ultracentrifugation (DGUC) and gradient gel electrophoresis (GGE) (Bautovich 
et al, 1973; Krauss & Burke, 1982; Griffin et al, 1990). The combined 
application of these techniques, established that LDL exists in the plasma of all 
individuals as a small number of discrete populations or subclasses. This led to a 
consensus on the classification of LDL subclasses based on hydrated density and 
particle size into three major fractions designated LDL-I to III (peak density 
intervals: 1.022 -1.032 (LDL-I), 1.032 - 1.038 kg/L (LDL-II) and 1.038 - 1.050 
(LDL-III) and a relatively minor fraction LDL-IV (1.050 -  1.063 kg/L) (Krauss 
& Burke, 1982). The overlapping paucidispersity of these fractions within a 
single sample of plasma was classified into LDL subclass patterns or phenotypes, 
consisting of either predominantly large, buoyant LDL-I or II (Pattern A), small, 
dense LDL-III (Pattern B, > 50% LDL-III) or an intermediate pattern of LDL-II 
and III (Pattern /, 40-50% LDL-III).
The techniques most widely used to separate LDL subclasses are preparative 
ultracentrifugation and polyacrylamide gradient gel electrophoresis (GGE). 
Ultracentrifugation separates LDL subclasses on the basis of density by 
sequential ultracentrifugation (Havel et al, 1955), zonal ultracentrifugation 
(Wilcox et al, 1970) or DGUC (Swinkels et al, 1987; Griffin et al, 1990; Krauss
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& Blanche, 1992; Krauss & Burke 1982; Chung et al, 1986) whereas GGE 
isolates the LDL subclasses on the basis of size (Krauss & Blanche, 1992; 
Rainwater, 1998). Each method has advantages and disadvantages. 
Ultracentrifugation methods allow for quantitative analysis; however, the 
procedures are labour intensive and pose a potential disruption of apolipoproteins 
due to high salt concentrations (Na and K bromides are commonly used as 
density gradient media) (Murdoch & Breckenridge, 1994). GGE has the 
advantage of small sample size and is less laborious; however, it is 
predominantly qualitative and commercially available gels are obsolete in the 
UK. Furthermore, apart from the methods of Chung et al (1986), both 
procedures require at least 24 h. Chung et al (1986) drastically reduced 
centrifugation times, separating LDL subclasses in 3.5 h, by employing short 
path-length vertical rotors. Vertical and near vertical rotors were also utilised by 
Graham et al (1996), who developed a method to separate all classes of 
lipoprotein in a single spin of 3 h employing self-generated gradients of 
iodixanol. The advantages of this method is the use of iodixanol as a density 
gradient media, iodixanol is capable of self-generating density gradients, is non­
toxic and iso-osmotic at all densities (Ford et al, 1994); therefore, reducing the 
potential dissociation of apolipoproteins.
Swinkels et al (1987) was one of the first workers to pre-stain plasma, with the 
protein stain coomassie blue, prior to centrifugation. The tubes were observed 
visually and gradient fractions were analysed for lipid and protein. Indeed, most 
of the DGUC methods require the fractionation of the contents of the centrifuge 
tubes and subsequent analysis for lipid and/or protein; alternatively, the gradient 
effluent is analysed continuously using a spectrophotometric autoanalyser 
(Griffin et al, 1990; Chung et al. 1986).
Other more rapid procedures include: 3% polyacrylamide gel electrophoresis 
(Quantimetrix, Lipoprint™) (Hoefner et al, 2001) and nuclear magnetic 
resonance (NMR) (Otvos et al, 1992). However, the Lipoprint procedure is only 
qualitative and the NMR technique requires very expensive equipment.
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This study aims to identify LDL subclasses separated by self-generating 
gradients of iodixanol. The objectives were to develop a procedure that rapidly 
resolves LDL subclasses to identify LDL phenotype; to ensure that the method is 
rapid, reproducible and suitable for high throughput analysis; and to validate the 
method by direct comparison with the established methods of salt DGUC 
(SDGUC) and GGE.
3.1.2 Materials
3.1.2.1 Preparation o f plasma
A total of 260 blood samples were used to establish optimal conditions for the 
density gradient and to examine associations between LDL subclasses with total 
plasma TC, TAG and HDL-C. The samples were taken from normal, healthy 
male and female volunteers who, on the basis of their plasma TAG, would be 
expected to exhibit a range of different LDL subclass profiles. Volunteers 
included members of University staff and subjects recruited for dietary 
intervention studies. Blood was collected by venepuncture from fasted 
volunteers into K2EDTA, and plasma harvested by low speed centrifugation (at 
2000g for 20 min) and stored in 4 ml aliquots at 4°C prior to analysis, which was 
undertaken within 48 h. A subgroup of 47 plasma samples was randomly 
selected for comparison with LDL subclass profiles obtained by SDGUC (Griffin 
et al, 1990).
3.1.3 Methods
3.1.3.1 Development o f  a self-generated iodixanol gradient for the detection o f  
LDL subclasses
The following methodology employed to separate LDL subclasses was based on 
a procedure for the separation of the major lipoprotein classes originally 
described by Graham et al (1996). In addition, the pre-staining of plasma to 
detect LDL subclasses was a modification of the procedure pioneered by 
Swinkels et al (1987).
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In the original procedure (Graham et al, 1996) lipoproteins were separated on a 
two-step gradient consisting of a lower layer of plasma (5 ml) adjusted to 12% 
(w/v) with respect to iodixanol in an 11.2 ml polycarbonate Optiseal™ centrifuge 
tube, and a tris-buffered saline (TBS) solution (5 ml) adjusted to 6% (w/v) 
iodixanol as the upper layer. Finally, a small cushion of 20% (w/v) iodixanol 
was under-layered and an overlay of TBS was added. Tubes were centrifuged in 
a VTi 65.1 rotor for 3 h at 16°C. In the present study, this gradient was adapted 
by reducing the volume of the lower layer to 3 ml and increasing both the 
volume and concentration of the upper layer to 7.9 ml and 9% iodixanol (w/v) 
respectively. Furthermore, a NVT 65 rotor replaced the VTi 65.1. The rationale 
behind these changes is: the upper layer will provide a larger, clearer space for 
LDL subclasses to migrate. An increase in density of the upper layer will 
provide a shallower gradient more suitable to separate LDL subclasses (Graham 
et al, 2000). The iodixanol cushion and TBS overlay were omitted to save time 
and to minimise variability introduced during gradient preparation; and the 
smaller volume of sample would be more suited to large intervention studies. In 
addition, the NVT 65 near vertical rotor will reduce wall adherence of 
chylomicrons as seen with vertical rotors, such as the VTi 65.1 (Graham et al, 
2000); and at the same time maintain the necessary RCF.
Prevaration o f the idoixanol Gradient
Plasma was mixed with Optiprep7^  (iodixanol at 60% (w/v)) and either pre­
stained with Coomassie Blue R 250 (200 jA of 50 g/1 in PBS) or non-stained (200 
/A of PBS added instead of stain solution) to provide a final concentration of 
12% (w/v) with respect to iodixanol (final density = 1.067 kg/L). For example, 
plasma (2.6 ml) was added to Optiprep™ (0.7 ml) and 200 /A of Coomassie Blue 
R 250 or 200 jA of PBS was added to the mixture to provide a working sample of
3.5 ml. In addition, blank tubes were prepared in the same manner; however, the 
bottom layer consisted of 12% (w/v) iodixanol in PBS. For the upper layer, 
OptipreprM was mixed with PBS to provide a 9% (w/v) iodixanol solution (final 
density = 1.050 kg/L). Aliquots of 7.9 ml of this solution were dispensed into
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Beckman Optiseal™ centrifuge tubes (11.2 ml) before carefully under-layering 3 
ml of the working sample with a syringe and cannula. The centrifuge tubes were 
housed in a Beckman NVT 65 near-vertical rotor and centrifuged at 341,000g(av), 
16°C, acceleration program 5, deceleration program 5, for 3 h (at speed) in a 
Beckman Optima XL-100 ultracentrifuge.
Measurement o f gradient density
To determine the density profile of the gradient, a blank gradient was 
fractionated into 0.5 ml fractions by upward displacement. Upward displacement 
was achieved by an homemade device fashioned from an Optiseal™ tube plug 
and a pipette tip, the tip was designed to fit a “flat cap assembly” for the 
Beckman Fraction Recovery System (Figure 3.1a). Tubes were punctured from 
the bottom and Maxidens (John Graham consultancies, Merseyside, UK), an 
hydrophobic, dense (1.9 kg/L), and inert solution, was used to upwardly displace 
the gradient (Figure 3.1b). The outside of the blank tube was marked with 
calibrations to denote the fraction number (Figure 3.5). The refractive index of 
each 0.5 ml fraction was determined by refractometry and converted to density 
using the following formula:
p = rja-b.
Where a = 3.4172, b = 3.5637, r| = refractive index, and p = density. The 
calibrations denoting fraction number on the blank tube were then assigned a 
density value. N.B. to calculate the values of a, and b density solutions of 
iodixanol were prepared and measured using a density meter (Parr Scientific, 
London) and a reffactometer (Abbe Refractometer, Bellingham and Stanley); the 
two values were plotted and a y = mx + c curve was constructed. Both m, and c 
related to a and b respectively in the above equation (Figure 3.2).
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Figure 3.1 Gradient collection. (A) Shows a photograph of a specially designed device (LH 
picture) for gradient collection and clamping on to a Beckman ‘flat cap assembly’ (RH picture). 
(B) Shows, diagrammatically, the process of upward displacement.
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Determination o f a and b
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Figure 3.2 Determination of a & b constants. Both RI and density readings were taken for six 
different concentrations of iodixanol (5 -  30% (w/v) in PBS) and plotted. The y = mx + c 
equation was employed to give values to a and b in the p = qa-b equation
Validation o f  lipoprotein purity
For the analysis o f gradient fractions, a non-stained plasma sample was prepared 
as described above. The tubes were fractionated and a cholesterol profile o f the 
lipoprotein separation was determined by measuring the cholesterol 
concentration on each gradient fraction, as described in Section 2.3.1. The nature 
and position o f the principal lipoprotein classes in the gradient (VLDL, LDL and 
HDL) and Lp(a) was also confirmed by agarose gel electrophoresis (Section 
2.4.2.3).
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Because of the laborious nature of gradient collection and analysis of fractions 
for lipid and/or protein three alternative, experimental, detection methods were 
examined:
Detection method 1. Analysis o f gradient effluent at 400 nm
Both the methods of Griffin et al (1990) and Chung et al (1986) increased 
analytical performance by detecting LDL subclasses by continuous analysis of 
the gradient effluent. Griffin et al (1990) analysed protein by monitoring, 
spectrophotometrically at a wavelength of 280 nm, whereas Chung et al (1986) 
employed the continuous analysis of cholesterol by introducing cholesterol 
reagent into the gradient effluent using sophisticated equipment. Iodixanol, 
however, cannot be measured at 280 nm due to its absorption in the UV 
spectrum, and lack of the necessary equipment prevented continuous analysis of 
cholesterol. Therefore, measuring in the visible region of the spectrum at 400 
nm may provide a profile of the orange/yellow carotenoids, which should 
determine the LDL peak.
To analyse the gradient effluent non-stained tubes were upwardly displaced as 
described above. However, instead of collecting gradient fractions, the gradient 
effluent flowed through a spectrophotometer (Beckman DU 650) and software 
(Beckman DU 600 series software) generated a gradient profile at a wavelength 
of 400 nm.
Detection method 2. Analysis o f a pre-stained gradient at 620 nm
A method to visualise LDL subclasses (Swinkels et al, 1987) employed the use 
of pre-staining plasma with the protein stain Coomassie Blue, before generating a 
discontinuous density gradient. The authors used a low concentration and 
amount of Coomassie Blue; briefly: KBr density adjusted serum (3.4 ml) was 
pre-stained with 20 //I of 15 g/L aqueous solution of Coomassie Brilliant Blue 
R250, before a step-wise over-layering of progressively more buoyant KBr 
density solutions were added into a 14 ml centrifuge tube. However, the pH of 
the serum and density solutions was adjusted to 4.5 -  5.0 with HC1 to facilitate
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staining. The authors visualised the LDL bands, followed by fractionation of the 
stained bands and subsequent lipid analysis. In this study, to avoid the 
potentially deleterious effects of staining plasma at low pH, plasma was pre- 
stained at physiological pH (7.2). Therefore, a greater volume and concentration 
of stain was employed.
The pre-stained gradient was analysed identically to detection method 1; 
however, the wavelength was set at 620 nm. This wavelength was chosen by 
scanning an aqueous solution of Coomassie Brilliant Blue R250 for its optimal 
optical density, using a Beckman DU 650 spectrophotometer.
Detection method 3. Generation o f LDL subclass profiles by digital photography
As an alternative to continuous flow analysis, tubes were digitally photographed 
and analysed using software designed to analyse ID gels (Total-Lab ID gel-scan 
software, Nonlinear Dynamics, Newcastle, UK) with the hypothesis that the 
software will treat the image as a gel.
After centrifugation, OptisealrM tubes containing the stained LDL bands were 
photographed against a vertical light box using a Nikon D1X digital camera set 
at the highest resolution. To standardise the conditions for photographing the 
LDL bands, the tubes were placed into a Beckman centrifuge tube rack at a fixed 
distance from the camera that was held in a predetermined position relative to the 
tube rack by means of a stereo-tactic clamp. Photographs were downloaded to a 
PC and incorporated into Total-Lab ID gel-scan software. The software 
converted the photograph of the stained LDL bands into LDL profiles with an x- 
axis of distance (mm) against a y-axis of pixel intensity. The ‘gel-scan’ software 
was employed to assign Rf values to the primary LDL peak and any secondary 
peaks. These values were then converted to density by cross-reference to a 
photograph of the blank tube calibrated in density intervals. In addition, the 
software was applied to calculate areas under the curve.
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3.1.3.2 Analytical performance
To perform precision tests larger blood samples (100 ml) were taken from 
volunteers to examine the variability of LDL separation on the iodixanol gradient 
by calculating the CV within and between rotors. For within-rotor variability, 
eight replicate LDL profiles were prepared from four individuals, each with a 
different LDL phenotype, in four separate runs. For between-rotor variability, 
eight additional replicate LDL profiles were prepared from two of these 
individuals in two separate runs.
3.1.3.3 Comparison with the NVT 65.2 rotor
The gradient characteristics and LDL separation in the 8 -pocket NVT 65 rotor 
were also compared with the larger 16-pocket NVT 65.2. Although the 
concentration of plasma and stain in the 12% working sample was identical to 
that described for the NVT 65, because the NVT 65.2 rotor uses smaller, 4.9 ml 
tubes, 1.5 ml of working sample was under-layered beneath 3.4 ml of 9% 
iodixanol.
3.1.3.4 Comparison with DGUC and GGE and interpretation o f  LDL subclasses
To validate the iodixanol method, LDL subclasses were co-isolated and 
compared using previous established methodologies. In a subgroup of subjects (n 
= 47), the patterns of LDL heterogeneity produced on iodixanol gradients were 
interpreted by direct comparison with LDL subclasses defined by an established 
DGUC procedure (Griffin et al, 1990) as described in Chapter 2, section 2.4.1.2. 
This allowed determination of the correspondence between density intervals on 
the iodixanol gradient with LDL subclasses I-IV as previously described (Krauss 
& Burke, 1982; Griffin et al, 1990; and Krauss & Blanche, 1992). In addition, to 
establish a diagnostic cut-off density on iodixanol that corresponded to a 
predominance of LDL-III (LDL subclass Pattern B); LDL densities on iodixanol 
were related to the relative percentage abundance of small, dense LDL-III as 
measured by the comparison method.
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In addition, gradient gel electrophoresis (2-16%) was carried out on a small 
number of selected samples (n = 8) to illustrate the relationship between LDL 
subclasses separated by density (iodixanol and SDGUC) and LDL particle size as 
described in section 2.4.2.2.
3.1.3.5 Analysis o f  plasma lipids
Whole plasma was analysed for TC, TAG and HDL-C as described previously 
(Section 2.3).
3.1.3.6 Statistics
The analytical performance of the iodixanol gradient in terms of specificity and 
sensitivity was measured relative to its ability to predict a predominance of 
small, dense LDL-IIIsdguc (> 50%). Correlation and Receiver Operator Plots 
(ROC plots) were produced to evaluate the diagnostic power of the cut-off 
density and area under the LDL profile lying above this cut-off density to 
discriminate a predominance of small, dense LDL. The statistical significance of 
the cut-off density on iodixanol was tested by construction of a 2  x 2  contingency
9 9table and calculation of % . Pearson correlation and product moment (r ) 
coefficients were determined to examine the relationships between LDL density 
and other lipid parameters.
3.2 Results
3.2.1 Gradient characteristics and separation o f  principal lipoproteins
The iodixanol gradient was found to be curvilinear with an extended, shallow 
linear region between fractions 5-21 (Figure 3.3). Cholesterol and agarose gel 
profiles showed two major peaks corresponding to HDL (fractions 2-5; density 
1.109-1.056 kg/L) and LDL (fractions 11-17; density 1.041-1.021 kg/L). 
Evidence of a shoulder at fraction 18-19 indicated traces of lighter lipoproteins of 
intermediate density (IDL density 1.021-1.017 kg/L). The appearance of VLDL
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at the very top of the gradient was noted in fraction 21 (density <1.009 kg/L). 
Lp(a) is a heterogeneous particle with a density lying between that of HDL and 
LDL with a pre-beta migration on agarose gels, above that of VLDL. Traces of 
Lp(a) were detectable in fractions 6-12 (density 1.056-1.036 kg/L).
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Figure 3.3. Distribution of plasma lipoproteins. Full fractionation of a non-stained and blank 
gradient iodixanol gradients respectively using the NVT 65 rotor, the gradient was collected into 
equi-volume fractions (0.5 ml). Cholesterol, density and agarose gel profiles are displayed. The 
cholesterol profile showed two major peaks; the first peak fraction 2-6 was HDL (density range 
1.109-1.056 kg/L) and the second peak fraction 11-17 was LDL (density range 1.041-1.021 
kg/L). There is evidence of a shoulder at fraction 18-19 which is likely to be IDL as the density is 
very low with a range from 1.021-1.017 kg/L. Fraction 21, although not shown on agarose gel, 
was VLDL (p  = 1.009 kg/L). Lp(a) banded between Fraction 6-12 (density range 1.056-1.039 
kg/L) as shown on the agarose gel and a small shoulder was evident within the cholesterol
profile.
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3.2.2 Detection methods
Both detection methods 1 & 2, employing the continuous analysis of gradient 
effluent resulted in ‘noisy’, irreproducible results (results not shown). In 
addition, detection method 1 gave very low absorbance values (< 0 .1).
3.2.3 Reproducibility o f LDL separation on iodixanol gradient
Detection method 3 gave highly reproducible results and was therefore the 
procedure of choice; the following show the results of this method.
Within-rotor variability: the within-rotor CV for LDL peak density for 4 different 
subjects (8  samples/rotor) were 2.1% (p=  1.025 kg/L), 0.6% (p=  1.026 kg/L), 
0.3% (p  = 1.027 kg/L) and 0.4% (p  = 1.034 kg/L). Between-rotor variability: 
there was non-significant variation in Rf values for LDL from two subjects (peak 
densities = 1.027 kg/L and 1.034 kg/L) between rotors (2 x 8 : Rf = 0.377 ± 0.001 
versus 0.377 ± 0.003 - CV = 0.6%; and 0.511 ± 0.001 versus 0.516 ± 0.002) - CV 
= 0.4%. On conversion of Rf values into density, LDL peak densities were 
identical for each sample between rotors.
3.2.4 Comparison between NVT 65 and NVT 65.2 rotors
A comparison between rotors revealed that the larger 16-pocket NVT 65.2 
produced a density gradient that was very similar in shape and its LDL 
separation characteristics to that of the smaller 8 -pocket NVT 65 but in a run 
time of only 2.5 hours. LDL peak densities between these two rotors were highly 
correlated (p < 0.001) with density from the NVT 65.2 requiring a linear addition 
of 0.006 kg/L.
3.2.5 LDL heterogeneity on iodixanol
Shown in Figure 3.4 are the LDL subclasses separated from the pre-stained 
plasma of eight different subjects by iodixanol gradient ultracentrifugation
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(upper panel), and polyacrylamide gradient gel electrophoresis (lower panel). 
The clear variability in LDL banding patterns between and, to a lesser extent, 
within subjects indicated that the iodixanol gradient resolves structural 
heterogeneity in LDL that corresponds to that achieved with electrophoresis. 
Closer examination of the LDL subclass profiles obtained by the two reference 
methods and the iodixanol gradient in Figure 3.5 revealed many similarities and 
some subtle differences in patterns of heterogeneity. Profiles of LDL density and 
particle size as measured by the methods of SDGUC and GGE respectively have 
previously been shown to be closely related (Griffin et al, 1990). Although the 
shape and peak density of the LDL profiles on iodixanol was, in general, 
comparably consistent with the LDL profile of subjects with LDL subclass 
pattern A (PB, RB, GV) and B (LW, BE, PD), the LDL profiles differed to the 
reference methods by showing a greater proportion of buoyant LDL. This was 
more notable in subjects with an intermediate (7) phenotype (JW, RG). From a 
comparison of the peak LDL densities on iodixanol with the density intervals on 
SDGUC it was possible to calculate LDL density intervals on iodixanol that were 
equivalent to that defined for LDL subclasses ‘I’ to TV’ (Table 3.1). As reported 
previously (Graham et al, 1996 & 2000), LDL densities in iodixanol are lighter 
than that defined in salt gradients and the LDL subclasses are distributed over 
narrower density intervals. An LDL density on iodixanol of greater than 1.028 
kg/L was identified as a critical cut-off point that delineated small, dense LDL- 
III from the lighter LDL-II on SDGUC and GGE (note that LDL-IV is a 
relatively minor fraction in terms of its relative abundance and expression in 
normal, healthy individuals).
SDGUC IDGUC
LDL subclass Density (kg/L) Rf Density (kg/L)
LDL-I 1.025-1.034 0.26-0.32 1.022-1.025
LDL-II 1.034-1.044 0.32-0.40 1.025-1.028
LDL-III 1.044-1.060 0.40-0.56 1.028-1.036
LDL-IV >1.060 >0.56 >1.036
Table 3.1 Comparison of LDL densities on iodixanol and salt gradients
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Figure 3.4 Separation of LDL subclasses. LDL subclasses separated from the pre-stained 
plasma of eight subjects by iodixanol DGUC (A) and GGE (B). The middle section shows
density calibration marks.
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Figure 3.5 LDL subclass profiles. Comparison of LDL subclass profiles separated by IDGUC 
with SDGUC and GGE. Shown are the LDL subclass profiles produced from the eight LDL 
subclass separations shown in Fig. 3.2. LDL subclass profiles from the salt DGUC were obtained 
by continuous spectrophotometric monitoring of protein at 280 nm, as described previously 
(Griffin et al, 1990). LDL subclass profiles by iodixanol and GGE were obtained by digital 
photography and Total-labID gel-scan software. LDL subclass patterns are shown in 
parentheses. Hatched areas denote regions corresponding to sdLDL-III.
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3.2.6 Iodixanol density > 1.028 kg/L as a predictor o f small, dense LDL-III 
(Pattern B)
The diagnostic characteristics of a density of > 1.028 kg/L in terms of its power 
to discriminate a predominance of small, dense LDL-III (pattern B) was 
examined. This was achieved by plotting both the distribution of LDL peak 
density and the area under the LDL profile on iodixanol lying above this density 
against the percentage abundance of small, dense LDL and LDL subclass pattern 
as determined by SDGUC (Figure 3.6). Both LDL peak density and area under 
the LDL profiles lying above 1.028 kg/L in iodixanol correlated significantly (P 
< 0.001) with the relative percentage abundance of LDL by SDGUC (Figure 
3.6). The distribution of LDL density showed a bimodal clustering of LDL 
density into predominantly light and dense populations representative of LDL 
subclass patterns A (LDL-III < 40%) and B (LDL-III > 50%) respectively, with 3 
subjects showing an intermediate pattern I. The cut-off density of 1.028 kg/L and 
a relative percentage area under the LDL profile above this density of > 50% 
were both highly significant as predictors of small, dense LDL-III (x = 42.6 and 
42.9 respectively, P < 0.001). An area under the LDL profile of > 51% (density 
> 1.028 kg/L) was shown to give 100% specificity and sensitivity in 
discriminating a predominance of small, dense LDL-III (pattern B). This was 
marginally better as a predictor of small, dense LDL-III than the cut-off density 
of 1.028 kg/L alone (94% sensitivity, 92% specificity) (employing a receiver 
operator plot, Figure 3.7).
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Figure 3.6. sdLDL associations. Relationship between the peak density and area under the LDL 
profile (density > 1.028 kg/L) (IDGUC) and the relative percentage of sdLDL-III (SDGUC). 
Scatter plots show relative percentage of sdLDL-III and LDL subclass patterns in a subgroup of 
47 subjects as a function of the peak density and area under the LDL profile on iodixanol. For 
LDL peak density, r = 0.84 (r2 = 71 %); P < 0.001. For relative % LDL density > 1.028 kg/L, r =
0.88 (r2 = 77%); P <  0.001.
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Figure 3.7 Ability of IDGCU to predict LDL-III. ROC plot showing diagnostic characteristics 
o f an LDL peak density o f > 1.028 kg/L and area under the LDL profile > 1.028 kg/L in 
predicting a predominance o f small, dense LDL-III.
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3.2.7 Relationship with other lipids and HDL
LDL peak density on iodixanol correlated positively with plasma TAG (r = 0.72 
(r2 51%), P < 0.0001) and inversely with HDL-C (r = -0.49, (r2 = 24%) P < 
0.0001) (Table 3.2 & Figure 3.8). The area under the LDL profile (p > 1.028 
kg/L) showed equally significant correlations with plasma TAG and HDL-C 
(data not shown). When grouped according to LDL subclass pattern as 
determined by LDL density intervals on iodixanol, LDL subclass patterns 
consisting of smaller and denser LDL were characterised by raised plasma TAG 
and lower HDL-C but not total plasma cholesterol (Table 3.2). These correlations 
were consistent in sign and order of magnitude to that described using the 
established comparison methods.
Plasma lipids by LDL subclass 
pattern (IDGUC kg/L)_____________
Plasma Pearson P Pattern Pattern Pattern ‘B’
lipid correlation ‘A’ T (> 1.028)
M (< 1.027) (= 1.027) n = 45
n = 203 n = 12
TAG 0.72 < 0 .0 0 0 1 1.26 ± 1.78 ± 2.42 ± 0.85
0.45 0.35
HDL-C -0.49 < 0 .0001 1.31 ± 1.07 ± 1.01 ± 0 .21
0.35 0.21
TC -0.05 0.384 5.88 ± 5.96 ± 5.81 ±0.89
1.06 0.71
Table 3.2 Correlation of LDL peak density with lipids. Plasma lipids o f n =260 were 
correlated with peak density (IDGUC) and grouped according to LDL subclass.
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Figure 3.8 Relationship of LDL peak density and plasma lipids. LDL peak density (IDGUC) 
correlated positively with plasma TAG (r = 0.71 (r2 51%), P < 0.0001) and inversely with HDL-C
(r = -0.49, (r2 = 24%) P 0 .0001).
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3.3 Discussion
A predominance of small, dense LDL is inextricably linked to increased risk of 
CHD and forms a major component of an atherogenic lipoprotein phenotype 
found in the metabolic syndrome and type-II diabetes (Bemeis et al, 2002; 
Grundy et al, 1997). Since the earliest recognition of structural heterogeneity in 
LDL, advances in the clinical measurement of small, dense LDL have been 
hindered by the need for prolonged, labour intensive centrifugation and lack of a 
universally recognised interpretation of LDL subclasses. These problems have, 
in part, been overcome by the introduction of more rapid procedures, including 
tube gel electrophoresis (Quantimetrix Lipoprint™ (Hoefher et al, 2001) and 
nuclear magnetic resonance (Otvos et al, 1992), and wider recognition of a 
definitive classification of LDL subclasses based on the reference methods of 
density gradient centrifugation and GGE (Krauss & Burke 1982; Griffin et al, 
1990; Krauss & Blanche, 1992).
Iodixanol, a self-generating gradient media, revolutionised the separation of 
serum lipoproteins by centrifugation by simplifying the preparation of density 
gradients, dramatically reducing run times and in the process increasing sample 
throughput. The original application of this technique for the separation of the 
principal serum lipoproteins by Graham et al (1996) has been recently adapted 
into a method capable of resolving the predominant LDL subclass (Sawle et al, 
2 0 0 2 ), though in this case the gradient was not developed specifically to resolve 
LDL subclasses or validated against salt DGUC. The present study builds on the 
original work by describing a highly reproducible density gradient that has been 
optimised to resolve LDL subclasses from pre-stained plasma in either 2.5 or 3 h 
(NVT 65.2 or NVT 65, respectively). Further developments over this earlier 
work include the analysis of LDL subclass profiles by digital photography and 
gel scan software, and the characterisation and diagnostic evaluation of LDL 
profiles by direct comparison with a previously established reference method 
(Griffin et al, 1990).
The procedure for the pre-staining of plasma with Coomassie Blue was modified 
from that described by Swinkels et al (1997), with the main reason to avoid
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having to decrease the pH of plasma. A low pH increases staining affinity for 
protein so that the pre-staining of plasma requires less stain. In the iodixanol 
method, a relatively greater amount of stain was required to achieve a similar 
degree of staining but at physiological pH. The detection of stained LDL bands 
by photography effectively removed the need for time consuming spectroscopic 
monitoring or compositional analysis of eluted gradient fractions and at the same 
time eliminated problems associated with lipoprotein recovery. The iodixanol 
gradient was stable and highly reproducible, with respect to LDL peak density, 
within and between runs. Variation in LDL subclass patterns between subjects 
was comparable to that achieved by the comparison methods, making it possible 
to visually recognise LDL patterns on iodixanol consisting of either 
predominantly light, intermediate or dense LDL. The appearance of secondary 
LDL peaks and points of inflexion or shoulders in the LDL profile provided clear 
evidence of single sample heterogeneity. In many cases, this was as markedly 
distinct as that resolved by the reference method of SDGUC; in some cases, 
however, the patterns between the two methods were dissimilar, with iodixanol 
appearing to recover more buoyant LDL.
The high salt concentration and cumulative g-force required by other reference 
methods can produce adverse effects that can include the dissociation of lipids 
and apolipoproteins from the surface of LDL (Murdoch & Breckenridge, 1994). 
This is primarily because high salt concentrations cause water to dissociate from 
the LDL particle, making LDL denser in salt. In contrast, iodixanol is a non­
ionic, iso-osmotic media (Ford et al, 1994) that requires a relatively low 
cumulative g-force (648 x 105 g.min versus 288 x 106 g.min SDGUC) that, in 
addition to preserving the hydration of LDL, is more likely to maintain the 
structural integrity and conformation of the LDL particle. These differences in 
conditions, together with the nature of the detection systems (protein staining 
versus continuous absorbance at 280 nm) and the characteristics of the gradient, 
could explain the lack of concordance in LDL profile between salt and iodixanol 
gradients. Moreover, in preserving the chemical composition and functional 
properties of LDL, and being physiologically inert, iodixanol gradients should be 
favoured for the preparation of unstained LDL for use in metabolic studies, 
although this must be from unstained samples as stain may alter the
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physicochemical properties of LDL. The preparative potential of this gradient 
offers an advantage over electrophoretic (Alabakovska et al, 2002; Rainwater et 
al, 1998; Hoefner et al, 2001) and NMR techniques (Otvos et al, 1992).
LDL subclass pattern B has been associated with increased CHD risk in a host of 
case-control and prospective cohort studies (Austin et al, 1988; Griffin et al, 
1994; Gardner et al, 1996). This abnormal LDL pattern or phenotype is 
determined by the relative proportion of small, dense LDL making it essentially a 
qualitative trait. An absolute increase in the number of small, dense LDL 
particles as measured by the concentration of total serum or preferably LDL apo 
B (hyperapo B) has also been consistently associated with increased CHD risk 
(Kwiterovich et al, 1995). Conversely, LDL subclass pattern B can exist in the 
absence of a raised LDL particle number (Griffin et al, 1999). These 
observations raise the possibility that a qualitative trait, such as LDL subclass 
pattern alone, could be under or over-estimating the risk associated with small, 
dense LDL. Previous methods have attempted to quantify the trait by generating 
an LDL score based on area under the LDL profile and as a function of its Rf 
(Hoefner et al, 2001; Gardner et al, 1996). Alternative measures include making 
compositional measurements of total lipoprotein (LDL) mass or the 
concentration of apo B on eluted LDL fractions (Griffin et al, 1990 & 1994). In 
the present study, LDL was characterised on iodixanol by peak density and the 
relative percentage area under the LDL profile (density > 1.028 kg/L). The 
latter, as an area corresponding to small, dense LDL that should be analogous to 
LDL subclass pattern B as determined by salt DGUC, was only marginally more 
discriminating of small, dense LDL than an LDL peak density of 1.028 kg/L. In 
addition, the absolute pixel volume under the LDL profile was also determined 
as a semi-quantitative estimate of LDL concentration or particle number (data 
not shown). However, this measure failed to provide any additional information 
for predicting a predominance of small, dense LDL, thus confirming, at least in 
this population, the relative superiority of a qualitative description of small, 
dense LDL.
The iodixanol gradient was validated using plasma samples from a range of 
normal, healthy male and female subjects participating in dietary trials at the
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University of Surrey. The resultant distribution of LDL subclasses showed 17% 
to have LDL subclass pattern B. This is a lower frequency of expression for this 
phenotype than would be expected for a mixed population (adult men 30-35%, 
post-menopausal women 15-25% (Bemeis et al, 2002).
At an area under the LDL profile (density > 1.028 kg/L) of 51% there was no 
misclassification of LDL subclass pattern B. The relationship of LDL density on 
iodixanol with plasma TAG and HDL-C were entirely consistent with that found 
in an ALP (Griffin et al, 1990).
In summary, this report presents novel methodology for the rapid separation and 
identification of LDL subclasses using iodixanol gradient density centrifugation 
coupled with digital photography. This method offers the advantages of being 
simple to perform, drastically reduces labour intensity by avoiding the multiple 
over-layering associated with salt gradients, eliminates the need for tube 
fractionation for qualitative analysis, and is highly reproducible. It can also be 
utilised, preparatively, for the isolation of LDL subfractions and, with access to 
the appropriate rotors and equipment, is inexpensive to run. It produces patterns 
of LDL heterogeneity that correspond to that resolved by current methods and 
can be easily adapted to other vertical or near-vertical rotors such as the NVT
65.2 or VTi 65.2. A realistically high throughput for routine clinical analysis can 
be achieved with the analysis of 24 samples in one working day, with the 
Beckman NVT 65, 8 -pocket rotor and 48 samples per day with the NVT 65.2, 
16-pocket rotor. In addition, the method has been validated against our 
established DGUC procedure (Griffin et al, 1990) and has recently been 
published (Appendix I, Davies et al, 2003).
Chapter 4 Quantification of the optimal n-6:n-3 in the UK diet (the OPTILIP 
study)
Abstract
Background: Prospective epidemiological and intervention studies suggest that the 
ratio o f n-6/n-3 fatty acids is associated with risk o f ischaemic heart disease. Dietary 
PUFA o f the n-3 series, linolenate (18:3) but especially the longer chain fatty acids in 
fish oil, eicosapentaenoic and docosahexaenoic acids (LC n-3: 20:5 & 22:6) exert 
favourable effects on blood lipids, lowering plasma TAG and redistributing subfractions 
o f LDL and HDL.
Objectives: The extent to which the above effects can be optimized through dietary 
intakes on n-3 PUFA, and potentially offset by a high intake o f dietary n-6 PUFA 
(linoleic acid), is unknown. The aims o f this study were to determine the optimum ratios 
and chain lengths o f n-6/n-3 fatty acid-rich diets for cardiovascular health by means o f 
measuring surrogate markers o f an ALP and CVD risk. With the hypothesis that the 
diets containing the lower ratios o f n-6/n-3 fatty acids and predominance o f LCP n-3 
will produce the greatest plasma TAG lowering effect.
Design: A randomly controlled, parallel study was designed to determine the optimal 
intake o f dietary n-6/n-3 fatty acids (OPTILIP) with respect to blood lipids and 
lipoproteins. This was achieved by comparing four diets with varying n-6/n-3 ratios 
(3:1-5:1); one containing additional LC n-3 (from fish, notably salmon, and a LC n-3 
enriched spread), two with additional linolenate (from a rapeseed oil based spread and 
cooking oil) and one with a combination o f LC n-3 and linolenate, with a control based 
on a estimated UK diet (10:1). Healthy male (n=141) and postmenopausal females 
(n= lll) aged 45-70 were randomly allocated to one o f the five diets for six months. 
Blood lipids and lipoproteins were measured by commercially available assays in 
pre(12 h fast) and postprandial plasma samples, LDL and HDL subfractions were 
measured by iodixanol density centrifugation and 4-30% gradient gel electrophoresis 
respectively.
Results: The dietary interventions were well accepted and successful in achieving the 
target intake ratios o f n-6/n-3 fatty acids. The major effects were reductions in pre and 
postprandial plasma TAG, sdLDL and increases in the larger, lipid-rich HDL2 
subfraction that was more pronounced in males on the two LCP n-3 (fish-rich) diets.
Conclusions: The two diets enriched with LCP n-3 PUFA produced beneficial changes 
in plasma TAG and lipoprotein subfractions in males consistent with previous 
favourable effects o f fish-oil supplementation on blood lipids. However, overall, the diet 
containing LCP n-3 only was the most effective in modifying these biomarkers o f 
cardiovascular risk.
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4.1 Introduction
4.1.1 Background
While n-3 and n-6 polyunsaturated fatty acids are essential nutrients in the human diet; 
the optimal levels of these fatty acids in, both absolute and relative terms, remain 
uncertain. Estimates of minimum requirements for linoleic acid and n-3 fatty acids are 
in the range of 1 - 2% and 0.2 - 0.5% of energy respectively. The suggested ratio of n- 
6/n-3 should be between 5:1 and 10:1 (Wijendran & Hayes, 2004; Nishida et al, 2004) 
because an excess intake of one series can have adverse effects on the metabolism of the 
other series. In the UK the intake of animal fats and butter has declined and that of oils 
rich in linoleic acid has increased over the past 25 years (Sanders, 2000). As a 
consequence, the intake of linoleic acid has risen from 3 - 4% of the energy intake to 
around 5 - 6% over the past 15 years and the ratio of n-6/n-3 fatty acids in the diet has 
risen from about 3:1 to about 10:1 (Sanders, 2000). The potentially adverse effects 
resulting from the consumption of a high ratio include: effects on the supply of DHA for 
development of the nervous system; altered immune function and a heightened 
inflammatory state and risk of CVD. Prospective epidemiological studies have indicated 
that intakes of n-3 fatty acids are associated with decreased risk of CVD (Hu et al, 
2002). This decreased risk may be a function of lowering both fasting and post-prandial 
plasma TAG, the reduction in plasma TAG has been discussed in detail in Section 1.3.4.
1.4.1.2 PUFA and postprandial lipaemia
Postprandial lipaemia has been shown to be reduced by the ingestion of n-3 fatty acids 
through either the consumption of an oily fish-rich diet or via the supplementation with 
n-3 LCP (Weber & Raederstoff, 2000). The mechanism proposed is through the reduced 
production of hepatic VLDL, as is the case for fasting plasma TAG. There are strong 
correlations with fasting and postprandial TAG (Lairon, 1996) and recent studies have 
investigated the effects of the ratio of n-6/n-3 fatty acids (Brady et al, 2004) and the dose 
response of n-3 fatty acids on postrprandial lipaemia (Finnegan et al, 2003). Brady et al
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(2004) found that postprandial lipaemia was reduced in both high and moderate n-6 fatty 
acid groups who were supplemented with equal amounts of n-3 LCP; there were also 
concomitant reductions in postprandial apoB48 -  a marker of CM metabolism. In 
contrast, Finnegan et al (2003) found there were insignificant differences in postprandial 
lipaemia after 6 months of n-3 LCP or n-3 SCP (short chain polyunsaturates) from 
baseline (this was regardless of the dose of n-3 fatty acid given). However, this 
intervention only showed small reductions in fasting plasma TAG.
It has been proposed that insulin plays a role in postprandial lipaemia and n-3 LCP have 
an insulin sensitising effect in animal models (Storlien et al, 2000). In the postprandial 
state, insulin has an anti-lipolytic effect on hormone sensitive lipase (HSL) and increases 
LPL activity in adipose tissue; whereas in IR, adipose tissue fails to capture NEFA 
released by adipose tissue LPL (Frayn, 1998), thus resulting in increased availability of 
NEFA for VLDL production and hence higher plasma TAG levels. Higher VLDL-TAG 
levels, especially the larger more buoyant subtype, can lead to increased lipid exchange 
and hydrolysis with LDL and HDL via CETP, LPL and HL activity respectively 
(Packard et al, 2000). This results in a more CE rich TAG poor VLDL particle (remnant 
VLDL) which is highly atherogenic (Segrest, 2002); furthermore, the now TAG rich 
LDL and HDL undergo HL activity which results in smaller, denser LDL and HDL 
particles (Zambon et al, 2003). Therefore, with increased insulin sensitivity the 
metabolic fate of NEFA would be directed to uptake and oxidation, rather than increased 
availability to the liver. Isoenergetic, high PUFA diets and higher levels of serum lipid 
PUFA esters are associated with increased insulin sensitivity (Vessby, 2000). It would 
be reasonable to speculate from this that high PUFA diets that are rich in n-3 fatty acid 
intakes would result in heightened insulin sensitivity. However, few studies have shown 
an insulin sensitising effect of n-3 LCP in healthy normolipaemic subjects; neither 
Brady et al (2004) nor Finnegan et al (2003) showed an increase in insulin sensitivity 
even though fasting plasma TAG and postprandial lipaemia were improved. Other 
studies, reviewed by Vessby (2000), also failed to show any change in insulin sensitivity 
(measured by the eugylycaemic clamp or minimal model).
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1.4.1.3 Proposed mechanisms o f n-3 LCP lowering ofplasma TAG
The precise mechanism by which PUFA and especially n-3 LCP attenuate VLDL 
production, whether in the fasting or postprandial state has yet to be elucidated. Possible 
mechanisms that may contribute to the attenuation of VLDL production are listed in 
Table 4.1. It has been suggested that microsomal transfer protein (MTP) may be down 
regulated and therefore lipid transfer and apoB assembly may be reduced (Wang et al, 
1994). Other mechanisms include the availability of NEFA for VLDL production being 
redirected to other physiological functions such as /2-oxidation (Jump, 2004); 
alternatively, the re-esterification of NEFA to fatty acyl-CoA thioesters by acyl- 
coenzyme A synthetase (ACS) and the final stage of TAG synthesis by diacylglycerol 
acyltransferase (DGAT) may be affected through transcriptional regulation (Jump, 2002; 
Botham et al, 2003). Furthermore, PPARor has been shown to down regulate ApoCIII; 
an inhibitor of LPL and therefore n-3 fatty acid induction of PPARcr may improve LPL- 
mediated lipolysis (Lee et al, 2003).
Mechanism Comment Source
MTP Lipid transfer to developing Berriot-Varoqueaux et al, 2000;
lipoproteins, ApoB assembly Wang et al, 1994; Botham, 2003
Availability of FAs PPARcr involved with p- Jump, 2004
oxidation and FA uptake
ACS re-esterification of NEFA to fatty Jump, 2002
acyl-CoA thioesters
DGAT synthesis o f TAG Botham et al, 2003
Body fat re-distribution Body fat distribution can alter Frayn, 2000
lipid metabolism
Lipolysis PPARcr can down regulate Lee et al, 2003
ApoCIII
Table 4.1 Possible mechanisms for the attenuation of VLDL production. Various mechanisms have 
been implicated on how n-3 fatty acids may attenuate VLDL production.
Since n-3 fatty acids and indeed the n-6 family are promoters of gene transcription, it 
would be intuitive to relate gene polymorphisms involved in lipid metabolism to the 
proposed mechanisms. It may be that polymorphisms in the genes and hence proteins 
involved in lipid metabolism might provide clues as to how certain subjects or groups 
respond differently to the quantity and quality of dietary PUFAs. Numerous
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polymorphisms may underlie the structural and metabolic heterogeneity in plasma 
lipoproteins and their investigation may help explain the complexities in the aetiology of 
dyslipidaemia and CVD. However, few studies have investigated polymorphisms and 
the response to n-3 fatty acids with regards to the symptoms of an ALP. Two recent 
studies have reported differential effects of fish-oil on blood lipids and LPL activity in 
different apo E genotypes in a male ALP population (Khan et al, 2002; Minihane et al, 
2000). The results showed that subjects with the s4 allele increased the activity of LPL 
compared to none s4 allele carriers (Khan et al, 2002) and the response to fish-oil with 
regards to lipids showed both apo E2 and E4 carriers achieved reductions in fasting and 
postprandial TAG concentrations, with apoE2 favouring the postprandial and HDL-C 
response and apoE4 favouring the fasting plasma TAG and LDL III response. In 
addition, ApoE4 carriers also showed increases in plasma TC and LDL-C with a 
decrease in HDL-C (Minihane et al, 2000).
4.1.2 Plasma and membrane fatty acids
The fatty acid composition of cellular membranes is an important aspect of the function 
of cells and tissues (Burdge et al, 2002). The relative proportions of n-6 and n-3 fatty 
acids are implicated in various physiological functions including that of: the retina, 
CNS, cardiovascular, skeletal muscle, liver, immune, and multiple cell types (Jump, 
2004) and therefore an increase in one series over another may result in disruption of 
physiological function. Dietary fatty acid compliance can be monitored by analysing 
plasma phospholipids and RBC phosphoglycerides as short and medium term 
biomarkers of dietary compliance respectively (Arab & Akbar, 2002). The fatty acid 
profiles of both plasma and RBC membranes should reflect the dietary consumption, 
providing subjects are stable in body mass and in good health (Arab & Akbar, 2002). 
Studies on dietary n-3 intakes have shown that plasma fatty acids reflect the dietary 
intake (Finnegan et al, 2003) and can be converted to LCP (Burdge et al, 2003). The 
same principle applies to RBC fatty acids, which reflect longer term compliance (months 
rather than days) (Vidgren et al, 1997; Tynan et al, 1995).
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4.2 Aims and objectives
Dietary PUFA of the n-3 series especially the longer chain fatty acids in fish oil, EPA 
and DHA exert favourable effects on markers of CVD, and actually reverse the lipid 
abnormalities found commonly in insulin resistant states known collectively as an ALP 
(Griffin, 2001). The extent to which dietary n-6 PUFA and ALNA may modulate and/or 
contribute to these effects is unknown; this is the first study to investigate the ratio of n- 
6/n-3 fatty acids in a middle aged to elderly UK population with respect to ALP markers 
in relation to CVD. The objectives were to design suitable food based diets, with no 
supplementation, that varied in n-6/n-3 ratio and in the composition of n-3 fatty acids 
(linolenic acid and n-3 LCP) and assess the effects of the diets by means of measuring 
surrogate markers of an ALP and CVD.
In order to achieve this objective, four diets with n-6/n-3 fatty acid ratios ranging from 3 
to 5:1 were designed to be compared with the estimated current UK diet (ratio 10:1) in a 
free-living population.
4.3 Materials & Methods
4.3.1 Subjects
Male and postmenopausal female subjects aged 45-70 years were recruited from general 
practices in Camberley, Surrey and North Mymms, Hertfordshire and from among the 
staff of King’s College London and its associated hospitals. The subjects were healthy 
and exclusion criteria included the following: body mass index < 2 0  and > 3 5  kg/m2; 
fasting serum TC > 8 mmol/1 and TAGs > 6.0 mmol/1; abnormal liver function and 
haematology; clinical history of cholestatic liver disease, pancreatitis, diabetes mellitus, 
myocardial infarction, or peptic ulcer; current use of anticoagulants, or known 
hypersensitivity to heparin. Screening tests were performed to ensure subjects fitted the 
above criteria before recruitment to the intervention.
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The subjects were provided with the required foods for the dietary intervention period at 
regular intervals. The study protocol was reviewed and approved by the King’s College 
London, East and North Hertfordshire, and, the North West Surrey local Human 
Research Ethics Committees, and all participants gave written, informed consent.
4.3.2 Study Design
The study was designed as a 6 month randomised parallel controlled dietary intervention 
conducted in a free-living population (n = 252). Subjects were studied in 3 cohorts that 
did not overlap; each cohort was completed over approximately the same seasonal 
period. Four dietary treatments were designed versus a control; four of the treatments 
were designed with a decreased n-6/n-S ratio in comparison with the national average of 
10:1 (Sanders, 2000) (control group). Of the four treatment diets two were increased in 
LCP and two were increased linolenate, in short-hand: LCP 3:1, ALNA 3:1, LCP 3:1 & 
ALNA 3:1, and ALNA 5:1 (Table 4.2 describes the proposed diets in detail).
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Description Total
Fat
SFA MUFA PUFA 18:2n-
6
18:3n-
3
n-3
LCP
n-3 n-6:n-
3
Control 39 14 17 6 5.45 0.50 0.05 0.55 10
LCP 3:1 39 14 17 6 4.6 0.75 0.65 1.40 3
ALNA 3:1 39 14 17 6 4.6 1.35 0.05 1.40 3
LCP& 39 14 17 6 4.6 1.10 0.30 1.40 3
ALNA 3:1 
ALNA 5:1 39 14 17 6 5.0 0.95 0.05 1.00 5
Table 4.2 Dietary design. Shows the composition, in percentage of total energy intake, o f the proposed 
treatment and control diets with regards to the composition of dietary fat.
The dietary intervention was designed to represent the various alternative ways of 
altering the ratio in the UK diet without resorting to the use of supplements or oils such 
as flaxseed oil that are not widely consumed. The interventions to increase the intake of 
linolenic acid involved altering the proportion of linolenic acid in spreads and cooking 
oils by using rapeseed oil based products. The increased intake of n-3 LCP was 
achieved by encouraging the consumption of oily fish, particularly salmon, to provide 
0.9 g n-3 LCP/d and by using a spread containing n-3 LCP to provide an additional 0.4 g 
n-3 LCP/d. The impact of the dietary intervention was based on the analysis of nutrient 
intake data for men and women aged 45 - 65 years from the Dietary and Nutritional 
Survey of British Adults (Gregory et al, 1990). It was estimated that approximately 35 g 
of fat intake (approximately 30% of the total fat intake) could be manipulated. An 
assumption was made that subjects would consume 2 0  g of fat as yellow fat spread 
providing 16 g fat/d and 16 g as cooking oil per day. The intervention was a 
combination of one of five margarines containing 80 g fat/1 0 0  g spread (2 0  g spread/d), 
either low-erucic acid rapeseed oil or high oleic sunflower oil (16 g oil/d), and tinned 
fish, fish pate and other fish products. During the study all subjects maintained their 
habitual diets except that a proportion of the dietary fat was replaced with the vegetable 
oils and spreads that were provided, and 2 portions a week of the allocated fish. The 
margarines were manufactured and supplied by Unilever Research (Vlaardingen, 
Netherlands). The spreads were designed to keep the intake of saturated and
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monounsaturated fatty acids similar across all dietary groups. High oleic sunflower and 
rapeseed oils were purchased in a single batch from Anglia Oils, Hull.
Subjects allocated to an increased intake of n-3 LCP were provided with tinned salmon 
and salmon pate and asked to consume two portions of oily fish per week. To act as an 
incentive, the subjects were reimbursed for the cost of any oily fish consumed. The 
groups not receiving additional n-3 LCP were provided with 2 cans of tuna tinned in 
either high linoleic sunflower oil or olive oil.
4.3.3 Compliance
Estimates of dietary intake were made by 7-day weighed food intake at the start and end 
of the study. During the pre-experimental period the subjects were issued with scales 
and instructed on how to weigh and record all food and drink consumed in a food diary 
for 7-days, as a measurement of their nutrient intake at baseline. The records did not 
have to be on consecutive days, but had to include both week and weekend days to be 
representative of habitual eating patterns. On completion of the diary, an investigator 
checked the food record with each volunteer to clarify the information was 
comprehensible. Another 7-day weighed food intake diary was completed after 6 
months of the intervention.
In addition, estimates of dietary intake by 3-day duplicate diet collections were made at 
3 months in a subset of subjects. Twelve subjects in each dietary group were requested 
to make 3-day diet collections. Subjects were requested to collect duplicates of all foods 
consumed and to make a record of fluids consumed. A total of 58 subjects made 
satisfactory food collections. Out of these 58 subjects, 55 subjects provided satisfactory 
weighed food intake records. Dietary intakes were calculated from the UK Nutrient 
Data Base (The Stationery Office, Norwich) and using the US Food Composition 
database (SRI4). The nutrient intake was calculated using a specially written Visual 
Basic routine in Microsoft Excel. The duplicate diets were analysed elsewhere by
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chemical analyses. Plasma esterified fatty acids and RBC phosphoglyceride fatty acids 
were measured elsewhere, as markers of short and long-term compliance respectively.
4.3.3 Biochemical analysis
Methodologies for the analysis of lipids, lipoproteins, lipases, insulin and glucose are 
described in Chapter 2 (Section 2.2 -  2.6).
4.3.4 Postprandial protocol
The evening before each study day subjects consumed a standardised low fat meal and 
then fasted for 12 h. The following morning a baseline blood sample was taken (see 
Section 2.2) before the consumption of a standardised high fat meal, consisting of: 50 g 
fat, 17 g of protein, and 75 g of CHO in the form of a muffin and milkshake. Blood 
samples were taken at 2, 3, and 6 h for the analysis of plasma TAG, NEFA, insulin, and 
post-heparin lipases. Subjects were provided with a standardised low-fat meal following 
the 3 h blood sample, consisting of a low fat yogurt and a piece of fruit.
4.3.5 Anthropometric and hloodpressure measurements
Blood pressure and anthropometric measures were taken as described in Section 2.7 and 
2 .8  respectively.
4.4.6 Statistics
Statistics were performed as described in Section 2.10.
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4.4 Results
4.4.1 Baseline characteristics
The baseline characteristics of the subjects are shown in Table 4.3, the mean overall age 
was 60.2 y and this did not differ between allocated dietary groups or between males and 
females. Body mass for males and females was 82.5 and 68.4 Kg respectively; there 
were no significant differences in body mass between dietary groups at baseline or 
follow-up. This was also true for BMI, waist, WHR, and systolic and diastolic blood 
pressure. There were, however, within diet differences for weight, BMI, WHR and 
systolic and diastolic blood pressure. Subjects showed a small increase in body mass on 
all diets, with a concomitant increase in BMI and WHR; yet there were no changes in 
waist measurements, and hip girth actually decreased (P < 0.05). Since body mass 
increased on all diets this should have influenced the control and test diets equally and 
therefore had no overall impact on markers of risk. Systolic and diastolic blood 
pressures were reduced on all diets; however, the change in systolic and diastolic blood 
pressure was not significantly different between groups and therefore the same principle 
that applied to body mass is applicable here.
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Control LCP ALNA LCP/ALNA ALNA
3:1 3:1 3:1 5:1
Female Male Female Male Female Male Female Male Female Male
(n=14) (n=30) (n=26) (n=35) (n=21) (n=32) (n=27) (n=24) (n=18) (n=31)
Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean
Age (y) 57.8 ± 57.7 ± 61.3 ± 60.3 ± 58.8 ± 61.2 ± 60.7 ± 1 61.2 ± 61.8 ± 60.6 ±
1.3 1.4 1 1.1 1.4 1.33 1.2 1.3 1.2
Mass 70.9 ± 82.3 ± 66.7 ± 83.74 68.4 ± 86.2 ± 69.0 ±1.8 78.5 ± 68.0 ± 80.7 ±
(kg) 2.8 1.9 1.7 ±1.8 2.3 2.1 2.3 2.3 2.2
BMI 26.6 ± 26.4 ± 24.6 ± 26.8 ± 25.3 ± 27.2 ± 26.1 ±0 .6 26.0 ± 26.7 ± 26.6 ±
(kg/m2) 0.8 0.5 0.7 0.5 0.8 0.6 0.7 0.8 0.6
WHR 0.82 ± 0.93 ± 0.80 ± 0.93 ± 0.81 ± 0.92 ± 0.79 ±0.01 0.91 ± 0.80 ± 0.92 ±
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
SBP 128 ± 139 ± 131 ± 134 ± 126 ± 146 ± 130 ± 4 .0 134 ± 132 ± 142 ±
(mmHg) 4.7 4.6 3.9 3.09 5.1 4.1 4.2 4.2 4.1
DBP 74 ±2.0 84 ± 77 ± 82.3 74 ± 87 ± 75 ± 2.6 80 ± 76 ± 82 ±
(mmHg) 2.5 2.3 ±1.62 2.8 2.0 1.9 2.5 2.1
Table 4.3 Subject baseline characteristics in each dietary group.
4.4.2 Dietary information
With regards to basic dietary information, the only significant differences between diets 
at baseline was a higher percentage of total fat energy in the control diet compared to 
LCP/ALNA 3:1 (P < 0.05) and in percentage energy as SFA with the control diet versus 
LCP 3:1 and ALNA 3:1 respectively (P < 0.05 for both) (Table 4.4). Therefore, both 
percentage energy from fat and SFA at follow up were analysed using ANCOVA to 
correct for baseline differences. No significant differences in corrected end point values 
for total and saturated fat were observed.
There were significant differences between the control diet versus all the treatment diets 
when comparing percentage energy from PUFA (Table 4.4) after 6 months with no
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significant differences between the treatment diets. However, the original designs of 
the diets, with regards to percentage energy from fats, are described in Table 4.2, while 
Table 4.5 compares the proposed and achieved data for each diet. All the diets were 
equal in total fat with no significant differences between diets, the proposed total fat 
percentage of energy was 39%; however, the actual value averaged 36.4%. As with total 
fat, both SFA and MUFA did not reach the proposed values of 14 and 17% respectively 
(actual results were 11.6 and 14.3% respectively). With respect to total PUFA, the 
control diet resulted in a significant increase when compared to the treatment diets and 
this increase was ~ 2 % more than the proposed value of 6%; the treatment diets 
approximated the proposed value of 6 % with an average of 6.7%. When comparing the 
ratio of n-6/n-S fatty acids the achieved results were similar to the proposed values; 
although, ALNA 3:1 did not reach the ratio of 3:1 and LCP 3:1 and LCP/ALNA 3:1 
were lower than 3:1. Both the control diet and ALNA 5:1 were higher than the proposed 
ratios of 10:1 and 5:1 respectively (Table 4.5).
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% Energy
Dietary Total SFA MUFA PUFA 18:2n-6 18:3n-3 n-3 LCP n-3 n-6:n-3
treatment fat
Control
Proposed 39 14 17 6 5.45 0.50 0.05 0.55 10
Achieved 37 ± 12 ± 14 ± 3 8 ± 2 7 ± 2 0.5 ± 0.2 0.17 ±0.5 0.67 ± 11.5 ±
6 3 0.23 4.1
LCP 3:1
Proposed 39 14 17 6 4.6 0.75 0.65 1.40 3
Achieved 36 ± 11 ± 15 ± 3 6 ± 2 4.4 ± 0.95 ± 0.5 0.67 ± 1.63 ± 2.9 ±
7 3 1.8 0.32 0.69 0.94
ALNA 3:1
Proposed 39 14 17 6 4.6 1.35 0.05 1.40 3
Achieved 36 ± 12 ± 14 ± 2 7 ± 5.1 ± 1.06 ± 0.16 ± 1.22 ± 4.4 ±1.0
5 3 1.5 1.2 0.34 0.17 0.37
LCP/ALNA
3 il
Proposed 39 14 17 6 4.6 1.10 0.30 1.40 3
Achieved 35 ± 11± 14 ±3 7 1.5 4.2 ± 1 1.16 ± 0.69 ± 1.85 ±0.5 2.4 ±
5 2 0.37 0.32 0.52
ALNA 5:1
Proposed 39 14 17 6 5.0 0.95 0.05 1.00 5
Achieved 37 ± 12 ± 15 ± 3 7 ± 2 4.6 ± 0.74 ± 0.5 0.19 ±0.2 0.93 ± 6.6 ±3.4
6 3 1.6 0.46
Table 4.5 Dietary fatty acids intakes. Shows the proposed intake o f dietary fatty acids and the actual
intakes achieved.
With regards to n-6 and n-3 dietary fatty acids, there were no differences in the 
proportions of energy from LA, ALNA, EPA and DHA. Figure 4.1 depicts the 
dietary percentages of LA, ALNA, EPA, and DHA for each diet, with statistical 
information in the legend. The major outcomes for the dietary fatty acids were greater 
proportions of energy from LA in the control diet, ALNA 3:1 and ALNA 5:1 with the 
control achieving the highest levels as designed. ALNA was raised in the LCP 3:1, 
ALNA 3:1, and LCP/ALNA 3:1 diets to a greater degree than the control and ALNA 
5:1 with the LCP/ALNA 3:1 achieving the highest percentage of ALNA. Both EPA 
were only elevated in the LCP 3:1 and LCP/ALNA 3:1 and to approximately the same 
extent for each dietary group.
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1,2,3,4,6,7 _1,2,3,4,7,8
m m
1,3,5,7,8 1,3,5,7,8
po .6
e f l i i  El .  ££ Q 0.0
Baseline
Endpoint
Baseline
Endpoint
Dietary group
Figure 4.1 Dietary intakes of n-6 and n-3 fatty acids. 1. Significant difference between groups. 2. 
Significant difference between control and treatment groups. 3. Significant difference between control 
vs. LCP 3:1 & LCP/ALNA 3:1.4. Significant difference between control vs. ALNA 3:1 & ALNA 5:1.
5. Significant difference between LCP 3:1 & LCP/ALNA 3:1 vs. ALNA 3:1 & ALNA 5:1. 6. 
Significant difference between ALNA 3:1 vs. ALNA 5:1.7. Significant difference between ALNA 5:1 
vs. LCP/ALNA 3:1. 8. Significant difference between ALNA 5:1 vs. LCP 3:1. P < 0.05.
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Out of the 60 subjects requested to make duplicate diet collections, 53 subjects 
successfully made the collection with an additional satisfactory weighed food intake. 
Table 4.6 compares the estimates of intakes from 7-day weighed intakes with 
estimates from chemical analyses from 3-day duplicate diet collections. Estimates for 
intakes of energy, protein and particularly carbohydrate were lower compared with 
the chemical analysis. However, estimates for total fat intake were very similar to 
those obtained by calculation. Estimates for intakes of EPA and DHA tended to be 
greater in the analysed diets than those derived from the dietary calculations. 
Estimates for the intakes of LA, ALNA, EPA and DHA were significantly correlated 
between both methods. These estimates suggested that n-3 LCP fatty acids account for 
about 0.7% of the dietary fatty acids and that ALNA accounts for 2.2% in diets not 
containing additional n-3 fatty acids.
4.4.3 Plasma and RBC fatty Acids
As dietary assessment has limitations in terms of compliance to dietary interventions 
(Arab & Akbar, 2002) both RBC membrane and plasma fatty acids were analysed as 
long and short term markers of compliance respectively. Both RBC and plasma fatty 
acids were measured at baseline, 3, and 6 months. With regards to plasma and RBC 
fatty acids: OLO, LA, ALNA, AA, EPA, DP A, DHA, total n-6, total n-3, and the ratio 
of n-6/n-3 fatty acids there were significant within subject effects of time, the 
interaction of time and diet and significant between subject effects of diet. The results 
of the major fatty acids of interest are shown in Figures 4.2 & 4.3 and a more 
comprehensive analysis of fatty acids is shown in Appendix II. The main outcomes 
were increases in n-3 fatty acids and decreases in n-6 fatty acids in LCP 3:1 and 
LCP/ALNA 3:1; therefore, producing a decrease in the ratio of n-6/n-3 fatty acids 
within these dietary groups. The changes were mainly due to significant increases in 
plasma EPA and DHA (Figure 4.2), which were replacing LA, AA and DHLA.
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RBC EPAA,b,c,d,e
A,b,c,d,e Plasma EPA
Baseline
Mid-point
End-point
no
3
RBC DHAA,b,c,d2
-5 2
A,b,c,d,e Plasma DHA
T l 1
no
3
r
n”0
Dietary group.
Figure 4.2 Plasma and RBC essential fatty acids
Values are means ± SEM .a Significant effect o f time (p < 0.01);b significant effect o f the interaction of 
time & d ie t;c significant effect of diet between groups;d significant differences between diets LCP 3:1 
& LCP/ALNA 3:1 vs. diets ALNA 3:1 & ALNA 5 :1 ;esignificant differences from the control diet. P < 
0.001 , 2P < 0.05. The major differences in both RBC and plasma fatty acids were increases in EPA &
DHA in the n-3 LCP diets.
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LA AA DHLA EPA DHA
Plasm a F a tty  A cid
DHLA
LCP/ALNA 3:1
Figure 4.3 Changes in plasma and RBC membrane fatty acids. Both the n-3 LCP diets (LCP 3 :1 & 
LCP/ALNA 3:1) showed the highest changes in plasma (A) and RBC (B) EPA and DHA after 6 mo of
the intervention.
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4.4.4 Associations with dietary, RBC and plasma fatty acids
There was a strong correlation between the ratio o f n-6/n-3 fatty acids derived from 
RBC compared to plasma in the total group (n = 252, R = 0.51, P < 0.0005) (Figure 
4.4); however, when diets were analysed separately ALNA 3:1 and ALNA 5:1 
showed weak insignificant correlations (R are shown in the legend). With regards to 
the ratio o f n-6/n-3 fatty acids derived from dietary information there were strong 
correlations with both RBC and plasma ratios o f n-6/n-3 fatty acids (R = 0.39, P < 
0.005 & R = 0.48, P < 0.0005 respectively) (Figure 4.5).
a
16
14
10
Dietary group 
ALNA 5:1
R2 = 0.04
□  LCP/ALNA 3:1
Total Population 
R2 = 0.25
n. D
R2 = 0.16
□ ALNA 3:1
R2 =  0.01
□ LCP 3:1
R2 =  0.27
□ Control
R2 = 0.18
RBC n-6:n-3
Figure 4.4 Association between RBC and plasma fatty acid n-6/n-3 ratio. As a total group (n = 252) there 
were strong correlations with plasma and RBC n-6/n-3 fatty acid ratio; however, diets 3 & 5 did not show
significance when analysed separately.
Diet No.
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Figure 4.5 Association between dietary ratio of n-6/n-3 fatty acids and both RBC & plasma n-6:n-
3. Strong and significant correlations were observed between dietary and RBC fatty acids and dietary 
and plasma n-6/n-3 fatty acid ratios when all subjects (n = 252) were analysed. The correlations within
dietary groups were weaker and insignificant.
110
Appendix II shows correlations with individual fatty acids for dietary fatty acids 
versus RBC fatty acids, dietary fatty acids versus plasma fatty acids, and RBC fatty 
acids versus plasma fatty acids. The strongest correlations were with % dietary 
energy EPA correlating positively with RBC (EPA, DHA and total n-3 fatty acids) 
and negatively with RBC (AA, ADR and total n-6 fatty acids).
4.4.5 Fasting Lipids
When data was analysed as a whole group (M & F), the differences between diets at 
end-point were in plasma TAG and the ratio of TAG/HDL-C (P = 0.02 and 0.03 
respectively); post-hoc tests revealed these differences resulted from a reduction in 
plasma TAG and TAG:HDL-C in LCP/ALNA 3:1 compared to ALNA 3:1 (Figure 
4.6, Table 4.7). There were significant improvements in markers of an ALP with LCP 
3:1 and LCP/ALNA 3:1 (results shown in Table 4.7 and in Figures 4.6 -  4.8). Plasma 
TAG decreased by 9.1% and 6.3% on LCP 3:1 and LCP/ALNA 3:1 respectively (p < 
0.01  and < 0.05 respectively), with concomitant reductions in sdLDL as %AUCB 
(6.3% and 4.7% respectively, P < 0.05 for both). Furthermore, there were significant 
increases in HDL2 (%AUC) with LCP/ALNA 3:1 showing the largest increase with 
14.4% (p < 0.01) whereas LCP 3:1 showed a lesser increase (5.6%, p < 0.01). Total 
HDL-C did not show any significant changes in these two diets and there were no 
significant differences for any of the lipid parameters within either ALNA dietary 
groups.
m
m
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TAG
TAGHDL-C
Dietary group
Figure 4.6 Between diet effect for plasma TAG and TAG:HDL-C. Analysis o f plasma TAG and 
the ratio of TAG:HDL-C at end-point in the total. * = P < 0.05.
C
on
tr
ol
 (
41
) 
L
C
P3
:1
(6
1)
 
A
L
N
A
3:
1(
52
) 
LC
P/
AL
NA
 
3:1
 
(5
1)
 
AL
NA
 
5:1
 
(4
9)
 
pA
N
O
V
A
 
M
ea
n 
SD 
p 
TT
 
M
ea
n 
SI
) 
p 
TT
 
M
ea
n 
SD 
p 
TT
 
M
ea
n 
SD 
p 
TT
 
M
ea
n 
SD 
p 
T
T g"5toO
ooPQ
E-
3 -S
2 ‘gtoO .3
T3
4)
£
O
- C
5j13 
■5 
_c
IE •—
•| ^   ^ cu
c  —1cd c/5 O cd
r3 >-
= S_toO^
’35 ^
E-H d
e
cd 
= c<- 
o  oC/5
«  <5 ~  ^  3  t- 
C .  cd
5 1
55 3
O .£  
«  2  
£  g
s  IS1
— 3a. 1/5 
- r  .£
= icd ^>_ C/5
o  cCM 4>
4/-3 <D>ot-i
Q-
E
= 80 22o £ u a  9- 3 3 «
"O >Q <  C5* iS CQ
i *c/5 y
^  c  -SQ o — 1 -o W ^ c/)’O ^  CC 5/5 <3 Q2d) ^a-
§ j H i■A 3 ^ -r- ? = i? S
4)
W)
C
3
£
U
r'
■^t
_a/
«
E-
II ALNA 5:1
LCP/ALNA 3:1
ALNA 3:1
LCP 3:1
Control
(jui/8) Xjisuap q a i  V C8w
5
ALNA 5:1
*  _  LCP/ALNA 3:1
ALNA 3:1
LCP 3:1
Control
X)
Cd
JQ_Ja>
goc<l>
-a
c
cdo
£’2
>/■>
o
cd ©
£  V 
>> a.«- a> •——  rr\
<u -a 
OD a> 
S >*  >r
C • a> —•o ^
id <
5 2
■iu52 —1
m
<
-J
<cuU-1
H3 tiv*v
114
UIJQ
X
6
<H
o
£
£
O<H
<N
Q
Xn®
1.60
1.50
.40
1.30
1.20
.10
.00
.90
.80
1.70
1.60
1.50
1.40
1.30
1.20
1.10
1.00
o >r r-
Diet Category
Baseline
End-point
Figure 4.8 Differences in TAG, TAG:HDL-C and HDL2 in the total population. Within diet 
changes in plasma TAG show LCP 3:1 & LCP/ALNA 3:1 resulted in significant reductions compared 
to the other dietary treatments (with LCP 3:1 being more favourable); TAG:HDL-C mirrored the TAG 
results. HDL2 was increased in the same two diets; however, in this case LCP/ALNA 3:1 showed
greater increases.
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When subjects were separated by gender, females displayed no significant differences 
between diets in any of the variables measured. Whereas males showed significant 
differences between diets with plasma TAG, TAG:HDL-C, and %AUCB, (P = 0.01, 
0.02, 0.01, respectively) (Figures 4.9 -  4.11). Both TAG and %AUCB showed 
differences between diets at baseline and therefore were re-analysed adjusting for 
baseline. The difference between all diets for TAG remained (P = 0.012) and multiple 
comparison tests showed LCP 3:1 and LCP/ALNA 3:1 were lower compared to 
ALNA 5:1 (P= 0.09 and 0.06 respectively). After adjusting for baseline %AUCB, 
end-point %AUCB lost significance between all diets; nevertheless, LCP/ALNA 3:1 
resulted in a lower %AUC than ALNA 3:1 (P = 0.081). With regards to TAG:HDL-C 
there were no significant differences at baseline and end-point post-hoc tests revealed 
there was a significant reduction in LCP/ALNA 3:1 compared to ALNA 3:1. Because 
of differences between diets at baseline and end-point the pre-post difference in LDL 
peak density was analysed and showed no change between diets (Figure 4.12)
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Figure 4.9 Differences in plasma TAG separated by gender. The upper panels (A) show end-point 
differences in plasma TAG. The bottom half (B) shows the A within diet. * depicts significant 
difference between diets (P < 0.05), t  shows significant difference within diets (P < 0.01). There was a 
significant difference between diets with (P = 0.012).
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Figure 4.10 Differences in TAG:HDL-C separated by gender. The upper panel (A) shows end-point 
differences in plasma TAG:HDL-C. The bottom half (B) shows the delta change between pre and post 
diet. * depicts significant difference between diets (P < 0.05), t  shows significant differences within
diets (P < 0.05).
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Figure 4.11 Changes in sdLDL separated by gender. The upper panel (A) shows end-point 
differences in sdLDL as %AUCB. The bottom half (B) shows the A change within diet. The decrease 
in sdLDL was predominantly in men recruited to LCP/ALNA 3:1. f  shows significant difference
within diets (P < 0.01).
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Figure 4.12. Changes in LDL peak density separated by gender. The top half of the graph (A) 
depicts the delta change in LDL peak density with females situated on the LH side and males on the 
RH side. The bottom half (B) shows within diet changes, with females LCP/ALNA 3:1 resulted in a 
significant reduction and ALNA 3:1 showed a trend with the fall in LDL peak density.
* = P < 0.05.
120
Within groups, females showed a significant increase in HDL2 %AUC (P = 0.021) 
with ALNA 3:1 (Figure 4.13) and a slight reduction in LDL peak density (P = 0.08) 
(Figure 4.12). Females on LCP/ALNA 3:1 showed significant decreases in VLDL-C 
(Appendix II), HDL2 %AUC (Figure 4.13), and LDL peak density (Figure 4.12, P = 
0.036, 0.005, and 0.025 respectively). Females on the control diet showed a 
significant fall in TAG:HDL-C (P = 0.02, Figure 4.10) and some evidence of a 
decrease in TAG (P = 0.07, Figure 4.9). There were no significant within group 
changes in females on LCP 3:1 and ALNA 5:1.
Males assigned to the control, ALNA 3:1, and ALNA 5:1 showed no significant 
differences in any of the lipid measures. Whereas males on LCP 3:1 showed 
reductions in plasma TAG, TC:HDL-C, VLDL-C, TAG:HDL-C, and LDL peak 
density (P = 0.003, 0.017, 0.04, 0.003, and 0.05 respectively, Figures 4.9 -  4.12 and 
Appendix II) and an increase in HDL2 (%AUC) (P = 0.02, Figure 4.13). LCP/ALNA 
3:1 produced reductions in sdLDL %AUCB (P = 0.005, Figure 4.12), plasma TAG (P 
= 0.07, Figure 4.9), and TAG:HDL-C (P = 0.08, Figure 4.10). In addition, there was a 
slight increase in VLDL-C (P = 0.06, Appendix II).
The majority of improvements seen in fasting lipids were seen in markers of an ALP, 
the plasma TAG was shown to correlate with sdLDL (%AUCB and peak 
density),HDL2, and TAG:HDL-C (Table 4.8).
Pearson TAG SdLDL TAG:HDL-C h d l 2 LDL peak
Correlation (mmol/L) %AUCB (%AUC) density
& significance 
R 1 .541(**) .896(**) -.459(**)
(g/ml)
.633(**)
P .000 .000 .000 .000
R .541(**) 1 .658(**) -.488(**) .861(**)
P .000 .000 .000 .000
R .896(**) .658(**) 1 -.658(**) .740(**)
P .000 .000 .000 .000
R -.459(**) -.488(**) -.658(**) 1 -.509(**)
P .000 .000 .000 .000
R .633(**) .861(**) .740(**) -.509(**) 1
P .000 .000 .000 .000
Table 4.8 Associations with markers of an ALP. ** Correlation is significant at the 0.01 level (2- 
tailed). The table shows significant interrelationships between markers o f an ALP.
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Figure 4.13 Within diet changes in HDL2. * = significance at P < 0.05. There were significant 
differences within ALNA 3:1 and LCP/ALNA 3:1 for females and LCP 3:1 for males.
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4. 4. 6 Postprandial lipid data
Plasma TAG and NEFA were analysed after a 12 h fast and subsequently at 2, 3, and 
6  h after a high fat test meal (Section 4.3.4 for details). Both total and incremental 
areas under the curve were calculated for both analytes. There were no significant 
differences between diets, for either plasma TAG or NEFA for total or incremental 
AUCs, whether analysed as a whole group or subdivided by gender. There were, 
however, significant within-diet differences for both measures, with LCP 3:1 showing 
a significant reduction in plasma TAG (TAUC) (P = 0.03); ALNA 3:1 showed 
decreases in TAUC and IAUC for NEFA (P = 0.006 and 0.06 respectively); and 
ALNA 5:1 an increase in NEFA (IAUC) (P = 0.08) (Table 4.9). The response curves 
at baseline and end-point for postprandial TAG on all diets except LCP/ALNA 3:1 
continued to rise or remain elevated for the full 6  h, whereas LCP/ALNA 3:1 began to 
fall after 6 h (Figure 4.16). The response curves for NEFA showed all dietary groups 
responded similarly, with a fall in NEFA at 2 h and an increase at 3 h and a further 
increase above baseline at 6  h, the response curve shape was not altered at end-point 
(Figure 4.16).
When subjects were separated by gender, females showed no significant differences 
between or within dietary groups. On the other hand, males showed a significant 
increase in TAG (IAUC) within the control group (P = 0.03); decreases in TAG 
(TAUC) and NEFA (IAUC) within LCP 3:1 (P = 0.02 and 0.01 respectively); and 
NEFA (TAUC) within ALNA 3:1 (P = 0.03). NEFA (IAUC) was also raised on 
ALNA 5:1 (P = 0.03).
123
s!
'o
£
£
Control2.5
0.5
LCP 3:12.5
0.5
ALNA 3:1
2.5
0.5
LCP/ALNA 3:1
0.5
2.5 ALNA 5:1
0.5
0
" TAG  Baseline 
TAGEBjioint 
" NEFA Baseline  
"NEFA Efpbint
2 3 6
Time (h)
Figure 4.14 Postprandial time course for plasma TAG and NEFA.
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Total 
population 
TAG (TAUC)
Baseline
Control
Mean ±
SE
828 ± 56
P
LCP 
3:1 
Mean ±
SE
958 ± 59
P
ALNA 
3:1 
Mean ±
SE
1017 ± 60
P
LCP/ALNA 
3:1 
Mean ±
SE
799
P
ALNA 
5:1 
Mean ±
SE
943 ± 58
P
End-point 859 ± 64 0.36 870 ± 53 0.03 1022 ±67 0.74 752 ± 44 0.26 967 ±61 0.61
TAG (IAUC)
Baseline 337 ±33 409 ± 38 442 ± 30 327 ±26 416 ± 28
End-point 399 ±37 0.01 398 ±31 0.60 473 ± 36 0.70 334 ±24 0.59 438 ±30 0.33
NEFA (TAUC)
Baseline 327 ±41 304 ± 42 361 ±35 321 ±30 326 ±33
End-point 30 5± 33 0.32 305 ±35 1.00 319 ±29 0.02 313 ± 31 0.41 334 ±37 0.86
NEFA (IAUC)
Baseline 73 ±35 75 ±37 133 ±31 61 ±27 86 ±34
End-point 82 ±38 0.54 69 ±33 0.01 86 ±27 0.03 53 ±31 0.29 105 ±37 0.10
Table 4.9 Dietary effects on postprandial lipaemia. Significant within diet differences were shown 
with the control diet resulting in an increase in TAG (TAUC); LCP 3:1 showed a decrease in TAG 
(TAUC); ALNA 3:1 showed significant decreases in NEFA total and incremental AUC; and ALNA 5:1
increased NEFA (IAUC).
4.4.7 Markers o f  insulin resistance
There were no significant differences between dietary groups in any o f the markers o f 
insulin resistance (glucose, insulin, and HOMA) whether in the fasting or postprandial 
state. There was an increase in fasting glucose within LCP 3:1 (P = 0.02) with a 
concomitant increase in fasting insulin (non significant), 2  h insulin (non significant) 
and HOMA (P = 0.06). None o f the other diets showed any significant differences 
within diets. While glucose showed no response to the test meal with insignificant 
differences from the fasting state to 2  h postprandial measures, insulin increased over 
3-fold with all diets with no significant differences within or between diets (Table 
4.10). When separated by gender, the increase in fasting glucose remained in LCP 
3:1 with females (P = 0.06), otherwise there were no differences between or within 
diets for any other o f the markers o f insulin resistance.
4.4.8 Post-heparin lipase activities
Two post-heparin blood samples were taken at 6  h after the high fat test meal, one at 5 
min. and another at 15 min. Both total and hepatic lipases were measured on both
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time points (TLA5, TLA15, HLA5, and HLA15 respectively). There were no 
significant differences between diets for all 4 lipase activity measures. ALNA 3:1 
showed an increase in HLA5 within diet (P = 0.051); whereas ALNA 5:1 showed a 
decrease in HLA5 within diet (P = 0.02). LCP/ALNA 3:1 resulted in a small decrease 
in HLA15 (P = 0.054). Neither LCP 3:1 nor the control showed any significant 
differences within diet. When separated by gender, the decrease observed in HLA5 
within ALNA 5:1 remained with males but not females (P = 0.02). However, the 
converse was true for ALNA 3:1 with females showing a significant increase in HLA5 
(P = 0.02). In addition, females showed a significant increase in HLA15 (P = 0.005) 
within LCP/ALNA 3:1 that was not observed in males. Furthermore, within the 
control both HLA5 and HLA15 showed significant decreases (P = 0.04 and 0.01 
respectively). Although LCP 3:1 showed no within changes when males and females 
were analysed together, there was a trend for both TLA5 and HLA5 to decrease (P = 
0.09 and 0.07 respectively). Results are shown in Appendix II.
There were no significant correlations with any of the changes observed in fasting and 
postprandial lipids with any of the changes in dietary measures or with the changes in 
plasma and RBC fatty acids.
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4.5 Discussion
The main aims of this study were to ascertain the effects of varying the ratio of n-6/n- 
3 fatty acids on CVD risk, with special attention given to outcomes relating to an 
ALP. Furthermore, the study assessed the length of the carbon chain in combination 
with the ratio of n-6/n-3 fatty acids and attempted to answer the question: which of 
the following combinations has the greatest effect on markers of CVD and an ALP: n- 
3 LCP, n-3 SCP, or a mixture of the two?
4.5.1 Dietary intake
Assessment of the dietary composition by records of weighed food intake depends 
upon the accuracy of the food recording as well as the completeness of the food data 
base on which the calculations are based. Under-reporting of food intake is well 
documented (Livingstone & Black, 2003). However, the estimates for energy intake 
in the present study are similar to those reported in the National Dietary and 
Nutritional Survey (Henderson et al, 2003). The collection of duplicate food portions 
is subject to different errors, notably incomplete dietary collections. Nevertheless, it 
does facilitate the accurate analysis of fatty acids (Sanders & Reddy, 1992). The aim 
of the study was to validate whether estimates of the intake of polyunsaturated fatty 
acids by a 7-day weighed food intake diary gave accurate estimates of the intakes of 
n-3 fatty acids. The estimates of intake suggested daily consumption of 1.7 g n-3 fatty 
acids in men and 1.4 g n-3 fatty acids in women. The estimated intakes of n-3 LCP 
were 0.3 g/d in men and 0.4 g/d in women and were higher than estimates of 0.2 g 
made in planning the study. This may have been due to selection bias towards 
recruitment of subjects who were prepared to eat fish. However, in the National 
Dietary and Nutritional Survey the mean daily intake of n-3 fatty acids were 2.27 g in 
men and 1.7 g in women and intakes of n-6 fatty acids were 12.9 g and 9.4 g in men 
and women respectively giving n-6/n-3 ratios of 8:1 and 5:1 respectively. In the 
National Dietary and Nutritional Survey it was estimated that 18% and 23% of the 
intake of n-3 fatty acids came from fish in older men and women which would give 
intakes of n-3 LCP of approximately 0.4 g/d, which is very close to our estimates. 
These estimates of n-3 LCP intakes are similar to those recently reported by Brady et 
al (2003) on 18 subjects, although they observed a lack of agreement between the two
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dietary assessment techniques (duplicate diet and estimated dietary records) for the 
determination of dietary fat and fatty acid intake.
In the OPTILIP study, chemical analysis of the diets provided estimates of total fat 
intake for comparison with food diaries. However, the analysed diets were found to 
have a lower proportion of protein and carbohydrate than estimated from the food 
diaries. The reason for this discrepancy is not entirely clear. The estimate of LA and 
ALNA determined by chemical analyses was close to the calculated estimates. The 
estimates of intake of n-3 LCP from dietary records were closely correlated with the 
analysed values but the amounts of EPA and DHA in the analysed diets were greater 
than those estimated from food tables. One possible reason for this is that food tables 
only report intake to the nearest 0.1 g and foods such as meat, eggs and non-oily fish 
make small but significant contributions to dietary intake of n-3 LCP.
In conclusion, accurate estimates of the intake of n-3 fatty acids can be made from 
weighed dietary intake records providing care is taken to record carefully the types of 
oils and fats used.
4.5.2 Fatty acids
Fatty acid intakes were analysed from 7-day weighed food records, and fatty acid 
composition in RBC membranes and plasma phospholipids. The 7-day weighed food 
records showed that the ratios of n-6/n-3 fatty acids were relatively close to the 
proposed ratio for each diet, with the control, ALNA 3:1 and ALNA 5:1 showing 
slightly higher ratios and LCP/ALNA 3:1 resulting in a slightly lower ratio. The 
ratios of n-6/n-3 fatty acids in the RBC and plasma fatty acids did not reflect the n- 
6/n-3 ratios from the dietary analysis. However, there was a relative decrease in the 
n-6/n-3 ratio for LCP 3:1 and LCP/ALNA 3:1 and a relative rise in the control; 
therefore, the change was consistent with dietary intake. Furthermore, there was a 
strong and significant positive correlation between the dietary ratio of n-6/n-3 fatty 
acids and both plasma and RBC membrane ratio of n-6/n-3 fatty acids.
With regards to individual fatty acids, the major changes observed were increases in 
dietary LA in the control diet and increases in EPA & DHA in the high n-3 LCP diets
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which were confirmed by corresponding increases in plasma and RBC phospholipids. 
However, the correlations between plasma and RBC LA and dietary LA were weak, 
suggesting that LA was directed to other physiological functions or saturated and 
elongated to n-6 LCP as described by Arab (2003). Evidence of the latter was 
observed as dietary LA correlated positively with plasma and RBC AA, DHLA, and 
ADR respectively. Additionally, the control diet displayed lower levels of n-3 LCP in 
plasma and RBC membranes suggesting that n-6 fatty acids were incorporated at the 
expense of the n-3 LCP; indeed dietary LA showed negative correlations with both 
plasma and RBC EPA and DHA respectively. With the high n-3 LCP diets the 
converse was evident, as plasma and RBC n-6 fatty acids were lower within the two 
diets and n-3 LCP were increased. Positive correlations were shown between dietary 
EPA & DHA and plasma and RBC EPA & DHA and negative correlations with 
plasma and RBC LA, DHLA, AA, and ADR, suggesting replacement of n-6 fatty 
acids by n-3 LCP as described by Vidgren et al (1997).
With regards to dietary ALNA, the proposed values were designed to be highest in 
ALNA 3:1 followed by LCP/ALNA 3:1, ALNA 5:1, LCP 3:1 and control. However, 
the achieved values were somewhat different with the descending values in the order: 
LCP/ALNA 3:1, ALNA 3:1, LCP 3:1, ALNA 3:1 and control with significant 
differences between groups. Plasma and RBC ALNA showed similar patterns to 
dietary ALNA. There were weak but significant positive correlations with dietary 
ALNA and RBC ALNA, EPA, and negative significant correlations with RBC LA 
and ADR. Dietary ALNA showed stronger positive correlations with plasma ALNA, 
EPA, DPA, and DHA; there were no significant negative correlations with any of the 
n-6 fatty acids although LA, DHLA and AA all showed negative r values. As with 
dietary LA, dietary ALNA was shown to be incorporated into phospholipid 
membranes and there was evidence of desaturation and elongation to longer chain n-3 
fatty acids, especially with respects to plasma fatty acids. The evidence for 
replacement of the n-6 fatty acids was not as strong for ALNA compared to 
replacement of n-3 fatty acids with LA; this may be because ALNA has a low affinity 
for cholesteryl esters and phospholipids (Burdge et al, 2003) and maybe directed 
towards P-oxidation; hence, the higher correlation in plasma fatty acids compared to 
RBC membranes.
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In a similar study, Finnegan et al (2003) investigated 5 dietary treatments: a control 
diet consisting of higher n-6 fatty acids, a moderate and high n-3 LCP (EPA & DHA), 
and a moderate and high ALNA group. Both moderate and high ALNA groups 
resulted in significantly increased levels of plasma ALNA and EPA from baseline to 
follow-up (6  months) in plasma fatty acids; plasma DPA was also increased after 6 
months, but only in the high ALNA treatment. These results are similar to the present 
study with the higher ALNA enriched diets resulting in higher plasma ALNA. In 
contrast, the present study did not show an increase in plasma EPA or DPA in the 
plasma fatty acids with the ALNA 3:1 and ALNA 5:1 diets. Although there were no 
increases in plasma fatty acid ALNA there were insignificant increases in both EPA 
and DHA in RBC membranes. In the Finnegan study, plasma AA tended to increase 
insignificantly with both ALNA groups; the present study showed no change in 
plasma AA on the higher ALNA diet (ALNA 3:1) and in contrast to Finnegan et al 
(2003) plasma AA decreased insignificantly with the moderate linolenic group 
(ALNA 5:1).
In the Finnegan study, the two n-3 LCP diets both increased the proportions of EPA 
and DHA with little effect on DPA; there was also a slight decrease in plasma AA but 
not significant. The OPTILIP study showed agreements with Finnegan et al (2003) 
with increases in plasma EPA and DHA conversely, plasma DPA levels were 
increased in both n-3 LCP diets (both equally high in n-3 LCP). Furthermore, plasma 
AA was also decreased from baseline to follow-up in both n-3 LCP diets.
In a study by Mabile et al (2001), subjects were given 6 g/d of fish oil equating to 300 
mg of EPA and 200 mg of DHA which were slightly higher than the 0.3 -  0.4 g/d of 
n-3 LCP achieved in the present study. Two subject groups (NTG and HTG) 
increased incorporation of EPA and DHA into RBC membranes -  with less 
consistency with DPA. This incorporation was at the expense of both RBC 
membrane LA and AA. These results are in agreement with the OPTILIP study, with 
n-3 LCP diets showing incorporation of EPA and DHA into the RBC membrane at the 
expense of LA and AA.
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4.5.3 Fasting plasma lipids
The main outcomes between dietary groups were the significant decreases in plasma 
TAG and TAG:HDL-C. This difference was between LCP/ALNA 3:1 vs. ALNA 3:1 
and was within the male subjects; there were no significant differences with the 
control diet. Within dietary groups there were significant favourable changes in the 
following of CVD/ALP markers: TAG, HDL2, sdLDL AUC, LDL (Fr), non-HDL-C, 
TAG:HDL-C, and LDL peak density. There was also a decrease in VLDL-C and the 
ratio of LDL-C/HDL-C, albeit non significant. The beneficial outcomes were mainly 
seen in the high n-3 LCP diets and were all ALP markers (TAG, TAG:HDL-C, 
sdLDL, and HDL2). The changes in LDL-C (Fr), non-HDL-C, and VLDL-C were 
found in the higher linolenic diet, ALNA 3:1. The control diet and the moderate 
linolenic diet (ALNA 5:1) showed no significant changes in any of the fasting lipid 
parameters.
A new ultracentrifugation procedure was employed to analyse sdLDL (Davies et al, 
2003). This procedure provided an AUC for sdLDL (%AUCB) and its reciprocal 
(%AUC A) a measure of larger, more buoyant LDL and a measure of LDL peak 
density. Results showed there was a significant decrease in sdLDL (%AUCB) within 
both LCP 3:1 and LCP/ALNA 3:1 with concomitant reduction of LDL peak density. 
There were no significant differences between groups when males and females were 
analysed together, when males were analysed alone there was a significant reduction 
in sdLDL (%AUCB) with LCP/ALNA 3:1 versus ALNA 3:1. This gender effect was 
noticeable with other markers of an ALP, such as TAG, TAG:HDL-C, and LDL peak 
density; however, HDL2 was increased in both males (LCP 3:1) and females 
(LCP/ALNA 3:1). Considering the TAG-lowering effect of n-3 fatty acids (especially 
from fish oil) (Weber & Raederstorff, 2000), it is not surprising there were 
concomitant improvements in both LDL and HDL subclasses. With elevated levels of 
plasma TAG, there is a greater flux of NEFA to the liver. This can lead to larger, 
more buoyant, TAG rich VLDL being secreted from hepatocytes. The large VLDL 
undergoes transfer of CE for TAG with both LDL and HDL (Packard, 2000). The 
now TAG-rich LDL and HDL are hydrolysed, by hepatic lipase, to smaller denser 
particles (LDL III and HDL III respectively) (Zambon, 2003). In addition, both large 
VLDL and chylomicrons are stripped of TAG by the lipolytic action of LPL to form
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IDL and chylomicron cholesterol-rich remnants; the remaining IDL TAG is 
reciprocally exchanged with CE from HDL2 and IDL is converted to LDL 
(Kwiterovich, 2002). The strong interrelationships between markers of an ALP 
provide evidence to support this mechanism.
The relationship between n-3 fatty acids and their TAG-lowering effect has been 
recently reviewed (Caroll & Roth, 2002; Weber & Raederstorff, 2000) and a meta­
analysis by Harris (1997) of 72 human trials given 7 g/d or less of n-3 fatty acids 
showed a plasma TAG lowering effect of 25% for NTG and a 28% lowering effect for 
HTG subjects. In addition, Harris (1997) found there was no significant effect on 
HDL-C within the HTG group; whereas, LDL-C increased slightly but significantly. 
The NTG group responded to n-3 fatty acid intake but with significant increases in 
HDL-C, LDL-C and therefore plasma TC. The OPTILIP study is in agreement with 
Harris (1997) in terms of lowering plasma TAG, albeit, to a lesser extent. With 
regards to plasma TC, HDL-C and LDL-C there were no changes in any of the dietary 
groups, in fact LDL-C (Friedwald formula) tended to decrease with the high ALNA 
3:1 diet; which has been shown previously with high ALNA diets (Bloedon & 
Szapary, 2004). Harris (1997) did not analyse any studies with respect to LDL and 
HDL subclasses.
More recently, Finnegan et al (2003) investigated the dose response to both n-3 LCP 
(as EPA & DHA) and n-3 SCP (ALNA) (described above). Fasting plasma TAG 
concentrations fell in the high n-3 LCP dietary group (-7.7%) and the change was 
significantly different compared to the high ALNA group; these changes are in accord 
with the results of this present study i.e., the differences in plasma TAG were between 
LCP/ALNA 3:1 versus ALNA 3:1. Additionally, the magnitude of plasma TAG 
lowering was similar with -7.7% by Finnegan et al (2003) for the n-3 LCP group and 
-9.1% and -6.3% for n-3 LCP 3:1 and n-3 LCP/ALNA 3:1 respectively. In contrast, 
the Finnegan study did show a significant effect of time in raising plasma TC, LDL-C, 
and apo B, with no significant effect of the interaction of time and diet or diet alone. 
There was an increase in LDL-C after 6  months in the high n-3 LCP group, though 
the percentage change showed no significant difference compared to the control 
group. In addition, the increase in LDL-C may reflect remodelling of LDL to a larger 
more buoyant species which has been previously suggested (Griffin, 2000; Suzukawa
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et al, 1995). In contrast, in the OPTILIP study LDL-C (Friedwald formula) was 
reduced on the ALNA 3:1 diet (within diet); but, showed no significant difference 
between groups. Finnegan et al (2003) also showed no significant change in LDL-C 
in the high ALNA group either within or between dietary groups.
Although there were similarities between Finnegan et al (2003) and the present study, 
the former used purified fish oil and vegetable oil supplements in contrast to whole 
fish, fish paste, and oils and spreads. Furthermore, the ratios of n-6/n-3 fatty acids 
were not taken into account in the Finnegan study, and wider age groups of 
moderately hyperlipidaemic subjects were studied. No studies to date have 
investigated the n-6/n-3 fatty acid ratios from whole foods with specific markers of an 
ALP, in a middle aged to elderly UK population; therefore, direct comparison 
becomes difficult. Nevertheless, one very recent study investigated the ratio of n-6/n- 
3 fatty acids in two dietary groups, a moderate n-6/n-3 ratio (3.5:1) and a high n-6/n-3 
ratio (7.1:1) (Brady et al, 2004); plasma TAG and sdLDL were both lowered in this 
intervention (Table 1.7) with no significant changes in other fasting CVD/ALP 
markers. Interestingly, there was no significant difference in the magnitude of plasma 
TAG and sdLDL reduction between diets suggesting the n-6 PUFA did not affect the 
decreases seen in the two ALP markers. However, this study focused on a group of 
Indo-Asians residing in the UK who may respond differently compared to other 
populations. While the OPTILIP study was in agreement with respect to the changes 
in plasma TAG and sdLDL with the lower n-6/n-3 fatty acid ratio, the moderate and 
high n-6/n-3 ratio diets (ALNA 5:1 and control) did not show any effects on plasma 
TAG or sdLDL or any adverse effects with respect to fasting lipids.
Other n-3 fatty acid supplementation studies that have addressed the ALP include 
Minihane et al (2000); in this case fish oil supplementation had a profound effect on 
LDL subclasses (LDL III -26%) and plasma TAG (- 35%); but no effect on HDL-C 
and HDL subclasses were not measured. The present study showed a similar pattern 
of findings but with less marked changes (plasma TAG fell 9.1% and 6.3% and 
sdLDL %AUCB decreased 6.3% and 4.8% within LCP 3:1 and LCP/ALNA 3:1 
respectively). The magnitude of plasma TAG-lowering may be a dose response 
effect; Minihane et al (2000) provided 6  g of fish oil (3 g of n-3 LCP), in contrast to 
OPTILIP which only provided ~ 0.68% of total energy/day (in the high n-3 LCP
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groups) which was - 1.6 g/day -  i.e., equivalent to half of the dose given in the 
Minihane study. Furthermore, Minihane et al (2000) only examined male subjects 
with an ALP (i.e., high plasma TAG and low HDL-C). Petersen et al (2002), 
investigating the effect of fish oils in a type II diabetic population, as in other studies, 
found a plasma TAG lowering effect with a concomitant increase in HDL2; no 
changes were observed in HDL-C, LDL-C, or LDL size. Similar results were found 
in OPTILIP with regards to TAG and HDL2. Again, the magnitude of change was 
somewhat lower with OPTILIP and this is probably a dose effect, since Petersen 
employed fish oil capsules with high doses of EPA and DHA. With regards to LDL 
size, Minihane et al (2000) and Suzukawa et al (1995) both found an increase in LDL 
size with relatively high doses of fish oil capsules; with the Suzukawa group 
employing Omacor, which is a pharmacological preparation (85% EPA/DHA). There 
were also concomitant reductions in plasma TAG in both studies, with no changes in 
HDL-C or HDL subclasses. The only study to show an increase in HDL-C was the 
GISSI-Prevenzione trial (1999); though the change in HDL-C was not significantly 
different from the control group. OPTILIP is in agreement with the majority of 
research mentioned above with regards to the lowering of plasma TAG and the HDL- 
C response. However, with respect to LDL and HDL subclasses there are somewhat 
conflicting results. Nevertheless, the present study has shown favourable outcomes 
with regards to fasting lipids with the LCP 3:1 and the LCP/ALNA 3:1 diets.
As mentioned, there are no previous randomised controlled interventions investigating 
the effects of whole foods on the ratio of n-6/n-S fatty acids. Since the original 
observations by Bang et al (1971) there have been many epidemiological studies that 
have observed low incidences of CVD in communities consuming high intakes of fish 
(reviewed by Weber & Raederstoff, 2000). An epidemiological study by Dewailly et 
al (2002) showed an inverse correlation with plasma phospholipid EPA and EPA + 
DHA intake with plasma TAG and a positive correlation with HDL-C. The study 
examined Canadian native populations that consumed large amounts of fish and 
exhibited lower incidence of CVD. The present study was in agreement with 
Dewailly et al (2002) with regards to the correlations with TAG and HDL-C but did 
not measure CVD as an end-point.
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4.5.4 Postprandial response
The majority of the waking day (~18/d) man is in the fed state and the magnitude of 
postprandial lipaemia is dependent on the quality and quantity of dietary fats 
(Sanders, 2003) and carbohydrates (Liljeberg & Bjorck, 2000). NEFA represent the 
greatest circulatory source of energy and concentrations vary extensively throughout 
the day. In the fasted state the activity of HSL is the major route of delivery of NEFA 
into the circulation, whereas in the postprandial state the lipolysis by LPL on TAG- 
rich lipoproteins provides NEFA to replenish the adipocyte (Holm et al, 2000; Frayn, 
1998). However, since CM-TAG and VLDL-TAG are in competition for LPL 
activity, with CM-TAG being the preferred substrate, VLDL-TAG clearance can be 
attenuated by raising CM and VLDL can accumulate (Karpe, 1997). Furthermore, not 
all of the NEFA released by LPL is channelled into the adipocyte for storage as TAG, 
indeed remaining NEFA are either attached to the surface of remnant particles or 
carried by albumin to peripheral tissues. In a dyslipidaemic state, such as an ALP or 
hyper apoB, inefficient uptake of NEFA by adipocytes can occur in the postprandial 
state resulting in increased NEFA in the circulation (Karpe, 1997). This may be due 
to hyperinsulinaemia, as insulin has an anti-lipolytic action (de Vries et al, 2003). 
The increased NEFA in the circulation can lead to greater VLDL-TAG secretion by 
the liver, especially the larger lipid rich subclass; large VLDL-TAG will transfer CE 
from LDL and HDL at an increased rate, which can lead to increased action of HL 
and the production of atherogenic sdLDL, and less cardio-protective sdHDL (Zambon 
et al, 2003).
Chronic n-3 PUFA intake has been previously shown to dramatically improve 
postprandial lipaemia (reviewed by Roche & Gibney, 2000). N-3 fatty acids may 
exert their plasma TAG-lowering effect by reduction of VLDL synthesis. 
Considering VLDL-TAG competes with CM-TAG for clearance through LPL then a 
reduction of VDLD-TAG synthesis would hypothetically improve CM clearance. In 
the present study TAG (TAUC) was reduced within LCP 3:1 with the effect being 
confined to men; the control diet showed a significant adverse effect with an increase 
in TAG (IAUC), within ALNA 3:1 and ALNA 5:1 showing insignificant increases 
and LCP/ALNA 3:1 showing insignificant decreases in both TAG (TAUC) and
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IAUC. Finnegan et al (2003) showed that the change in TAG (TAUC) in a high EPA 
& DHA (-0.8%) group was significantly different compared to a low ALNA group 
(23%). However, there were no significant differences on the high n-3 LCP diet, 
whereas the high ALNA diet showed an adverse effect within diet with an increase in 
TAG (TAUC). OPTILIP is in partial agreement with Finnegan et al (2003), with the 
ALNA-enriched diet increasing postprandial lipaemia (albeit non significant), though 
in this case the control diet showed the greatest increase in postprandial lipaemia with 
a 37.4% increase in TAG (IAUC). In addition, the present study showed similar 
responses with TAG (IAUC) increasing in all diets. It is difficult to explain why the 
mixed LCP 3:1 diet showed the greatest response, insulin is known to have an anti­
lipolytic effect on LPL (de Vries et al, 2003). However, there were increases in 
fasting glucose and HOMA within this diet, suggesting increased insulin resistance 
and therefore increased postprandial lipaemia. There were no significant changes 
with NEFA total or incremental AUC or with total or hepatic lipase when males and 
females were analysed together. Notably, the improvement in postprandial lipaemia 
had a gender effect favouring males; when this is considered then both total and 
hepatic lipase showed a reduction. A decrease in hepatic lipase would show an 
increase in LDL and HDL size (Borggreve et al, 2003; Kwiterovich, 2002) and indeed 
the LCP 3:1 dietary group did show increases in HDL2 (%AUC) and decreases in 
sdLDL (%AUCB). Even though LPL was not measured directly in this study, the 
improvements seen in HDL2 seen in the LCP diets may reflect improved lipolysis via 
LPL as described by Patsch et al (1998). Furthermore, the IAUC for NEFA within the 
LCP 3:1 diet was decreased therefore decreasing the availability of NEFA to the liver 
for VLDL synthesis. However, there were no changes in apoB suggesting a decrease 
in VLDL size but not the number of VLDL particles, since there is only one apoB 
molecule/VLDL particle (Sniderman, 2004; Elovson, 1988).
4.5.5 Mechanisms for the lowering ofplasma TAGs by n-3 fatty acids
The plasma TAG-lowering effects of n-3 fatty acids by lowering the production of 
VLDL-TAG may be explained by various molecular mechanisms. Apo B and 
microsomal TAG transfer protein (MTP) are essential proteins for the assembly and 
secretion of VLDL-TAG from the liver. N-3 fatty acids (especially LCP) may 
attenuate the processes involved with the assembly and secretion of VLDL; MTP has
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been proposed to promote lipid transfer of TAG, CE, and PL from the ER membranes 
of hepatocytes to developing lipoproteins within the lumen of the ER (Berriot- 
Varoqueaux et al, 2000). The precise mechanism by which n-3 fatty acids attenuate 
this process is unclear and it may be due to hepatocytes having a reduced ability to 
synthesise or mobilise TAG for secretion (Wang et al, 1994). Alternatively, it may be 
a simple case of availability. N-3 fatty acids may be diverted to other physiological 
functions other than re-esterification to form TAG for the production of VLDL, 
considering VLDL synthesis depends on fatty acid availability. Both the quality and 
quantity of fatty acids impacts on several physiological systems (Jump, 2004) with n- 
3 fatty acids being involved in many physiological and molecular processes. In 
addition, n-3 fatty acids may regulate the fate of other fatty acids, via transcription 
factors, towards other physiological functions and therefore decrease availability for 
VLDL synthesis. Studies have shown that PPARor regulates the genes involved in 
fatty acid uptake, /7-oxidation, and ^-oxidation (Jump, 2002); therefore, decreasing 
availability of NEFA for VLDL assembly and secretion.
It is unlikely that n-3 fatty acids have direct regulatory effects on transcription factors 
that regulate the production of genes involved with VLDL assembly and secretion 
since apoB remains unchanged with high n-3 diets (Shidfar et al, 2003; Griffin, 2001). 
The present study showed no change in the levels of apoB in any of the dietary 
groups, although plasma TAG was lowered in LCP 3:1 and LCP/ALNA 3:1 diets. 
This suggests a reduction in VLDL size due to lower levels of VLDL-TAG. If indeed 
the gene expression of MTP was down regulated by n-3 PUFA then both apoB and 
plasma TAG would be expected to be lowered. A recent study investigated the 
effects of n-3 fatty acids on MTP mRNA and found no change when rats were fed a 
high fish oil diet (Botham et al, 2003). Alternative regulatory targets influencing 
NEFA availability would be the mechanisms involved in the re-esterification of 
NEFA to fatty acyl-CoA thioesters (acyl-CoA synthetases, ACS) (Jump, 2002) andin 
the synthesis of TAG (diacylglycerol acyltransferase, DGAT). Indeed the 20-carbn 
n-3 coA thioesters are poor substrates for DGAT, which is the last step in TA.G 
synthesis (Botham et al, 2003). DGAT is an ER membrane enzyme; therefore, if20- 
carbon n-3 coA thioesters are poor substrates then they will be re-directed either to the 
mitochondria, perixisome or for phosphatidylethanolamine (PE), phosphatidylsdne
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PS, and phosphatidylcholine (PC) synthesis. PPARa have been shown to be up- 
regulated by n-3 fatty acids (Jump, 2002), therefore switching /7-oxidation on and 
promoting loss of body fat. The most effective dietary strategy in the present study 
was the LCP 3:1 diet. Although all diets resulted in a net weight gain, the LCP 3:1 
also showed a loss in waist girth; therefore suggesting either re-distribution of body 
fat and/or a gain in lean body mass. Unfortunately the OPTILIP study did not 
measure lean mass and therefore it was not possible to confirm this hypothesis. While 
n-3 fatty acids have been implicated, in a beneficial manner, in bone re-modelling 
(Watkins et al, 2001), the weight gain observed in OPTILIP is an unlikely scenario 
for a middle aged/elderly, non-exercising population. An alternative and more likely 
explanation is through a redistribution of body fat and body fat distribution is linked 
to deranged fatty acid metabolism. N-3 fatty acids may encourage increased (3- 
oxidation from visceral fat, therefore causing a reduction in waist girth; yet at the 
same time subcutaneous fat may accumulate. Both visceral fat and subcutaneous fat 
have been implicated in the aetiology of insulin resistance and dyslipidaemia (Frayn, 
2000). However, the general consensus is that visceral adiposity is the main culprit 
and subcutaneous fat can even have an insulin sensitising effect (Karelis et al, 2004).
The transcription factor(s) that regulates the synthesis of proteins involved with the 
synthetic steps from NEFA to VLDL would be likely candidates for the lowering of 
VLDL production. PPARa can increase the rate of lipolysis by LPL via the down 
regulation of Apo C-III, a protein that inhibits TAG hydrolysis and therefore 
contributes to the TAG lowering effect i.e. reduced NEFA availability (Lee et al, 
2003). Different apoE genotypes have been shown to respond differently to 
supplementation with n-3 LCP as fish-oil capsules (Khan et al, 2002; Minihane et al, 
2000). As described above, n-3 LCP reduce the production of VLDL-TAG; therefore, 
postprandial CM and CM-R have less competition with LPL and the apoB/E receptor 
respectively. Thus accumulation of VLDL remnants will not occur and clearance of 
CM and CM-R would be expected to increase; apoE4 carriers have a higher affinity 
for the remnant receptor and therefore clearance of TGRL would be improved 
(Vincent et al, 2002; Ye & Kwiterovich, 2000). However, this can lead to down 
regulation of the receptor and decreased clearance of LDL-C. On the other hand, 
carriers of apoE2 have a poor affinity for the remnant receptor and TGRL would be
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expected to accumulate (Vincent et al, 2002; Ye & Kwiterovich, 2000). The results 
of Khan et al, (2002) showed that the carriers of the apoE4 genotype showed the 
greatest response to fish-oil supplementation than non-carriers in terms of increasing 
PH-LPL activity, and adipose tissue LPL mRNA. With regards to lipids both apoE4 
and E2 carriers showed improvements in ALP markers (Minihane et al, 2000) with E2 
carriers resulting in greater improvements in postprandial lipaemia and HDL-C and 
apoE4 carriers displayed more marked improvements in fasting TAG and sdLDL. 
Although polymorphisms were not measured in the present study, they may contribute 
to the variance seen within dietary groups.
The major effects were in the LCP 3:1 and the LCP/ALNA 3:1 diets with reductions 
in plasma TAG, TAG:HDL-C, sdLDL and increases in HDL2 with additional 
lowering of postprandial lipaemia (plasma TAG TAUC) within the LCP3:1 diet. 
There was a strong gender effect with females only showing an increase in HDL2 
within the LCP/ALNA 3:1 and ALNA 3:1 diets. Whereas males responded best to 
the LCP 3:1 diet with additional decreases in VLDL-C, TC:HDL-C to the group as a 
whole. There were no changes in traditional markers of CVD, plasma TC, LDL-C 
and HDL-C nor in markers of insulin resistance, insulin and HOMA; although 
glucose was slightly increased within the LCP 3:1. In conclusion, both the LCP n-3 
diets were the most favorable towards markers of an ALP with the LCP 3:1 being 
slightly more effective in modifying these markers.
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Chapter 5.0 The effects of low-fat high and low glycaemic index diets 
Abstract
Background: While conventional dietary strategies for reducing CV risk employ 
the use o f low-fat, high-carbohydrate (LFHC) diets, there is debate over the 
potentially adverse effects o f LFHC diets in raising plasma TAG and lowering 
HDL-C. In this respect, the type o f carbohydrate, as defined by its capacity to 
raise blood glucose and insulin i.e. its Glycaemic Index (GI), may be critical. 
There is evidence to suggest that foods with a high GI may increase plasma TAG 
and thus exacerbate an ALP, whereas foods with a low GI may decrease plasma 
TAG, increase HDL-C and reverse an ALP.
Hypothesis: Subjects with an ALP will respond to a low-GI diet by reducing 
plasma TAG and normalising their dyslipidaemia.
Design: The study was designed to test the effects o f high and low GI diets on an 
ALP. Fourteen normal, healthy men (aged 35-55 years) characterised with an 
ALP, were randomly assigned to one o f two prescribed diets containing either a 
high proportion o f foods with a high GI (GI >80) or a low GI (GI<60). Dietary 
prescriptions were achieved by instructing volunteers to follow two cycles o f  a 7- 
day menu that provided a choice o f foods and mixed meals (with recipes) 
appropriate to either their high or low GI status. The study was free-living, with 
a crossover design, with subjects purchasing and preparing their own meals. 
Anthropometric measurements and blood biochemistry were determined at 
baseline and after 2 weeks.
Results: The low GI diet was accompanied by significant decreases in plasma 
cholesterol, TAG, HDL and LDL-cholesterol, body mass and BMI. In contrast, 
there were no significant differences in any o f these variables after the high GI 
diet. There was no change in the distribution o f LDL subclasses as measured by 
its peak density or in waist circumference for either group.
Conclusions: While the low GI diet was associated with more favourable changes in 
plasma lipids (with the notable exception o f a decrease in HDL-C), when compared to 
the high GI diet, the latter did not exert any significantly negative effects on this high- 
risk phenotype. Larger scale studies o f extended duration will be required to 
substantiate the impact o f GI on CV risk.
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5.1 Introduction
For the past 40 years traditional dietary therapy for reducing risk factors for CVD 
has involved the use of low-fat, high-carbohydrate (LFHC) diets because of their 
lipid-lowering properties (mainly, the reduction in total plasma TC and LDL-C 
(for review see Parks & Hellerstein, 2000). However, there is controversy as to 
whether this type of diet is entirely safe, especially for a population with an 
ALP/metabolic syndrome. This uncertainty is due to both recent (Saris et al, 
2000; Astrup, 2001; Vidon et al, 2001; Hudgins, 2000; Kasim-Karakas et al, 
2000; Mittendorfer & Sidossis, 2001; Baum & Brown, 2000) and past studies (as 
reviewed by Hellerstein, 2002; Parks & Hellerstein, 2000) that showed either 
detrimental changes in the lipid profile (i.e., the induction of HTG and reduction 
of HDL-C) or beneficial effects. Furthermore, some interventions have focused 
on the type of carbohydrate as being more important with regards to the above 
and distinguish between simple and complex carbohydrate (Hudgins, 2000, 
Poppitt et al, 2002; Saris et al, 2000). Other studies have advanced on the 
structure and functional relationship of CHO by assigning foods with a 
glycaemic index (GI) (Foster-Powell et al, 2002). Dietary strategies for the 
reversal of lipid abnormalities in an ALP/metabolic syndrome are still unclear 
with respect to the type of CHO.
5.1.2 Glycaemic index
The metabolic response to CHO-rich foods can be assessed by its glycaemic 
index (the incremental area under the curve of plasma glucose to a given food 
compared to a reference food, i.e. glucose or white bread (Foster-Powell et al, 
2002). Classifying carbohydrate foods into simple and complex (or sugar and 
starch) maybe too simplistic. This traditional classification does not take into 
account the different structures of starch (amylose or amylopectin), fibre content, 
method of processing, cooking procedures, and other macronutrients in the meal, 
all of which can affect the glycaemic response. The glycaemic index was first 
postulated more than 20 years ago (Jenkins et al, 1981) and since then there has 
been a plethora of studies relating glycaemic index with pathophysiological 
mechanisms, such as obesity, diabetes, CVD and cancer. However, there are
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relatively few randomized, controlled studies comparing the changes in 
lipoprotein subclasses with LFHC diets of equal energy and fibre content but 
differing in glycaemic index (GI). In addition, there are no studies that compare 
high and low GI diets within an ALP/metabolic syndrome (non-diabetic) 
population.
5.1.5 Glycaemic index and CVD
The chronic consumption of a low fat HGI diet may lead to deleterious changes 
in the lipid profile. The lower glucose and NEFA levels observed in the 
postabsorptive phase may lead to decreased satiety and over consumption of 
CHO (Ludwig et al, 1999). Excessive CHO may then drive hepatic VLDL-TAG 
overproduction (Parks, 1999), and therefore increase plasma TAG. The 
mechanism of this phenomenon could be due to de novo VLDL synthesis 
through the increased glycolytic production of acetyl CoA or a reduced clearance 
of TGRL as a consequence of insulin resistance suppressing LPL activity 
(Roche, 1999; Panarotto et al, 2002). Regardless of the mechanism, CHO- 
induced increases in plasma TAG can cause a remodelling of lipoproteins, 
converting LDL pattern A to pattern B and a reduction in HDL-C concentration 
and size (Krauss and Dreon, 1995). A habitual low fat LGI diet should normalise 
the lipid profile due to the extended release of glucose gastrointesinally and 
hence prolonged suppression of NEFAs and therefore improved insulin 
sensitivity.
5.1.6 Epidemiological evidence
A retrospective study (Frost et al, 1999) of the dietary and nutritional survey of 
British adults (Gregory et al, 1998) re-evaluated the influence of dietary CHOs 
when expressed as GI on serum lipids: TC, HDL-C, and calculated LDL-C. 
Glycaemic indices of diets were calculated from the original 7-day food diaries 
of 1420 subjects. The only association with GI was a negative correlation with 
HDL-C, which was more pronounced in women compared to men. In addition, 
plasma TC was negatively correlated with total CHO, which is in line with the 
effects of most LFHC diets (Hellerstein, 2000). A larger retrospective study of
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European outpatients with type I diabetes (Buyken et al, 2001) investigated the 
relationship of GI with plasma TC, HDL-C, calculated LDL-C, and plasma TAG. 
This multi-centred study examined weighed 3-day food diaries from outpatients 
from clinics in northern, southern, eastern, and western Europe, detailing 
ingredients, preparations, and whether the food was cooked or raw. GI was 
calculated from published indices, with the total GI of individual diets being 
determined by multiplying GI by available CHO in grams. The sum of all foods 
was divided by total daily CHO intake. In agreement with Frost et al (1999), 
only HDL-C showed a negative correlation with LGI diets and only within the 
northern, western, and eastern parts of Europe. Plasma TC, LDL cholesterol, and 
plasma TAG showed no correlations with GI.
A large prospective study (Liu et al, 2000) involving 75 521 female nurses (The 
Nurses’ Health Study) examined whether the risk of CHD is related to glycaemic 
load (GL). Food frequency questionnaires were completed on 3 occasions over a 
6 year period. The primary endpoint was the incidence of CHD over 10 years. 
The study concluded that dietary GL had a positive, significant association with 
CHD independent of other variables such as other existing coronary disease risk 
factors and dietary factors. However, this association was only evident in 
women with an elevated BMI. In a smaller cohort of the Nurses’ Health Study, 
Liu et al (2001) investigated the relations of GI and GL with plasma TAG and 
HDL-C. HDL-C (n = 280) showed a negative correlation with GI and GL, 
whereas fasting plasma TAG (n = 185) was positively associated with GL and 
GI.
5.1.7 Intervention studies
There have been 16 studies to date on the effects of the GI on lipid markers of 
CVD, the results of which show mixed responses with regards to plasma TAG 
and HDL-C, and there are only two studies on the effect of GI on LDL 
subclasses. However, many of these studies have observed beneficial effects on 
markers of insulin resistance and anthropometric measures with LGI diets. The 
studies have ranged from 6 -day to 6 -months with both crossover and parallel 
designs and have examined healthy, overweight, hyperlipidaemic, IGT, and
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diabetic (including type I & II diabetics) subjects (ranging from 6 - 6 1  subjects). 
These studies are reviewed in detail in Section 1.4.3.
LGI diets have also been shown to induce changes to total body mass, lean mass 
and fat distribution (Bouche et al, 2002). The authors, showed a decrease in fat 
mass and an increase in lean mass with a LGI diet compared to a HGI diet with 
no change in total mass, in a group of moderately overweight subjects. The 
change in body composition was associated with improved postprandial glucose, 
TAG and insulin profiles.
5.2 Aims and objectives
A study was designed to examine the acute effects of two high CHO diets on 
surrogate markers of CVD with an emphasis on the ALP/metabolic syndrome. 
The diets were designed to be identical in macronutrient composition with one 
diet consisting of a high glycaemic index/load and the other a low glycaemic 
index/load (HGI and LGI respectively). Subjects were recruited with risk factors 
associated with an ALP and/or the metabolic syndrome.
5.3 Materials & Methods
5.3.1 Study volunteers
Male subjects expressing an ALP (raised plasma TAG >1.5 mmol/L, low HDL- 
C < 1 mmol/1, and plasma TC < 6.5 mmol/L) were recruited (n = 14, aged 35- 
60). The subjects were free-living and were free of any medication known to 
affect lipid metabolism. In the event of lipid values being beyond clinical action 
limits the subjects were asked to consult their GP and were excluded from the 
study. Similarly, subnormal values for PCV or haemoglobin, and the existence of 
any liver, endocrine or cardiovascular disease as determined by a standard health 
questionnaire (Appendix III) were grounds for exclusion from the study. All 
selected subjects were asked to refrain from the use of dietary supplements and 
any other pre-existing dietary practices from the outset of the trial.
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5.3.2 Study design
The study was a crossover design with 2 x 2  week intervention periods separated 
by a 1-week wash-out period (Figure 5.1). All dietary manipulations were o f an 
open, free-living, design, that is, subjects were provided with lists o f foods and 
menus appropriate to their dietary phase. They purchased their own food and 
prepared their own meals at home. For the 2-week intervention periods with 
high and low GI foods, subjects were provided with a choice o f daily menus that 
were carefully formulated by a trainee dietician and food scientist to contain 
foods with either a high or low GI (see example o f foods Appendix III). Since 
the GI cannot adequately describe the glucose-raising potential o f a dietary 
carbohydrate, glycaemic loads (GL) were also calculated to provide a 
quantitative measure o f the capacity o f each diet to affect blood glucose.
Hiah GI foods High GI foods
Std. diet2  weeks 2 .weeks. _
Low GI foods
►
Low GI foods
Blood samples (vol): 1 (30 ml)
and visit No.
2 (30 ml) 3 (30 ml) 4 (30 ml)
Figure 5.1 Crossover design. Subjects were randomly assigned to either a HGI or LGI diet for 2 
weeks, following a one week wash-out period the subjects then crossed over to the other diet. 
Blood samples were taken on 4 separate occasions, at the beginning and end of each dietary
phase.
5.3.3 Blood samples
Subjects fasted overnight for 12 h before all visits. At the initial visit subjects 
were given a presentation explaining the concept o f GI and were shown 
examples o f both the HGI and LGI diet menus. The menus showed photographs 
o f typical high and low GI foods and examples o f foods (E.G. Yam) were 
exhibited to aid compliance. They completed a health questionnaire and were
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provided with a volunteer information sheet. If selected, subjects provided blood 
samples on four further occasions, at the beginning of the study and at the 
beginning and end of each intervention arm (Fig. 5.1). At each visit they were 
given dietary advice, diet diaries, and menus appropriate to their forthcoming 
intervention. At each visit, anthropometric measurements including body mass, 
BMI and waist were measured, after which they were given breakfast. All blood 
samples were taken by venepuncture by a trained phlebotomist. A total blood 
volume of 30 ml was taken at each visit.
5.3.4 Measures o f  food intake and dietary compliance
Food intake and dietary compliance were assessed by two 5-day food diaries 
completed during the high and low GI dietary phases, including one weekend 
day. Subjects were instructed on how to complete the diet diaries that included 
photographs of portion sizes (Appendix III). As the study was designed to test 
the effects of GI/GL on plasma lipids and lipoproteins it was important to 
maintain body weight during the trial, especially since low GI foods tend to 
produce relatively greater satiating effects than high GI foods and can promote 
weight loss (Roberts, 2003). In addition, the amount and composition of dietary 
fat and dietary fibre was controlled in an attempt to prevent non-GI induced 
effects in biochemical end-points. This was attempted by providing both 
standard oil and spreads and careful design of the provided menus.
5.3.5 Laboratory measurements
Total plasma TC, TAG, HDL-C, LDL-C and glucose were measured as 
described in Section 2.3. Plasma insulin was analysed as described in Section 
2.6. LDL subclasses were analysed as described in Section 3.1.3.1.
5.3.6 Study power calculations
The calculation of sample size (number of subjects) required to achieve a 
statistically significant change in plasma TAG in this study was based on existing 
values for the change and standard deviation of plasma TAG in response to high
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and low GI diets. An estimate of these values based on a study similar to the 
present study (Luscome et al, 2001) showed a decrease in plasma TAG of 0.33 
mmol/L (mean SD = 0.28 mmo/L) in response to moving from a high to a low GI 
diet. Power calculations based on these values indicate that 12 subjects were 
required to achieve an 80% probability (power) of obtaining P < 0.05. The 
standard deviations and changes in our other measured variables in response to 
the dietary intervention were more difficult to predict but unlikely to be more 
sensitive to changes in GI, necessitating the need for a larger sample size.
5.3.7 Statistical analysis
Data was analysed for normality and skewed parameters were logarithmically 
transformed before analysis. The effect of GI on all measured variables was 
assessed by 2-way repeated measures ANOVA with time (0, 2, 3, and 4 weeks) 
and GI status (high versus low GI) as the independent variables. Pre versus post­
dietary effects were assessed by paired Student t-test. A probability level of < 
0.05 was considered significant. In addition, a test for the order effect was 
employed using a General Linear Model. All statistical analysis was performed 
using SPSS statistical package (version 11.5).
Preliminary analysis of outcome measures revealed inconsistent responses 
between the dietary. Since the pattern of response to each dietary phase 
suggested an order effect, the results are presented in two formats, differentiated 
by the sub-headings: Crossover and Effect o f order respectively.
5.4 Results
5.4.1 Baseline characteristics
Table 5.2 shows the baseline characteristics of the subjects including 
anthropometric and biochemical parameters. Subjects were initially 
characterised by raised plasma TAGs, low HDL-C and a predominance of 
sdLDL and therefore expressed the phenotype of an ALP (Austin, 1990). In 
addition, subjects exhibited high insulin levels, raised BMIs and waist
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measurements (> 100 cm); consistent with the metabolic syndrome (Reaven, 
1994).
Baseline characteristics (n = 16)
Age 53 ± 7
Mass (kg) 87.8 ± 13.8
Waist (cm) 101.2 ±11.3
BMI (kg/m2) 28.2 ±3 .8
Choi. (mmol/L) 5.62 ± 0.84
TAG (mmol/L) 2.51 ±0.68
HDL-C (mmol/L) 0.95 ±0.14
LDL-C (mmol/L) 3.77 ±0.68
% sdLDL 49.6 ± 15.2
Glucose (mmol/L) 5.9 ± 0.7
Insulin (nmol/L) 142 ± 74.3
HOMA (Ins x glu/22.5) 37.8 ±21.5
Table 5.2 Baseline characteristics. Mean ± SD
5.4.2 Dietary composition
The only significant differences between the HGI and LGI dietary arms were, GI 
and GL (P values < 0.05); therefore, showing that the dietary advice through 
menus was successful. Although dietary fibre increased ~ 5 g during the LGI 
phase this did not quite reach significance. Table 5.3 provides a summary of the 
main dietary characteristics of the two diets, and Appendix III shows the 
complete dietary information with examples of menus.
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HGI LGI Difference
Energy (kJ) 9915 ± 1821 9468 ± 1945
-446 + 2110
CHO % 48 ± 6 47 + 7 -1 ± 7
Fat % 32 ± 6 33 ± 6 1 ± 6
Protein % 18 ± 3 18 ± 3 -0.2 + 4
Dietary fibre (g) 22 + 7 27 ± 9 5
GI 64 ± 8 50 ± 6 -13 **
GL 184 ± 58 138 ± 51 _46 **
Table 5.3 Dietary information. Means ± SEM. Shows the basic dietary composition and the 
GI and GL o f the two dietary phases (** = P < 0.01).
5.4.3 Anthropometries
5.4.3.1 Anthropometries crossover (n = 14)
Body mass, BMI and waist measurements were not significantly different with 
time during the HGI arm (Figure 5.2). However, with the LGI arm subjects there 
was a significant decrease in body mass of 0.7 kg within group that was 
accompanied by a reduction in BMI and waist measurements (P < 0.05, P < 0.05, 
and P = 0.051 respectively, Figure 5.2). When comparing between group end­
point values of both diets there were no significant differences with any of the 
anthropometric measures.
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Figure 5.2 Anthropometries. Changes in anthropometries showing significant reductions in 
body mass (BM) and BMI; with waist girth approaching significance within the LGI diet. * = 
significant difference within-group (P < 0.05).
5.4.3.2 Anthropometries, effect o f  order (n = 7)
When taking order into account, the within diet changes for body mass and BMI 
showed significant reductions on the LGI 1st arm (Table 5.4). However, there 
were no significant differences between groups and no significant effect o f order.
% Change in Anthropometries
HGI 1st
(N = 7)
LGI 2nd
(N = 7)
LGI 1st
(N = 7)
HGI 2nd
(N = 7)
Body mass (kg) -0.4 ± 1.1 -0.4 ± 0.36 -1.3 ±0.3  ** -0.4 ± 0 .26
BMI (kg/m2) -0.4 ± 1.1 -0.4 ±0.36 -1.3 ±0 .3  ** -0.4 ± 0.26
Waist -1.1 ± 0 .9 -2.0 ± 0 .9 -0.9 ± 1.1 -0.4 ± 0 .6
Table 5.4 Changes in Anthropometries (order effect). Means ± SEM. Shows the effect of 
order on body mass, BMI and waist. ** P < 0.001.
5.4.4 Lipids
5.4.4.1 Lipids, Crossover (n = 14)
There were no significant changes in any plasma lipids (between or within 
groups) other than the TAG:HDL-C ratio which showed a significant within
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group reduction on both diets over time, being more pronounced on the HGI diet 
(-17%). Plasma TAG was reduced within group on both diets at ~ 14% and 10% 
for HGI and LGI respectively, though neither reached significance. sdLDL 
(%AUCB) showed a concomitant reduction with plasma TAG with ~ 10% and 
2.0% respectively for both HGI and LGI arms, but neither reached significance. 
There were also non-significant changes in HDL-C, TC:HDL-C and the ratio of 
LDL-C/HDL-C within both arms of the study. Table 5.5 displays the means and 
the percentage change and Figure 5.2 summarises the most pronounced changes 
in plasma lipids. Comparisons between groups (end-point or differences) 
showed no significant differences.
Lipid (mmol/L) Baseline Post HGI %
Change
Baseline Post LGI %
Change
TC 5.54 ±0.19 5.48± 0.22 -1.1 5.38 ±0.29 5.26 ± 0.23 -0.2
HDL-C 0.93 ± 0.04 0.96 ± 0.04 3.6 0.93 ± 0.05 0.94 ± 0.03 2.9
LDL-C 3.67 ±0.16 3.68 ±0.19 0.4 3.68 ±0.22 3.58 ± 0 .20 -0.73
TAG 2.74 ± 0.36 2.02 ±0.17 -14.2 2.32 ±0.21 1.95 ±0.18 -9.9
TC:HDL-C 5.99 ±0.15 5.71 ±0.15 -4.2 5.79 ± 0.12 5.63 ± 0 .16 -2.75 t
LDL-C:HDL-C 3.95 ±0.11 3.83 ±0.14 -3.0 3.94 ±0.09 3.81 ± 0 .14 -.3.5
TAG:HDL-C 3.09 ±0.49 2.10 ± 0.15 -17.1 * 2.49 ±0.16 2.08 ± 0 .17 -13.8 *
LDL Peak d (kg/L) 1.036 ± 1.035 ± -0.1 1.036 ± 1.036 ± 0.0
0.003 0.003 0.003 0.003
sdLDL (%) 50.4 ±4.1 44.4 ±4.1 -10.2 52.3 ± 5.3 48.4 ± 3.9 -2.0
Table 5.5 Changes in plasma lipids. Means ± SEM. * = significant difference within-group, (P
< 0.05).
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Figure 5.3 Changes in lipids. Shows the more pronounced changes in plasma lipids (* = P <
0.05).
The changes over time were most evident in the subjects who performed the LGI 
phase first (LGI 1st); these 7 subjects all showed reductions in plasma TAG and 
6/7 showed a decrease in TC (with one showing no change, Figure 5.4 and Table 
5.6). There was a significant interaction between time and dietary order with 
respect to the cholesterol response (P < 0.05), but not with plasma TAG. 
Nevertheless, the reduction in plasma TAG was remarkable with a 29% fall (P < 
0.05); plasma TC was less dramatic with a decrease o f 6% (P < 0.05). In 
addition, there was a decrease in both LDL-C and HDL-C (-11.6%, NS and - 
6.3%, P < 0.05 respectively). These changes had no significant effect on 
TC:HDL-C or LDL-C:HDL-C (Table 5.5), but the TAG:HDL-C ratio was 
significantly reduced (-24%, P < 0.05).
Subjects who performed the HGI 1st showed a significant decrease in the 
TC:HDL-C ratio (-5%, P < 0.05) -  this was due to a small but non-significant 
increase in HDL-C and no change in plasma TC. There were no within diet 
changes with the ratio o f LDL-C/HDL-C or in sdLDL (peak density) on either
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dietary phase, though the LGI 1st and both HGI phases showed non significant 
reductions respectively in sdLDL (%AUCB, Table 5.6).
A Change in Lipids
TC (mmol/L)
HGI 1st
(N = 7) 
0.0 ± 0.23
LGI 2nd 
(N = 7) 
0.36 ± 0.28
LGI 1st
(N = 7)
-0.6 ±0.21
*
HGI 2nd 
(N = 7) 
-0.14 ±0.23
HDL-C (mmol/L) 0.05 ± 0.04
*
0.07 ± 0.06 -0.07 ± 0.02 -0.01 ± 0.04
LDL-C (mmol/L) 0.11 ± 0.19 0.27 ± 0.20 -0.49 ± 0.22 -0.09 ± 0 .10
TAG (mmol/L) -0.41 ± 0.37 0.04 ± 0.25 -0.78 ± 0.24
*
-1.03 ± 0 .58
TC.HDL-C -0.32 ±0.1
*
-0.11 ±0.21 -0.22 ± 0 .16 -0.24 ±0.31
LDL-C:HDL-C -0.09 ± 0.07 -0.05 ±0.12 -0.23 ±0.18 -0.15 ± 0 .17
TAG:HDL-C -0.7 ± 0.5 -0.16 ±0.18 -0.65 ± 0.25
*
-1.27 ± 0 .77
LDL Peak density (kg/L) 0.00 ± 0.00 0.00 ±0.00 0.00 ± 0.00 0.00 ± 0 .00
sdLDL (%AUCB) -6.1 ±5.1 0.13 ±0.45 -8.0 ±6.1 -6.0 ±4.1
Table 5.6 Changes in plasma lipids (order effect). A changes are presented showing 
significant differences mainly within subjects who were assigned to the LGI 1st phase. * = P <
0.05. Means ± SEM.
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Figure 5.4 Lipid changes (order effect). Shows the individual responses to the order of each 
dietary phase in plasmaTC and TAG. The effect o f order was significant with regards to TC (P <
0.05). * = P < 0 .05 .
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5.4.5 Effects o f  diets on markers o f IR
5.4.5.1 Effects o f  diets on markers ofIR, crossover (n = 14)
Insulin, glucose, and HOMA all showed reductions on both diets within both 
dietary groups (Table 5.7). The decreases in insulin were significant on the HGI 
phase but not on the LGI phase (P < 0.05 and P = 0.06 respectively). Similarly, 
glucose fell on both diets (~ 5%) but only significantly on the HGI diet (P < 
0.05). HOMA showed significant reductions within both dietary phases, but to a 
greater magnitude on the LGI diet with a drop of ~ 30% (P < 0.05 for both). 
Comparisons between groups (end-point or differences) showed no significant 
differences.
Baseline Post HGI %
Change
Baseline Post LGI %
Change
Insulin 142 ± 74.3 91.6 ±58 .2 -20 * 97 ±39.8 77.3 ± 63.8 -26
(pmol/L)
Glucose 5.9 ± 1.0 5.6 ± 1.0 -4.7* 5.9 ± 0 .7 5.6 ± 1.0 -4.8
(mmol/L)
HOMA 37.7 ±22.1 23.5 ± 16.5 -22.7 * 25.9 ± 11.9 19.8 ± 17.8 -30.1 *
Table 5.7 changes in insulin resistance markers. Means ± SEM. Shows the effect o f HGI and
LGI dietary phases on markers o f IR. * = significant difference within-group, (P < 0.05).
5.4.5.2 Markers o f IR, Effect o f  order (n = 7)
There was clear evidence of an order effect within the LGI 1st phase as all 7 
subjects showed reductions in insulin and HOMA (Figure 5.5). This reduction in 
insulin was marked (- 35%, P < 0.05), although there were reductions in insulin 
(within dietary phase) for the other arms but they were non-significant and 
showed mixed responses with the subjects (Figure 5.5). The drop in HOMA was 
marked, with significant reductions of 42% and 31% for the LGI 1st and HGI 2nd 
arms respectively (P < 0.05 for both). Furthermore, non-significant reductions 
were observed in glucose within both the LGI 1st and HGI 1st arms (-7.2%, P = 
0.27 and -  6.9%, P = 0.06 respectively).
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Figure 5.5. Insulin resistance markers. Shows group and individual responses in insulin and 
HOMA in order of dietary phase. * = P < 0.05. Pre-post = 2 weeks.
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5.4.6 Associations with diet, anthropometries and markers o f  IR
Body mass and BMI on the LGI diet showed positive correlations with waist 
girth (R = 0.85, P < 0.001 and 0.80, P < 0.001 respectively) and percentage 
energy from starch showed a positive correlation with body mass (R = 0.61, P = 
0.02). Waist girth correlated with plasma insulin and HOMA and the decrease in 
waist girth after the LGI diet showed a positive correlation with the decrease in 
HOMA (Table 5.8). This was not observed with the HGI arm.
Waist and IR marker correlations 
HOMA HGI HOMA LGI Ins Ins A HOMA
HGI LGI LGI
Waist girth HGI R 0.48 0.57
P 0.08 0.03
Waist girth LGI R 0.58 0.59
P 0.03 0.03
A waist girth R 0.531
LGI
P 0.051
Table 5.8 Associations with waist girth and markers of IR. Shows correlations with waist 
girth and markers of IR (red shows significance).
5.5 Discussion
The aims o f this study were to test the hypothesis that a LGI diet would reverse 
the abnormalities o f an ALP and a HGI diet would exacerbate this dyslipidaemia. 
When presented as a cross-over, as designed, the study presents little evidence to 
support this hypothesis. The LGI diet was accompanied by small reductions in 
body mass, BMI and greater reductions in markers o f  IR whereas the HGI 
produced the greatest effects on plasma lipids. Only the ratio o f TAG/HDL-C 
ratio showed significant reductions and this was true for both low and high GI 
arms o f the study. When comparing the effect o f order had on measured 
outcomes, it was quite clear that subjects who undertook the LGI arm first 
showed favourable outcomes in nearly all o f the measured variables. These 
improvements appeared to have a carry-over effect when moving over to the HGI 
phase. Whereas those who performed the study in the reverse order (HGI 
followed by LGI), showed no significant improvements after either arm. Indeed 
there was evidence o f adverse effects on plasma lipids; LDL-C and plasma TAG
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were raised after both HGI and LGI phases had been completed. It is important 
to note, when employing the statistical test for order, that only plasma TC 
showed a significant interaction with time and order. The reason the other 
measures did not show an effect of order may be because of the small sample 
size and that the GLM employed to test the order effect was not sufficiently 
powerful. Furthermore, two subjects gave extremely variable results one with 
plasma TC and the other in plasma TAG within the HGI and LGI arms 
respectively. Although the values appeared as outliers, statistical tests showed 
they were within the normal range of variance and removing the subjects from 
the analysis did not alter the outcome.
It is important to note that the results presented here are based on a comparison 
of means from pre-dietary phase to post-dietary phase. When comparing 
between group end-point or differences between the two phases, with regards to 
the original crossover design or when taking order of diet into account, there 
were no significant differences between the two dietary regimes. Therefore, 
although some of the data here does support the original hypothesis (i.e., 
reduction of plasma TAG) the magnitude of difference between the HGI and LGI 
was negligible.
5.5.1 The effect o f glycaemic index on plasma lipids
To date this is the first study to specifically test both high and low GI diets in an 
otherwise healthy population with an ALP. Two other studies have investigated 
the effect of GI on sdLDL (Luscombe et al, 1999 and Dumesnil et al, 2001) in 
the former study the subjects were type II diabetics. Although not mentioned, 
they did express ALP characteristics with elevated plasma TAG, low HDL-C and 
a small LDL particle diameter. This study had a similar outcome to the present 
study with no change in sdLDL particle size and plasma TAG between groups. 
In contrast to the present study, HDL-C was higher on the LGI diet compared to 
the HGI diet (comparison of end-point means). In contrast, Dumesnil et al 
(2001) observed a decrease in plasma TAG and an increase in LDL size with no 
change in HDL-C using moderately overweight subjects who expressed ALP 
characteristics. However, the LGI arm of the study was accompanied by an
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increase in energy from protein at the expense of CHO. This is likely to 
confound the GI effect, as high-protein diets have been shown to improve the 
lipid profile (Wolfe & Piche, 1999; Wolfe, 1995; Wolfe & Giovannetti, 1991). 
Therefore, this present study is the first to directly address the effect of LFHC 
diets (HGI vs. LGI) in a non-diabetic ALP population.
Of the 16 previous studies that examined the effect of LGI diets on plasma TAG, 
6  showed significant reductions and 10 showed no effect. Of the 6 studies that 
showed a fall in plasma TAG, Dumesnil et al (2001) reported a marked decrease 
from 2.00 mmol/L to 1.31 mmol/L (35% change) in just 6 -days, which was 
comparable to the present study in the group on the LGI diet 1st (29% reduction). 
However, as mentioned above, this study was designed with high protein intakes. 
In a study by Jarvi et al (1999), the authors observed an equivalent fall in plasma 
TAG in both high and low GI groups. In this case the GIs of both the HGI and 
the LGI diets were 83 and 57 respectively (white bread reference) -  the 
difference in GI was achieved by changing, mechanically, the nature of the 
CHO-rich foods, as for example prescribing whole beans versus ground beans. 
Other than this, the low and high GI diets were identical to each other in this 
study. Therefore, although this was a very well designed study, the authors state 
that both dietary treatments were an improvement over the subject’s habitual 
diet. The present study is in agreement with Jarvi et al (1999) in that plasma 
TAG levels were reduced in both arms of the study. Furthermore, it is 
reasonable to speculate that both arms of the present study were beneficial 
relative to the subjects’ habitual diets. In a similar study design, albeit with 
diabetics Wolever et al (1992) showed that plasma TAGs were not significantly 
different between the LGI and HGI diets. However, plasma TAGs fell on the 
LGI arm (- 0.54 mmol/L) and were raised during the HGI phase (0.13 mmol/L). 
These results are in accord with the present study, when considering the order 
and carry-over effect, i.e. plasma TAG increased (9.3%) going from HGI 1st -  
LGI 2nd and decreased (23%) from LGI 1st to HGI 2nd therefore depending on 
phase and order of dietary assignment.
Only two studies to date have specifically investigated non-diabetic, 
hyperlipidaemic subjects with high and low GI diets (Jenkins et al, 1987a and
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Jenkins et al, 1985). In the 1987 study, different subgroups of hyperlipidaemia 
were tested and it was reported that the groups with the raised plasma TAG 
levels showed a greater reduction than the group as a whole. Furthermore, the 
subgroup with raised plasma TC (type Ha hyperlipidaemia) showed no 
significant changes in serum lipids. Although, the analysis of subgroups is a 
useful investigative tool it also reduced the power of the study through reduced 
sample size, from 30 into subgroups of (6  type Ha, 7 type lib, 16 type IV and 
only 1 type III). In Jenkins’ 1985 study, 12 hyperlipidaemic subjects were 
categorised into 3 subgroups: 8 type IV, 3 type lib and 1 type III. This study also 
observed a decrease in plasma TAG during the LGI phase with 4 out of the 7 
subjects with higher baseline plasma TAGs compared to 2 subjects with lower 
baseline plasma TAGs; this was not tested statistically as the sample size was too 
small. In the present study, the initial plasma TAG level had no effect on the 
end-point measures when examined as a crossover design or when taking order 
into account, possibly because 12/14 subjects displayed high initial plasma TAG 
levels.
Frost et a l (1994) examined the effect of LGI dietary advice versus standard 
dietary advice (1982 British Diabetic Association dietary recommendations) in a 
group of type II diabetics (n = 51). The study was a parallel design for 12 weeks. 
Results showed significant reductions in plasma TAG within the LGI group but 
with no effect in the standard dietary advice group. Plasma TC, blood glucose, 
and fructosamine were reduced in both groups, whereas HDL-C showed no 
change in either group. The changes seen in the lipid profile in this study are 
difficult to interpret. Although the authors gave advice to keep all the dietary 
parameters equal except the GI, on analysis of food diaries percentage energy 
from fat was significantly less in the LGI group, which resulted in significantly 
greater CHO consumption. In addition, total non-starch polysaccharides were 
increased. These discrepancies may have contributed to the observed 
improvements in the lipid profile. The effects of LGI diets on HDL-C are 
inconclusive. The majority of studies show no significant changes; only a study 
by Luscombe et al (1999) observed increases in HDL-C with a LGI diet, there 
was also a decrease in HDL-C in the HGI group. In contrast, and in agreement
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with the present study, Wolever & Mehling (2003) showed an increase in HDL- 
C in the HGI group, with no change in the LGI group.
Total and LDL cholesterol have also shown mixed responses to low and high GI 
diets with 50% of studies showing a fall with a LGI diet with respect to plasma 
TC and 50% showing no change; the outcomes for LDL-C are less supportive for 
a LGI diet with only 2/3 studies showing a reduction.
5.5.2 Possible mechanisms o f LGI diets
The general consensus amongst studies is that there is a variable response in 
plasma lipids to high and low GI diets. This is probably due to a combination of 
limited sample size, difference in dietary designs, and poor dietary compliance. 
Nevertheless, improvements in markers of an ALP and the metabolic syndrome 
have been observed with LGI diets; though the possible mechanisms that confer 
these improvements have yet to be elucidated. Suggested mechanisms for the 
reduction of plasma TAG include a reduced production of VLDL due to 
decreased availability of NEFA through insulin sensitivity (Martins & Redgrave, 
2004). While human studies have shown a mixed response with regards to the 
effects of LGI diets on insulin sensitivity (Ludwig, 2002), animal studies have 
provided some evidence of a favourable response. In rats following a HGI diet 
hyperinsulinaemia occurred followed by insulin resistance within 8 - 1 2  weeks 
(Ludwig, 2002). Human studies with increased meal frequency or “sipping” 
have observed lower daily insulin and glucose responses due to delayed CHO 
absorbance (Jenkins et al, 1992); LGI diets may work in a similar way because 
of delayed gastric emptying and therefore a slower rate of CHO absorbance. 
Following a HGI meal, CHO is absorbed rapidly, increasing circulating blood 
glucose and therefore stimulating insulin release, glucagon suppression and an 
overall anabolic state. When lipogenesis, glycogenesis, and glucose uptake are 
stimulated, NEFA, lipolysis, and hepatic glucose uptake will be suppressed. 
Between 2 - 4 h after the consumption of a HGI meal, postprandial 
hypoglycaemia ensues. However, the metabolic state described above is 
maintained, albeit to a lesser extent. After 4 -  6  h, counterregulatory hormones 
are released due to the hypoglycaemia; which in turn stimulates gluconeogenesis,
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glycogenolysis, and lipolysis promoting elevated circulating NEFA. In theory, 
with LGI diets, normoglycaemia should be sustained between 4 -  6  h 
postprandially limiting stimulation of counterregulatory hormones and 
maintaining normal NEFA levels (Ludwig, 2002).
The above mechanism may explain how HGI and LGI diets differ with regards to 
circulating NEFA. With the HGI diet NEFA is ultimately elevated which can 
lead to increased uptake and utilisation for TAG re-esterification and VLDL 
synthesis and production in the liver. Parks and Hellerstein (1999) reviewed 
studies from the 1950’s to the present and the prevailing theory places insulin 
resistance as the most likely metabolic derangement, through failure to suppress 
lipolysis and NEFA release. However, insulin plays a controversial role as it 
stimulates the synthesis and storage of TAG and acutely inhibits VLDL 
secretion. This inhibition may be overcome, as the liver may have an 
overwhelming need to export the synthesised and stored TAG. In the present 
study, subjects showed characteristics of an insulin resistant state with raised 
insulin levels and evidence of visceral fat (waist >100  cm). The response to 
high or low GI diets provided evidence to suggest an improvement in insulin 
sensitivity and HTG and does not support the above theory with regards to HGI 
diets. Although it cannot be ruled out that both diets were an improvement 
relative to the subjects’ habitual diet. Furthermore, the favourable outcomes in 
insulin sensitivity and HTG were of a greater magnitude with subjects who 
performed the LGI diet first; although there were no relationships between the 
reduction in plasma TAG and insulin or HOMA levels; which may be due to 
small sample size and a large variation within these measurements. 
Unfortunately data on the time course of metabolic events were not collected 
with the present study and therefore only speculation regarding mechanisms of 
reducing HTG and other outcomes observed can be made.
Other potential sources of fatty acids for CHO induced TAG synthesis may be 
from de novo lipogenesis (Fried & Rao, 2003; Frayn & Kingman, 1995). Both 
glucose and fructose are enzymatically broken down to glycerol-3-phosphate 
(G3P), with fructose by passing the rate-limiting step of phosphofructokinase 
(Frayn & Kingman, 1995). G3P can be converted to glycerol or can continue in
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glycolysis to produce acetyl coA and ultimately fatty acids. Both fatty acids and 
glycerol can be utilised for the production of TAG. Although the above 
substrates for de novo lipogenesis can be made available in this manner, they 
contribute only a small amount to the fatty acid pool for increase TAG synthesis 
and VLDL production as the absolute rate is too slow (Fried & Rao, 2003; Parks 
& Hellerstein, 1999). In contrast, Schwarz et al (2003) provide evidence that de 
novo lipogenesis is a major contributor to HTG.
The consequences to LDL with CHO induced HTG may be two-fold and 
depends on VLDL production. If VLDL overproduction occurs then it may be 
either an increase in VLDL particle number or VLDL size or indeed both. With 
VLDL only possessing one molecule of apoB (Elovson, 1988) then an increase 
in particle number would lead to an increase in VLDL-C and ultimately an 
increase in LDL-C. If VLDL particle number is constant and VLDL size is 
increased due to elevated TAG then the consequence would be a smaller denser 
LDL particle -  through the action of CETP, LPL and HL. There is evidence that 
both these scenarios occur with CHO-induced HTG (Huff & Nestel, 1982; and 
reviewed by Parks & Hellerstein, 1999). In the present study, there was a 
reduction in both LDL-C pronounced with the LGI arm 1st and LDL size in both 
arms of the study suggesting a reduction in both VLDL particle number and size.
A third possible mechanism is through decreased plasma TAG clearance; early 
studies (Knittle & Ahrens, 1964; Mancini, 1973; Melish et al, 1980; Huff & 
Nestel, 1982) provided evidence that CHO-induced HTG is caused by a reduced 
rate of TAG clearance with insulin playing a critical role. The major enzyme for 
the lipolysis of TGRL is LPL and it is has been suggested that insulin decreases 
LPL activity in muscle after feeding high CHO meals (reviewed by Parks & 
Hellerstein, 1999). LPL activity is induced by apo CII and inhibited by apo CIII; 
apo CIII levels have been shown to be increased in the metabolic syndrome 
(Oliviero et al, 2003). The present study found subjects to be hyperinsulinaemic 
and showing characteristics of the metabolic syndrome. Insulin plays a role in 
both the synthesis and secretion of LPL; gene expression of LPL occurs via 
PPARa and PPARy (Hanyu et al, 2004; Martin et al, 1998); these nuclear
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receptors bind to perixisome proliferators-responsive element (PPRE) at the LPL 
gene promoter and increase LPL expression; however, in the acute postprandial 
phase insulin is more likely to have a posttranslational or translocational effect 
on LPL A study by Knutson (2000) showed that adipocytes in vitro treated with 
low levels of insulin stimulated the release of LPL from the plasma membrane 
mimicking translocation from paraenchymal cells to endothelial cells; 
furthermore, the study showed chronic stimulation with insulin resulted in no 
LPL release. Therefore, it is feasible that in an insulin resistant (IR) state, as in 
the metabolic syndrome (MS), as tissues become resistant to insulin LPL release 
and gene expression may be attenuated, resulting in reduced LPL activity and 
therefore decreased TAG clearance. The above, however, only occurs in muscle; 
adipose tissue increases in LPL activity in IR and therefore induces lipogenesis 
and gains in fat mass (Martin et al, 1998). With a LGI diet insulin levels would 
be expected to be normal and therefore LPL activity to be functioning normally; 
however, a study by Bouche et al (2002) showed LPL activity to be decreased 
with a concomitant reduction in insulin with a LGI diet. In this case subjects 
showed no improvement in markers of IR and therefore the decrease in LPL was 
probably due to lower insulin spikes and the reduction in fat mass observed. In 
the present study, both insulin and HOMA levels were reduced to a greater 
magnitude with the lower GI; however, there were no correlations with the 
reduction in plasma TAG.
5.5.3 The effect o f  LGI diets on body mass
LGI diets have been shown to promote reduction in body mass (Morris, 1999; 
Ludwig, 2002) or fat mass with increases in lean mass (Bouche et al, 2002). A 
reduction in fat mass can have profound effects on lipid metabolism and this may 
be a possible mechanism to explain how LGI diets exert their favourable effects 
on HTG. However, the studies that have shown lowering or no change in plasma 
TAG (Section 1.4.3) showed variable responses with respect to weight loss; with 
some showing correction for weight loss (Jarvi et al, 1999). Therefore, the 
reductions in plasma TAG did not always relate to weight loss. The present 
study showed a small but significant loss of weight and BMI in the LGI group 
but this was unrelated to the reduction in plasma TAG. Nevertheless, lipid
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abnormalities and IR are intimately associated with body fat and the distribution 
of adipose tissue appears to be a more important determinant of these 
abnormalities than overall body fat. Karelis et al (2004) describe three subtypes 
of obesity: 1. metabolically healthy obese; 2. At risk obese; 3. metabolically 
obese normal weight with different BMI and visceral fat status (Table 5.9).
Subtype BMI status Visceral fat
1. Metabolically healthy obese High Low
2. At risk obese High High
3. Metabolically obese normal weight Normal High
Table 5.9 Subtypes of obesity
While in the present study waist girths were elevated and did not change 
significantly with dietary treatment (regardless of weight loss) there was a 
positive and significant correlation with waist girth and insulin and HOMA 
respectively. Although subjects showed elevated BMIs (~ 28 kg/m2) they could 
only be considered to be overweight and not obese. Nevertheless, with elevated 
waist measurements it is likely the fat distribution is abdominal. Although there 
was no overall reduction in waist girth the small decreases were associated with 
decreased HOMA on the LGI arm of the study, thus providing evidence that IR 
markers are improved with decreases in abdominal fat.
The mechanisms by which abdominal body fat distribution contributes to IR and 
lipid abnormalities are controversial. In a review by Frayn (2000) a possible 
mechanism of how IR and the lipid abnormalities associated with IR are explored 
and the author explains the Portal Theory. This theory suggests that NEFA from 
visceral fat can reach the liver quickly via the portal vein and hence exert 
deleterious effects such as HTG and IR. Later Frayn (2000) finds flaws in the 
theory and suggests subcutaneous abdominal fat is a stronger candidate for IR 
due to having larger stores and therefore being a greater provider of NEFA. In 
contrast, Couillard et al (2002) related visceral fat and not subcutaneous fat to an 
increase in apo B48 and apo BlOO-containing TGRL postprandially. In the 
present study it was not possible to differentiate fat deposition and therefore the
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only conclusion possible was that a reduction in waist was associated with a 
decrease in HOMA and thus IR.
The slight weight loss with the LGI arm is hard to explain, since energy levels 
were not significantly different between the two arms of the study. Previous 
studies have shown decreases in satiety with LGI diets (Roberts, 2003), as 
measured by questionnaires. In the present study satiety was not measured and 
therefore this lies beyond the scope of discussion.
5.5.4 LGI diets and short chain fatty acids
An alternative theory to explain the beneficial effects on plasma lipids involves 
short chain fatty acids (SCFA). SCFAs are the product of fermentation in the 
colon and it has been proposed that indigestible CHO from LGI and high fibre 
foods are more likely to produce more SCFA than easy digestible high GI CHO 
(Kendall et al, 2004). SCFA were not measured in the present study and very 
few studies in humans have measured SCFA; therefore, only a brief speculation 
as to how they contribute to the lipid profile is discussed. SCFAs may play a 
role in apo B degradation, assembly, secretion, posttranslational modification and 
therefore reduce VLDL production (Marcil et al, 2002).
In conclusion, the present study provides evidence that a low-fat LGI diet can 
exert beneficial effects on biomarkers of CVD risk (Plasma TC, TAG, LDL-C, 
sdLDL). The only deleterious effect of the LGI diet was a decrease in HDL-C. 
The effects of the low-fat HGI did not, as hypothesised, exacerbate an ALP, nor 
did it show any convincing favourable effects. In addition the LGI diet was 
shown to reduce markers of IR with reductions in insulin and HOMA. The 
results of the present study were limited by sample size and a short wash-out 
period between the two arms of the crossover.
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Chapter 6.0 The effect of low and high-CHO hypoenergetic diets 
Abstract
Background: Both low and high-CHO hypoenergetic diets have been effective for  
weight-loss and lipid modifying, with low-CHO diets achieving greater decreases in 
plasma TAG relative to high-CHO diets.
Hypothesis: Overweight/obese people will respond to a low-CHO diet by reducing 
plasma TAG inducing a favourable effect on markers o f an ALP/metabolic syndrome.
Design: Both low and high-CHO diets were compared against a control for 6-months. 
Subjects were overweight/obese subjects (180) randomised to 1 o f the 3 diets. Endpoint 
measures were surrogate markers o f CVD and anthropometric measures associated with 
the lipid abnormalities o f the ALP/metabolic syndrome.
Results: Weight loss was similar in both treatment groups (~9%), although the low- 
CHO group increased lean body mass. Plasma TAG, LDL peak density, TAG:HDL-C, 
insulin, and HOMA decreased on both diets but to a greater magnitude on the low-CHO 
diet; whereas plasma TC, LDL-C, and HDL-C were reduced to a greater extent on the 
high-CHO diet relative to the low-CHO diet.
Conclusions: The high-protein, high-fat diet promoted relatively greater beneficial 
effects on markers o f an ALP/metabolic syndrome whereas the low-fat, high-CHO diet 
showed a cholesterol-lowering effect.
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6.1 Introduction
Obesity is a major growing concern in the western world through its association with 
increased CVD, certain cancers, gallbladder disease, osteoarthritis, gout, and pulmonary 
disease (Anonymous, 2000) and is now considered a world wide epidemic (Orzano et al, 
2004). Currently 20% of the UK population are considered obese and the level of 
obesity has tripled in the past 20 years, and is still rising. At this current rate, by the year 
2010 at least 1 in 4 adults will be obese (Joint Health Surveys Unit, 1999). Furthermore, 
this prevalence of obesity is likely to be under-reported as described recently by The 
Counterweight Project Team (Laws, 2004). Obesity has been associated with the 
aetiology of dyslipidaemia, the metabolic syndrome, and can lead to diabetes 
(Kutchsman & Hedley; Moller & Kaufman, 2004). Although obesity is not necessarily 
part of an ALP, there is a strong correlation between visceral fat and plasma TAG 
(Karelis et al, 2004; Couillard, 2002) suggesting that accumulation of visceral fat 
underlies the development of an ALP. In addition, it is possible to have a BMI within 
normal ranges and still possess a high proportion of visceral fat (Karelis et al, 2004). 
Consquently, weight loss is an important factor when considering the management of 
dyslipidaemia and CVD (Hooper et al, 2004) and there are a variety of popular weight- 
reducing dietary regimes. The majority of which manipulate macronutrient 
compositions by either reducing dietary fat and increasing CHO or increasing dietary fat 
and protein at the expense of CHO.
Recent interest has grown in high-protein high-fat (HPHF) weight loss diets lately on the 
strength of evidence that they can lower plasma TAG and increase HDL-C more 
effectively than low-fat high-CHO (LFHC) weight loss regimes (Foster et al, 2003; 
Samaha et al, 2003; Sharman et al, 2002; Volek et al; 2003). In addition, HPHF diets 
have displayed favourable effects on LDL subclasses (Sharman et al, 2002) and may 
therefore show promise in reversing the abnormalities associated with an ALP.
Low fat iso-energetic diets have been shown to induce HTG (Section 1.4.2), whereas 
low fat, weight-loss diets produce variable effects on plasma lipids including plasma
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TAG. However, HFHP weight loss diets have shown a greater potential to lower plasma 
TAG and raise HDL-C. HFHP diets are still consumed in modern hunter-gatherer 
societies (Cordain et al, 2002) and constituted the diet of ice-age Palaeolithic man 
(Colagiuri & Brand Miller, 2002) and as such may provide insight into the prevention of 
CVD. Early ethnographic studies indicate that hunter-gatherers would have subsisted on 
> 50% of energy from plant derived foods (reviewed by Cordain et al, 2002). However, 
more recent ethnographic compilation data suggests the majority of hunter-gatherer diets 
consisted of animal products (Cordain et al, 2002; Cordain et al, 2000), making their 
diets higher in fat than current recommended intakes. Despite this, modem day hunter- 
gatherers are free of CVD and demonstrate low levels of plasma TC and plasma TAG 
(Cordain et al, 2002), this may be due to a higher protein and fat intake, with less 
saturated more mono and polyunsaturated fats, and lower ratios of n-6/n-S fatty acids 
compared to western societies. The benefits of a lower ratio of n-6/n-3 fatty acids are 
discussed in detail in Chapter 4; briefly, it promotes a lowering of plasma TAG. In 
addition, the replacement of CHO with protein has also been shown to improve the lipid 
profile (Johnston et al, 2004; Wolfe & Piche, 1999). Even though CHO levels are low in 
these populations, it is likely the type of CHO is highly fibrous and exhibit low 
glycaemic indices (discussed in Chapter 5). Other non-dietary cardio-protective aspects 
of hunter-gatherer lifestyles include higher levels of physical activity (Walker et al, 
2003).
Evidence, from the skeletons of early man (paleolithic humans) indicate that they 
consumed similar diets to carnivorous animals and that larger more energy dense 
animals would have been preferred i.e., a high fat high protein diet (reviewed by Cordain 
et al, 2002). This dietary strategy has been suggested to be beneficial to our ice age 
ancestors and modem hunter-gatherers who show characteristics of insulin resistance 
(IR) (Brand miller & Colagiuri, 1999; Colagiuri & Brand Miller, 2002). Under these 
ice-age conditions the IR would not have led to hyperinsulinaemia and the associated 
lipid abnormalities that accompany hyperinsulinaemia (Colagiuri & Brand Miller, 2002).
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Foster et al (2003) compared a high-protein, high-fat diet (HPHF) with a low-fat low 
energy diet (conventional diet) for 1 year. Subjects (n = 63) were randomly assigned to 
either diet in a parallel design; the subjects allocated to the HPHF diet consumed 20 g of 
CHO with unrestricted protein and fat for the first two weeks. Thereafter, CHO was 
gradually increased until desirable weight loss was achieved. This approach was 
adopted from Dr Atkins’ New Diet Revolution book (Atkins, 2002). The conventional 
energy controlled diet consisted of 1200 -  1500 and 1500 -  1800 kcal for women and 
men respectively, with a macronutrient composition of ~ 60% CHO, 25% fat, and 15% 
protein. Weight loss was significantly greater on the HPHF at 3 and 6 months, although 
at 1 yr there was no significant difference between the two strategies. Plasma TAG was 
reduced with the HPHF group with concomitant increases in HDL-C and this was true 
throughout the study, with the conventional diet only showing decreases in plasma TC 
and LDL-C at 3 months with no significant change in any other lipid measures. Both 
diets resulted in an increase in insulin sensitivity, which may be associated with weight 
loss.
The effects of similar diets were examined in a larger study (Samaha et al, 2003). 
Subjects (n = 132) included obese, diabetics, and metabolic syndrome. The study 
protocol did not exclude lipid-lowering and diabetic drug therapy. The results showed 
that the HPHF diet induced greater weight loss at 2, 4 and 6 months compared to the 
conventional diet. Plasma TAG levels fell to a much greater extent on the HPHF diet, 
with an absolute drop of 38% compared to 7% with the conventional diet. Both weight 
loss and assignment to the HPHF diet were independent predictors of the fall in plasma 
TAG. There were no changes in any other lipid measures. Within the low fat group 
there were no changes in serum lipid values. Plasma glucose levels dropped to a greater 
extent with the HPHF group, limited to diabetics and due to weight loss. Therefore, 
HPHF diets have been shown to be beneficial with respect to plasma TAG and HDL-C 
which is partially related to weight loss. The effects of HPHF diets on the lowering of 
plasma TAG are shown in Table 6.1. Studies on the effects of HPHF diets for the 
treatment of an ALP/metabolic syndrome are limited, this is the only study to date to
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investigate markers of an ALP/metabolic syndrome in a relatively large male and 
female, overweight/obese UK population.
-28 (males) 
-22 (females)
Farnsworth et al 
(2003)
High protein diet vs. standard protein diet, fat constant_(12- 
wk), overweight, obese, hyperinsulinaemic subjects
-17 Foster et al 
(2003)
HPHF vs. conventional low-fat diet (12 mo), obese subjects
-20 Samaha et al 
(2003)
HPHF vs. LFHC (6 mo), obese subjects
-47 Yancy et al 
(2004)
HPHF vs. LFHC (24-wk), overweight, hyperlipidaemic 
subjects
-43 Westman et al 
(2002)
HPHF vs. baseline (no control), overweight, obese (24-wk)
-55 Volek et al 
(2000)
HPHF supplemented with n-3 fatty acids vs. habitual (men 
only)
-20 Layman et al 
(2002)
High CHO/protein ratio vs. low CHO/protein ratio, 
overweight women (10-wk)
-33 Sharman et al 
(2002)
HPHF vs. habitual diet, normal weight men (6-wk)
-44 Sharman et al 
(2004)
HPHF vs. LFHC, overweight men (6-wk)
-22 Volek et al 
(2003a)
HPHF vs. LFHC, overweight women, crossover design, (4- 
wk on each arm)
-33 Volek et al 
(2003b)
HPHF vs. LFHC (isoenergetic), normal weight women, 
crossover design (4-wk each arm)
Table 6.1 Plasma TAG lowering effects of low-CHO diets.
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6.1 Aims and objectives
This study aimed to determine the effects of HPHF and LFHC weight-losing diets with 
the view to decreasing body fat percentage, dyslipidaemia, and insulin resistance 
associated with an ALP/metabolic syndrome. The dietary interventions examined the 
long-term effects on body mass, BMI, lean mass, fat mass, serum lipids, glucose and 
insulin of a HPHF diet compared to a LFHC weight loss diet versus a control diet with 
no dietary advice.
6.2 Materials and methods
6.2.1 Study volunteers
All participants of the study were overweight or obese men and women aged 21-60 
years (BMI > 27 kg/m2 and < 36 kg/m2) who were not losing weight. Participants were 
required to contact their General Practitioner to ask them to confirm, following a 
medical examination, that they were eligible for the study based on the above inclusion 
criteria (or exclusion criteria listed in Appendix IV).
6.2.2 Study design
The study was a randomized parallel dietary intervention. Participants were randomly 
assigned into the HPHF, LFHC or control group for a 6 -month period. Endpoint 
measures include biomarkers of CVD and anthropometric measures associated with the 
lipid abnormalities of the ALP/metabolic syndrome.
All participants were made aware at the start of the study that they will be randomized 
into different dietary groups. The diets that were chosen for the study were selected on 
the basis of being the most highly popularised weight-losing diets in the UK. The diets 
included: Dr Atkins' New Diet Revolution - a HPHF eating plan (HPHF); Weight
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Watchers Pure Points Programme - a group-based low fat dietary programme (LFHC); 
and the control group maintained their habitual diet and received no dietary advice for 
the six month period.
6.2.3 Blood samples
Blood samples were taken and treated as described in Section 2.2 at 0, 3 and 6 months.
6.2.4 Laboratory measurements
Total plasma TC, TAG, HDL-C, LDL-C and glucose were measured as described 
previously (Section 2.3). Plasma insulin was analysed as described in Section 2.6. LDL 
subclasses were analysed as described in Section 3.1.3.1. All biochemical data was 
analysed at intervals of 0, 3 and 6 months.
6.2.5 Anthropometric measurements
Anthropometric measures were taken as described previously (Section 2.8). Body mass, 
waist girth, and calculated BMI measures were taken every month for the duration of the 
intervention.
6.2.6 Compliance
Dietary intakes were measured using 7-day food diaries that were coded by a registered 
dietician and entered into a nutrient analysis programme (Windiet, Aberdeen, UK) to 
assess total energy intake, macronutrient composition and a standard range of vitamins 
and minerals.
6.2.7 Study power calculations
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The sample size was calculated on the basis of the primary outcome measure of body 
weight loss (kg). The calculation was based on previous weight loss studies at the 
University of Surrey. Since weight loss is highly variable, the sample size was 
determined using data from a recently completed study (n = 60). Hence, sample size 
was based on achieving a loss in weight of 3 kg (SD ± 5) to give 80% power of 
achieving P < 0.05. A typical drop-out rate from weight loss studies under research 
conditions is approximately 20-30%. This study will involve a total n of 180 subjects 
distributed between 3 groups, i.e. 60 per group and as such was powered to withstand a 
30% dropout rate. The standard deviations and changes associated with other end-point 
measures in response to the dietary intervention were more difficult to predict but 
unlikely to be more sensitive to changes in macronutrients, necessitating the need for a 
larger sample size.
6.2.8 Statistical analysis
Statistical analysis was performed as described previously (Section 2.10). Briefly, data 
was analysed for both between and within group effects; therefore investigating the 
effects of time and the interaction of time and diet for within effects and comparing 
dietary groups for between group effects. This involved the use of a split-plot ANOVA. 
Further analysis was performed for the effect between groups by comparing the 
difference in variables after 6 months using a one-way ANOVA. In addition, univariate 
analysis was employed to test for any confounding variables E.G. gender and weight- 
loss employing analysis of covariance (ANCOVA). Pearson correlations and product 
moment (r2) coefficients were determined to examine the relationships between 
variables.
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6.3 Results
Due to the design of this dietary intervention i.e. three groups studied at three 
time points for the majority of the variables, the principal outcome measures 
(after 6 -months intervention) are described in the main body of text. While the 
more detailed results are depicted graphically or tabulated with the statistical 
results noted in the legends of the figures and tables.
6.3.1 Baseline characteristics
All subjects were obese as defined by an increased BMI ( > 3 0  kg/m2) and 
elevated body fat percentage (> 34%). Males tended to have higher plasma 
TAG, lower HDL-C and a higher percentage of sdLDL therefore showing some 
characteristics of an ALP (Griffin, 2000; Austin, 1990) (Table 6.1). Plasma TC 
and LDL-C were in normal ranges as was glucose, whereas insulin was slightly 
elevated, especially in men. The elevated insulin, TAG, low HDL-C, and high 
BMI reflected typical characteristics of the metabolic syndrome (Reaven, 1994) 
(Table 6.2).
Baseline characteristics Total population (n = 177) Females (n = 131) Males (n = 46)
Mean (± SE) Mean (± SE) Mean (± SE)
AGE 40.5 (0.8) 41.0 (0.9) 39.1 (1.4)
Body mass (kg) 89.0(1.0) 84.2 (0.9) 102.6(1.6)
BMI (kg/m2) 31.6 (0.2) 31.3 (0.2) 32.2 (0.4)
Waist (cm) 100.7 (0.8) 97.2 (0.8) 110.8(1.1)
Body fat (%) 34.6 (0.5) 34.8 (0.6) 34.0 (0.8)
Fat mass (kg) 30.9 (0.6) 29.5 (0.7) 34.9(1.0)
Lean mass (kg) 58.2 (0.8) 54.8 (0.7) 67.7(1.3)
TC (mmol/L) 5.71 (0.08) 5.7 (0.1) 5.62(0.14)
HDL-C (mmol/L) 1.20 (0.02) 1.26 (0.02) 1.03 (0.03)
LDL-C (mmol/L) 3.61 (0.06) 3.63 (0.07) 3.54 (0.09)
TAG (mmol/L) 1.44 (0.06) 1.30(0.06) 1.82 (0.13)
sdLDL %AUCB) 24.3 (1.44) 19.13(1.15) 37.44 (3.27)
LDL peak density (g/ml) 1.030(0.000) 1.029 (0.000) 1.033 (0.001)
Glucose (mmol/L) 5.5 (0.0) 5.4 (0.0) 5.7 (0.1)
Insulin (pmol/L) 68.37 (2.92) 63.67 (3.04) 81.51 (6.84)
HOMA 16.8 (0.7) 15.5 (0.8) 20.4(1.7)
Table 6.2 Subject baseline characteristics
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6.3.2 Dietary intakes o f macronutrients
When measured at baseline all diets were equal in total energy, percentage 
dietary total fat, total CHO, and protein. After 6 months of the dietary 
intervention energy intake was reduced within all dietary groups (39%, 41%, and 
24% for the HPHF, LFHC, and control groups respectively), with a significant 
effect of time (P < 0.0005) but with no significant difference between groups. 
The percentage energy intake from dietary fat increased 28% within the HPHF 
group and decreased 19% within the LFHC group whereas the proportion of 
energy from CHO decreased 55% within the HPHF group and increased 15% 
within the LFHC group. Percentage energy from dietary protein increased within 
both treatment groups but to a much greater magnitude in the HPHF group (60% 
and 19% for HPHF and LFHC groups respectively). There were no changes in 
the percentage energy from macronutrients within the control group. Table 6.3 
shows the results of the above and Figure 6.1 shows the intake of dietary intake 
in grams, both showing statistical information in the respective legends.
Energy/Nutrient HPHF LFHC CTRL
(n = 6) (n = 9) (n = 4)
Energy (MJ)1
0 mo 11.6 ± 0 .5 12.0 ± 0 .7 10.8 ± 0 .4
3 mo 6.9 ± 0 .5 6.3 ± 0.4 8.3 ±1.1
6 mo 7.6± 0.9 7.0 ± 0.5 8.4 ± 1.3
0 - 6 (% change) -4.6 ± 0.8 
Fat %1'2,3,4,5
-4.9 ± 1.0 -2.6 ± 0.8
0 mo 39.7 ± 1.1 38.1 ± 1.2 39.6 ± 1.7
3 mo 58.9 ±1 .5 27.2 ± 1.8 38.6 ± 2 .7
6 mo 51.7 ± 2.1 30.7 ± 2 .3 38.8 ±2.1
0 - 6  (% change)4,5 11.3 ± 2 .6  
CHO %2,3,4,5
-7.3 ± 2.5 -0.0 ±2.1
0 mo 36.8 ± 1.2 43.0 ± 1.8 43.6 ± 1.5
3 mo 10.4 ± 1.9 47.5 ±2.1 41.22± 3.8
6 mo 17.2 ± 2 .6 50.2 ± 2.4 43.1 ± 3 .2
0 -  6 mo (% change)4,5 -20.5 ± 2.0 
Protein o/o1’2,3,4,5
6.5 ± 2 .6 -0.8 ± 1.9
0 mo 15.9 ± 0 .7 13.5 ± 0 .6 14.8 ±0 .3
3 mo 27.4 ±1.1 17.9 ± 0 .8 15.6 ± 0 .4
6 mo 25.8 ± 1.4 16.3 ± 1.3 16.00± 1.8
0 -  6 mo (% change)4,5 9.6 ± 1.3 2.6 ± 1.0 0.9 ±1.5
Table 6.3 Energy and macronutrient intakes. Results are means ± SEM.1 significant effect o f  
tim e.2 significant effect o f treatment (diet).3 significant effect o f the interaction o f time and 
treatment.4 Significant difference between treatment groups.5 Significant difference from
control. P < 0.01
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Figure 6.1 Dietary intake. Shows the intake of fat, protein, and CHO at baseline, 3 & 6 months. 
Results are means ± SEM.1 significant effect o f tim e .2 significant effect o f treatment (d ie t).3 
significant effect o f the interaction of time and treatm ent.4 Significant difference between 
treatment groups.5 Significant difference from control. P < 0.05
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6.3.3 Anthropometric measurements
Body mass, BMI, and waist girth were measured at the beginning of the study 
and thereafter once every month for the total of 6  months. At baseline, there 
were no significant differences between the dietary groups. After 6  months, 
there was an equal decrease in body mass and BMI of 9% within the HPHF and 
LFHC groups respectively. Similarly waist girth was reduced by 10% for both 
treatment groups. There were no significant differences between dietary 
treatments for body mass and waist girth, although there were significant 
difference with the control group. BMI decreased to a greater magnitude in the 
LFHC compared to the HPHF group and the control. The results over 6  months 
with statistical information are shown in Figure 6.2.
Body fat percentage was measured at baseline, 3 and 6  months, there were no 
significant differences between groups at baseline. After 6 months of the dietary 
intervention body fat percentage decreased 6 .8% and 6.5% within the HPHF and 
LFHC groups respectively with concomitant decreases in fat mass (8.7% and 8% 
respectively for HPHF and LFHC groups) and the following changes in lean 
mass (0.5% and -0.3% for HPHF and LFHC groups respectively). There were 
significant differences between treatment groups and the control, but not between 
treatment groups (Table 6.4).
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Figure 6.2. Differences in body mass, BMI and waist girth. A = Body mass (weight), B = 
BMI, and C = waist girth. Results are means ± SEM.1 significant effect o f tim e .2 significant 
effect of treatment (d iet).J significant effect o f the interaction of time and treatment. 4 Significant 
difference between treatment groups.5 Significant difference from control. P < 0.01
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HPHF LFHC CTRL
Body fat %1’3 mean SEM mean SEM mean SEM
0 mo 35.76 0.80 34.39 0.89 33.79 0.92
3 mo 31.50 1.00 31.20 1.02 33.39 1.13
6 mo 28.61 1.08 28.15 1.20 34.42 1.20
0 -  6 mo (% change)5 -6.84 0.69 -6.53 0.56 0.54 0.29
Fat mass (kg)1,3
0 mo 32.45 1.03 30.36 0.90 29.94 1.05
3 mo 25.45 0.99 25.55 1.05 29.22 1.65
6 mo 23.24 1.15 22.76 1.25 31.11 1.74
0 - 6 mo (% change)5 -8.68 0.90 -8.08 0.56 1.02 0.40
Lean mass (kg)
0 mo 57.89 1.18 58.33 1.49 58.23 1.31
3 mo 56.95 1.29 57.11 1.71 60.26 2.22
6 mo 59.26 1.53 58.81 1.82 61.11 2.21
0 -  6 mo (% change) 0.53 0.98 -0.28 0.68 -0.01 0.45
Table 6.4 Changes in Anthropometric measures. Results are means ± SE M .1 Significant 
effect o f time. 2 significant effect o f treatment (diet).3 significant effect o f the interaction o f time 
and treatment. 4 Significant difference between groups.5 Significant difference from control.
6.3.4 Plasma lipids
Fasting lipids were measured at baseline, 3, and 6  months, there were no 
significant differences between groups at baseline. After 6  months all groups 
showed a decrease in plasma TC, LDL-C and HDL-C, with the LFHC group 
showing the greatest magnitude; with TC and LDL-C being significantly 
different from the control but not with the HPHF group (P = 0.038). With 
respect to plasma TAG and the ratio of TAG/HDL-C the HPHF group showed 
impressive reductions of 28% and 18% respectively. Whereas the findings for 
the LFHC group were a modest increase in the ratio of TAG:HDL-C of 6% and a 
decrease in plasma TAG of 13% with significant difference with the HPHF 
compared to the control respectively (P < 0.001). The ratio of TC/HDL-C 
showed a slight increase in the LFHC group with no change in the HPHF group 
whereas the findings for the ratio of LDL-C/HDL-C showed increases of ~ 5% 
for the treatment groups and more than double the increase in the control group.
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Small dense LDL was measured as %AUCB and peak density at baseline and 
again at endpoint, there was no interim measurement. There were no significant 
differences at baseline or end-point with %AUCB or peak density. However, 
when comparing the change in LDL peak density there was a significant 
difference between dietary groups (P = 0.015). Post-hoc tests revealed the HPHF 
group showed the greatest reduction compared to the control (P = 0.008, Figure 
6.4). Table 6.5 shows the percentage changes after the 6  month dietary 
intervention including statistical information, whereas Figures 6.3 -  6.5 and 
Table 6 .6  show the actual results of the plasma lipids at baseline, 3, and 6 
months.
Lipid/lipoprotein HPHF LFHC Control
TC4 -7.6 (2.6) -11.0(17) -4.5 (1.7)
TAG1’3’4 -28.3 (5.7) -12.7 (5.0) 5.0 (6.5)
HDL-C -6.4 (3.3) -14.3 (1.9) -11.2(1.4)
LDL-C1’4 -3.8 (3.1) -10.7(1.9) -1.6 (2.1)
TCiHDL-C1’3 0.7 (2.4) 4.9 (1.8) 9.7 (2.2)
LDL-CiHDL-C1’4 4.9 (3.0) 5.1 (1.9) 13.0 (2.6)
TAGiHDL-C1’3 -18 (7.6) 5.8 (7.7) 21.8(7.9)
sdLDL (AUCB%) -30.2 (7.1) -35.3 (4.7) -25.4 (4.4)
LDL peak density1,3 -0.3 (0.0) -0.2 (0.0) -0.14 (0.0)
Table 6.5 Percentage changes in lipids after 6 months. Results are means (± SEM ).1 
Significant difference between groups. 2 significant difference between treatment groups (HPHF 
vs. LFHC).3 significant difference between HPHF vs. control. Significant difference between
LFHC vs. control. P < 0.05.
181
182
A 1,2,3,4,6
□  Baseline
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Dietary group
A (3 -  0  mo)
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A (6- 0 mo)
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Figure 6.3 Changes in plasma TC and TAG. Shows the concentrations of TC (A) and TAG 
(C) at baseline, 3 mo and 6 mo. 'Significant effect o f tim e .2 significant effect o f treatment (diet). 
J significant interaction of time and treatm ent.4 Significant differences between treatment groups 
(HPHF vs. LFH C).5 Significant difference between HPHF vs. control,6 Significant difference 
between LFHC vs. control. P < 0.05.. Panel B and D show the A change in TC and TAG over
the full 6 mo intervention respectively.
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HFHP LFHC Control
Dietary group
Figure 6.4 Changes in sdLDL. LDL peak density showed a significant difference with the 
HPHF group vs. the control group (P = 0.008)
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Figure 6.5 Changes in HDL-C and LDL-C. Shows the concentrations and changes of HDL-C 
(A & B) and LDL-C (C & D) at baseline, 3 mo and 6 mo. ’Significant effect o f tim e .2 significant 
effect of treatment (d iet).J significant interaction of time and treatm ent.4 Significant differences 
between treatment groups (HPHF vs. LFH C ).5 Significant difference between HPHF vs. control, 
6 Significant difference between LFHC vs. control. P < 0.05. Panel B and D show the A change 
in TC and TAG over the full 6 mo intervention respectively.
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HPHF LFHC CTRL
TC/HDL-C1’2’3 mean SE mean SE mean SE
0 mo 4.82 0.15 4.87 0.11 4.87 0.10
3 mo 4.67 0.11 4.99 0.11 4.95 0.14
6 mo 5.07 0.18 5.08 0.11 5.27 0.16
0-6 mo (A change)2,5 -0.03 0.14 0.19 0.08 0.46 0.11
LDL-C/HDL/C1’2’3
0 mo 3.01 0.09 3.08 0.07 3.10 0.07
3 mo 2.89 0.08 3.11 0.08 3.19 0.09
6 mo 3.28 0.12 3.21 0.08 3.45 0.11
0-6mo (A change)2,5,6 0.11 0.09 0.12 0.06 0.39 0.08
TAG/HDL-C1’2
0 mo 1.29 0.11 1.31 0.11 1.23 0.11
3 mo 0.89 0.06 1.25 0.08 1.26 0.11
6 mo 0.97 0.07 1.21 0.08 1.42 0.13
0 - 6 mo (A change) -0.46 0.14 -0.17 0.09 0.10 0.14
Table 6.6 Plasma lipid ratios. 1 significant effect o f tim e.2 significant effect o f treatment 
(diet).3 significant interaction o f time and treatment. 4 Significant differences between treatment 
groups (HPHF vs. LFHC).5 Significant difference between HPHF vs. control, 6 significant 
difference between LFHC vs. control. P < 0.05.
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6.3.5 Markers o f insulin resistance
Markers of insulin resistance (glucose, insulin, and HOMA) were measured at 
baseline, 3, and 6 months, with no significant differences between groups at 
baseline. After 6 months glucose decreased 10% within the LFHC group which 
was ~ 2-fold greater, relative to the HPHF and control groups. With respect to 
insulin and HOMA the HPHF group showed the greatest reductions with 25% 
and 28% respectively compared to -8% and -17% within the LFHC groups. 
Wheras the control group showed increases in both insulin and HOMA. Table 
6.7 and Figure 6.7 show the results in detail with statistical information.
Glucose1
HPHF
mean SE
LFHC
mean SE
CTRL
mean SE
(mmol/L)
0 mo 5.47 0.06 5.46 0.07 5.48 0.06
3 mo 5.46 0.07 5.33 0.07 5.41 0.07
6 mo 5.29 0.10 4.93 0.09 5.20 0.08
Insulin3
(pmol/L)
0 mo 72.60 5.44 67.36 5.27 65.25 4.42
3 mo 76.61 11.33 63.08 6.96 68.24 6.82
6 mo 56.00 5.79 53.48 4.42 72.91 6.58
HOMA1’2 
0 mo 17.80 1.36 16.51 1.36 16.02 1.14
3 mo 17.83 2.42 15.15 1.53 16.59 1.68
6 mo 13.58 1.39 11.94 1.07 17.27 1.67
Table 6.7 Markers of insulin resistance. 1 significant effect o f time. 2 significant effect o f  
treatment (diet).3 significant interaction o f time and treatment. 4 Significant differences between 
treatment groups (HPHF vs. LFHC).5 Significant difference between HPHF vs. control, 6 
significant difference between LFHC vs. control. P < 0.05.
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Figure 6.7 Changes in markers of insulin resistance. ‘Significant effect of treatment (diet). 
S ignificant differences between treatment groups (HPHF vs. LFHC). ’ Significant difference 
between HPHF vs. control.4 Significant difference between LFHC vs. control. P < 0.05.
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6.3.5 Adjustments for body mass and gender
Males responded differently compared to females within the HPHF group with 
greater decreases in weight-loss, BMI, and waist girth compared to the LFHC 
group; whereas females showed an increase in lean mass within the HPHF group. 
However, subdividing by gender did not show any statistically different results 
compared to the results shown for the whole group above. With respect to 
plasma lipids adjusting for body mass resulted in a loss of significance between 
groups for plasma TC, TAG, TC:HDL-C, LDL-C:HDL-C, TAG:HDL-C, 
glucose, insulin, and HOMA. LDL-C remained significant between groups (P = 
0.044) but the difference between the LFHC group versus the control was lost. 
HDL-C gained significance between groups (P = 0.005) with the LFHC group 
showing a greater decrease compared to the control (P = 0.009).
When Subdividing into gender, comparing the difference after 6  months, females 
responded similarly to the whole group except for the significant difference 
between the LFHC and the control group was lost with plasma TC for both 
genders. Whereas males showed no significant effect between groups for all 
plasma lipids except for sdLDL (%AUCB) which showed a significant difference 
between groups and between the HPHF group versus the control (P < 0.05 
respectively). In addition, the percentage change, after 6  months, in sdLDL 
(%AUCB) was more marked in males compared to females and the whole group 
(Appendix IV).
6.3.6 Associations with ALP markers, IR markers, anthropometries and dietary 
intake
There were strong associations with markers of an ALP and markers of insulin 
resistance, with the difference in plasma TAG after 6 months showing positive 
correlations with the difference in insulin and HOMA after 6  months (R = 0.40, P 
< 0.001 and R = 0.38, P < 0.001 respectively. sdLDL (AUCB%) also showed 
strong associations with insulin and HOMA (R = 0.38, P < 0.001 and R = 0.39, P
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< 0.001 respectively). Furthermore, markers of an ALP were significantly 
associated with each other, with plasma TAG correlating strongly and positively 
with sdLDL and the ratio of TAG/HDL-C and weakly with HDL-C (Results 
tabulated in Appendix IV).
There were strong associations within the HPHF dietary group with plasma TAG 
versus body mass and BMI; sdLDL versus body mass, BMI, and waist. 
Glucose, insulin, and HDL-C showed weaker correlations with body mass, BMI 
and waist. Whereas plasma TC and LDL-C showed no correlations with any of 
the anthropometric measurements. Within the LFHC group plasma TAG only 
correlated weakly with waist (Results tabulated in Appendix IV).
As a result of poor compliance the total population was analysed with respect to 
macronutrient composition. The major associations were negative correlations 
with dietary protein and sdLDL (%AUCB) and the ratio of TAG/HDL-C 
respectively and a negative correlation with dietary fat and the ratio of 
TAG/HDL-C (Results tabulated in Appendix IV). Furthermore, body mass, 
waist, and BMI were associated positively with energy, fat, and alcohol 
respectively.
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6.4 Discussion
The aims of this present study were to investigate the effect of two weight-losing 
diets on surrogate markers of CVD risk, with the hypothesis that weight loss with 
a HPHF diet would show greater beneficial effects compared to a LFHC diet on 
markers of an ALP/metabolic syndrome. The major outcomes of the present 
study were reductions in body mass, BMI, waist girth, fat mass within the HPHF 
and LFHC groups, and a slight increase in lean mass confined to the HPHF 
group; a reduction in plasma TC and LDL-C within the LFHC group; a decrease 
in plasma TAG, the ratio of TAG/HDL-C, insulin, and HOMA within the HFHP 
group. The only unfavourable outcome was a decrease in HDL-C in both 
treatment groups which was more marked within the LFHC group.
6.4.1 The effect o f  HPHF diets on plasma TC and LDL-C
Both treatment diets produced significant reductions in TC and LDL-C within 
diet and compared to the control, with the LFHC group showing a greater 
response. In contrast Samaha et al (2003) showed no significant change in 
plasma TC or LDL-C, in a similar study in which obese subjects (n = 132) were 
randomised to either a HPHF or LFHC dietary group for 6  months duration. 
The lack of plasma TC and LDL-C lowering in the LFHC group is unusual, since 
most LFHC diets have been shown to produce reductions (Hellerstein, 2000). 
Samaha et al (2003) explained that many of the subjects were also taking lipid- 
lowering drugs which may prevent any further reduction of plasma TC and LDL- 
C. In addition, although subjects on the LFHC diet were encouraged to reduce 
energy and derive 30% or less of energy from fat there was no instruction on the 
type of CHO consumed. Therefore, these confounding variables may explain the 
stability of these two measurements even though weight-loss occurred. In a 
study investigating the long term effects of HPHF diets Foster et al (2003) found 
plasma TC and LDL-C to be significantly lower in obese subjects following the 
LFHC diet compared to the HPHF dietary group, although this difference was 
only after 3 months with no significant differences between groups at 6  or 12 
months. The present study is in partial agreement as the differences in plasma 
TC and LDL-C at 3 months were more pronounced in the LFHC group compared
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to the HPHF group, but in contrast to Foster et al (2003) this difference remained 
after 6  months. In a more recent study, Yancy et al, (2004) showed reductions in 
plasma TC in obese, hyperlipidaemic subjects on either a HPHF or LFHC diet 
after 6  months, but there were no significant differences between the two groups. 
LDL-C was decreased within the LFHC group and increased in the HPHF group, 
although there were no significant differences between groups. While these 
results show some agreement with the present study with respect to the relatively 
greater reductions in plasma TC and LDL-C in the LFHC group, the latter still 
showed decreases within the HPHF group over time. In a study of non-obese 
healthy subjects, Westman et al (2002) found an overall decrease in both plasma 
TC and LDL-C on a HPHF diet, although the authors reported that 12 out of 41 
subjects experienced an increase in LDL-C. It is important to note that this study 
was uncontrolled.
When subdividing into gender, women showed LDL-C-lowering in response to 
both treatment diets, with no difference between diets, whereas the men showed 
no significant response to either diet. Conversely, Farnsworth (2003) showed 
greater lowering of LDL-C in men in response to a high protein diet compared to 
a standard 15% protein diet; although this study only altered the ratio of protein 
to CHO and kept fat intake at a constant 30% for both diets. Other studies that 
recruited men only found similar results, with respect to LDL-C, to the present 
study (Volek et al, 2000; Sharman et al, 2002; Sharman et al, 2004). However, 
in contrast to the present study overweight women showed no change in LDL-C 
in response to hypoenergetic HPHF diets (Volek et al, 2004) and normal-weight 
women showed a slight increase in LDL-C with a isoenergetic HPHF diet (Volek 
et al, 2003).
6.4.2 The effect o f  HPHF diets on plasma HDL-C
HPHF diets have been open to criticism because they deliver liberal amounts of 
fat from meat and dairy produce that can increase LDL-C and thus increase CVD 
risk (Blackburn et al, 2001). However, Blackburn et al (2001) fails to mention 
the effect of HPHF diets on increasing HDL-C. On the other hand, Volek and 
Westman (2002) present evidence that LDL-C and plasma TC increase only
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slightly on HPHF diets and are accompanied by increases in HDL-C and 
therefore do not alter the LDL-C/HDL-C ratio. It is important to note that both 
of the above reviews predate some of the more recent long-term studies 
mentioned above. Although the present study did not measure CVD as an end­
point, plasma TC and LDL-C are considered surrogate markers of CVD risk and 
the results of the present study and others have shown that the plasma TC and 
LDL-C response to HPHF diets is variable. This variability may be partially due 
to the nature of the HPHF diet. Although the proportion of protein and fat are 
relatively high, the absolute amount of protein and fat intake actually decreased 
in the present study. This reduction in fat may explain, in part, the decreases in 
plasma TC and LDL-C and suggests that subjects were not at risk of CVD at 
least from high levels of TC and LDL-C. The studies mentioned above have 
either reported the percentage of macronutrients or only presented the total 
intakes post-diet, making it difficult to assess if any changes occurred in fat and 
protein. One could speculate that if increases in fat occurred, as could be the 
case with HPHF diets, then plasma TC and LDL-C may increase. Indeed Volek 
et al (2 0 0 0 ) reported the changes in macronutrient intake going from a habitual 
diet to a low-CHO ketogenic diet and found that both protein and fat were 
significantly increased, which led to significant increases in LDL-C after 6  weeks 
on the diet. It is important to note that the diet was supplemented with n-3 fatty 
acids which have been shown to increase LDL-C (Harris, 1997), making it 
difficult to identify the LDL-raising component of the diet.
While increases in LDL-C have been shown on HPHF diets the ratio of 
TC/HDL-C have been shown to decrease (Yancy et al, 2004; Volek et al, 2000) 
inferring a decreased risk of CVD. The present study showed increases in the 
ratio of TC/HDL-C after 6  months (with no significant difference between diets 
and no effect of gender), this was due to an unexpected decrease in HDL-C on all 
diets, and no effect on plasma TC or LDL-C. Studies have shown variable 
effects of HPHF diets on HDL-C, Foster et al (2003), Volek et al (2003), and 
Yancy et al (2004) showed an increase, whereas others found no change 
(Samaha et al, 2003; Volek et al, 2004; Volek et al, 2000) and Kwiterovich et al 
(2003) found a reduction in HLD-C. The latter study was in a population of
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children under the age of 10 on a ketogenic diet containing a high proportion of 
fat (75 -  80%) and therefore not necessarily a high-protein diet.
6.4.3 The effect o f  HPHF diets on LDL size
The increase in LDL-C (Volek et al, 2000) may be a consequence of an increase 
in LDL size, since low-CHO diets have been shown to increase LDL size, and 
LDL-C (Campos et al, 1995). In this study, subjects were randomised to low-fat 
or high-fat diets for 6  weeks each in a cross-over design (with equal proportions 
of protein within each dietary phase). Although the study by Campos et al 
(1995) was different in design to the present study (with respect to protein), the 
results were in agreement in that LDL peak density was reduced on a low-CHO 
diet. In contrast other studies (Volek et al, 2003; Volek et al, 2004) found no 
change in LDL size in women on HPHF diets that were similar in macronutrient 
composition to the present study (Protein ~ 29%, Fat ~ 60 %). The former study 
investigated women of normal weight and although there were no overall 
changes in this study, 30% of the women expressed a predominance of small, 
dense LDL (pattern B) and each of these women showed increases in LDL 
particle diameter. With respect to the latter study, all but one of the thirteen 
overweight women expressed a normal LDL phenotype (pattern A), which offers 
an explanation as to why there was no overall response to the HPHF diet. 
Therefore, the response to HPHF diets appears to depend on LDL phenotype at 
baseline. Sharman et al (2002) provides further evidence with normal-weight 
male subjects, after 6 -weeks of a HPHF diet the whole group showed increases in 
LDL size. When the group was subdivided into LDL phenotype A or B it was 
the pattern B subjects who showed the greatest response with 3 out of 5 pattern 
B subjects switching to pattern A, whereas the pattern A group remained pattern 
A. Similar results were observed in a study of overweight males (Sharman et al, 
2004), with an overall increase in large LDL and decreases in sdLDL after 6 - 
weeks of a HPHF diet. The subjects were subdivided into pattern A and pattern 
B phenotypes, and 75% of the pattern B subjects converted to pattern A. The 
present study did not subdivide into phenotypes due to the high frequency of 
pattern A subjects (> 90%). However, males showed a greater response to both 
the diets when compared to females with the HPHF group showing a larger
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magnitude; this is not surprising as males are often characterised with more 
sdLDL than females (Friedlander et al, 2000) especially pre-menopausal women 
(Austin et al, 1990). In the present study females showed a %AUCB of 19% and 
males 37% at the start of the intervention. Therefore, the effect of a HPHF diet 
on LDL particle size appears to depend on the initial LDL phenotype.
6.4.4 The effect o f  HPHF diets on plasma TAG
It is clear that the response to HPHF or low-CHO diets with respect to plasma 
TC, HDL-C, and LDL-C and LDL size is variable. However, the effects of 
HPHF or low-CHO diets on plasma TAG are much more consistent and produce 
a substantial lowering (Table 6.1). In the present study even though the 
reduction in plasma TAG was apparent in both the HPHF and the LFHC groups, 
with no significant difference between them, the HPHF group still showed a 
greater reduction after 6 months which could be attributed to a loss of body mass. 
Other criticisms of HPHF diets are that reductions in plasma TAG can be 
achieved by other dietary strategies that lead to a 5 -  10% weight loss (Blackburn 
et al, 2001). The present study showed similar weight loss in both experimental 
diets with an approximate reduction of 9%, yet the decrease in plasma TAG was 
2-fold greater in the HPHF group compared to the LFHC group (19.5% and 9.9% 
respectively). Plasma TAG was associated with body mass loss but not with 
energy reduction. In addition, studies employing iso-energetic diets have shown 
greater reductions in plasma TAG on HPHF diets compared to LFHC diets 
(Volek et al, 2003b; Sharman et al, 2002; Volek, 2000). Therefore, the 
underlying mechanism of plasma TAG-lowering may only be partly explained 
through the reduction of energy intake. Another marker of an ALP is the ratio of 
TAG/HDL-C and despite the lowering of HDL-C, this ratio fell on the HPHF 
diet relative to the LFHC diet, although this effect was somewhat negated by the 
loss of body mass with males showing a greater response on the HPHF diet. 
These results are in overall agreement with previous studies (Yancy et al, 2004; 
Westman et al, 2002; Sharman et al, 2004; Volek et al, 2004).
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6.4.5 Mechanisms o f lowering plasma TAG with HPHF diets
Other possible mechanisms for the reduction in plasma TAG produced by a 
HPHF diet include a decrease in endogenous TAG (VLDL) production or 
increase in TAG clearance that may be mediated through a reduction in insulin 
resistance (Martins & Redgrave, 2004). The present study showed greater 
decreases in fasting plasma insulin and HOMA on the HPHF diet after 6  months. 
Long term studies on the effects of HPHF diets on markers of insulin resistance 
are limited. Samaha et al (2003) showed an increase in insulin sensitivity with a 
HPHF diet whereas Foster et al (2003) showed favourable effects on both HPHF 
and LFHC weight-losing diets. The above results are surprising as high-fat diets 
have been shown to increase insulin resistance (Lara-Castro & Garvey, 2004); 
therefore it may be the high-protein proportion of HPHF diets that elicit the 
increase in insulin sensitivity. An interesting study by Layman et al (2003) 
showed equal levels of fasting insulin in both high-protein and high-CHO dietary 
groups (both groups equal in dietary fat), but the post-prandial response after 10 
weeks of a high-protein diet was significantly less than the high-CHO group 
suggesting an increase in insulin sensitivity.
One explanation for how HPHF diets may increase insulin sensitivity is through 
the lowering of the GI and GL of meals, due to the very low amount of CHO 
available. The concept of lowering the GI/GL of diets has been discussed in 
detail in Section 5.5; briefly, a lower GI/GL improves insulin sensitivity through 
a lower glycaemic response to food and hence stabilises blood glucose levels and 
therefore reduces availability of NEFA for VLDL production. This may provide 
an explanation on how HPHF diets lower plasma TAG levels. Although HPHF 
diets result in very low GLs they do not necessarily lower insulin levels, as both 
fat-rich and protein-rich meals are insulinaemic (Holt et al, 1997). Nevertheless, 
the present study provided evidence to suggest that a HPHF diet can improve 
insulin sensitivity by decreasing plasma insulin and HOMA. This may have 
been mediated through a decrease in body mass, and indeed both the decreases in 
plasma insulin and HOMA on the HPHF diet were associated with the decrease 
in body mass and BMI after 6 months. This association was not seen on the 
LFHC diet. Moreover, although there were no statistical associations between
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markers of insulin resistance and intake of macronutrients or energy, a decreased 
intake of macronutrients, as seen in the HPHF group, would be expected to 
attenuate the insulin response. Failure to demonstrate this may have resulted 
from the poor validity of the dietary questionnaires. Therefore, if iso-energetic 
HPHF diets increased insulin sensitivity this would provide evidence to suggest 
that the nature of the diet and not just weight loss contributes to this effect. This 
paradigm is supported by Sharman et al (2002) who found a significant decrease 
in fasting insulin levels after 6  weeks of an iso-energetic HPHF diet (although 
there was unintentional weight loss of 2 .2  kg), therefore providing evidence to 
support the above hypothesis.
The precise mechanisms by which HPHF diets decrease plasma TAG are 
unknown but may be related by promoting ketosis. Ketogenic diets are defined 
as being high in fat and low in CHO, protein and total energy and have been 
designed to mimic starvation (Cullingford, 2004). The following sequence 
describes the metabolic consequences of a high fat diet: fat from adipose tissue 
are broken down to fatty acids and acetyl CoA; the generated acetyl CoA cannot 
flow through the TCA cycle because oxaloacetate is needed for the synthesis of 
citric acid. This is because oxaloacetate is utilised in gluconeogenesis for the 
production of glucose. The oxaloacetate has to be generated from amino acids 
and if dietary protein is inadequate muscle protein is broken down. Since acetyl 
CoA does not get converted to citric acid then it is converted to ketone bodies 
(Scharrer, 1999). The metabolic response would include induction of lipolysis, 
gluconeogenesis, glycogenolysis due to higher ratios of glucagon/insulin and 
higher levels of other catabolic hormones, p-adrenergic catecholamines (Fukao et 
al, 2004). HPHF diets switch the main source of energy utilisation to fatty acids 
and ketones, the consequences would include reduced levels of plasma NEFA 
due to requirements of fatty acids for p oxidation and increased need of energy 
for the brain and heart supplied by ketones. NEFA supply to the liver would be 
reduced and therefore VLDL production would be reduced and a lowering of 
plasma TAG would be expected.
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Although the HPHF diet in the present and other studies contain a high 
proportion of protein, they show similarities with ketogenic diets in terms of 
energy from fat and total energy and have been shown to induce ketosis 
(Sharman et al, 2002; Foster et al, 2003). The ketogenic diet produces increased 
amounts of ketone bodies which are acetoacetate, 3-hydroxybutyrate, and 
acetone (Fukao et al, 2004). These ketone bodies are produced as a consequence 
of an abundance of hepatic intracellular acetyl-CoA caused by oxaloacetate being 
redirected into gluconeogenesis. In the relative absence of oxaloacetate, citric 
acid cannot be synthesised and acetyl CoA accumulates (Cullingford, 2004). In 
this situation, plasma TAG would be utilised for energy production (via ketosis) 
rather than storage and glucose synthesis would occur via glycerol and 
glyceraldehyde-3-phosphate resulting in a lowering of plasma TAG. Hepatic 
ketogenesis is also hormonally controlled, with insulin repressing and glucagon 
and cortisol stimulating. Although ketone bodies were not measured, it is 
reasonable to speculate from the reduced levels of insulin and the nature of the 
HPHF diet that ketogenesis would have occurred.
The general increase in insulin sensitivity on HPHF diets, including the present 
study, may be a result of an increase in lean body mass. Kim et al (2004), 
showed middle aged women with a higher proportion of skeletal muscle to 
visceral fat to have more favourable measures of insulin sensitivity. The present 
study also showed a 1.2% increase in lean mass in the whole group and a 3% 
increase in females, whereas males showed a decrease of 5%. The relatively 
greater loss of body fat and increase in lean body mass on the HPHF diet, may 
offer a possible explanation for the increase insulin sensitivity and its associated 
effects. In addition, an increase in lean body mass may promote an increase in 
resting metabolic rate and direct NEFA towards oxidative pathways.
Higher proportions of dietary protein and ketone bodies have been shown to 
increase satiety (Anderson & Moore, 2004; Scharrer, 1999 respectively). 
Evidence for the satiating effects of protein is strong with studies showing a 
delay of hunger and a reduced amount of energy consumed after a protein pre­
meal (reviewed by Anderson & Moore, 2004; Gerstein et al, 2004). Whereas the 
evidence for CHO as a satiety factor is conflicting with some studies providing
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evidence that CHO-rich foods increase appetite and others have found them to 
reduce hunger (reviewed by Reid & Hetherington, 1997). However, the type of 
CHO and timing of pre-meals are probably confounding contributors (E.G. fibre 
intake, GI, energy density). Dietary fat has been reported to be the least satiating 
food of the macronutrients (Stubbs & Whybrow, 2004). However, when mixed 
meals with a high protein content are consumed the difference in satiety of CHO 
and fat is more subtle (Stubbs & Whybrow, 2004). Furthermore, high levels of 
circulating ketone bodies may reduce food intake, as shown in rats being 
administered 3-hydroxybutyrate (Scharrer, 1999). This phenomenon is yet to be 
elucidated in humans on ketogenic, mixed fat diets and merits further 
investigation.
The present study showed both HPHF and LFHC diets to be beneficial with 
respect to markers of an ALP/metabolic syndrome and more traditional markers 
of CVD (TC and LDL-C). Both diets resulted in reductions in total body mass, 
fat mass, BMI and waist girth. However, the HPHF diet showed a small increase 
in lean mass. The improvements seen in markers of an ALP/metabolic syndrome 
on the HPHF diet could only be partially accounted for a loss of body mass. The 
decrease in plasma TAG was associated with an increase in insulin sensitivity. 
The precise mechanism by which this occurs is unknown but maybe 
multifactoral and involves a decreased production of VLDL, ketogenesis and an 
increased metabolic rate. HPHF diets have been criticised as being atherogenic 
because they contain high proportions of dietary fat and elevate LDL-C. The 
present study provides evidence to contradict this opinion by showing favourable 
effects on the lipid profile. The only negative outcome was a decrease in HDL-C 
and an increase in the ratio of TC:HDL-C, although this was found on all diets 
including the control. Despite this effect, all other markers of an ALP/metabolic 
syndrome were improved. In conclusion, this study presents evidence to support 
the hypothesis that HPHF weight-losing diets promote greater beneficial effects 
on markers of an ALP/metabolic syndrome relative to a LFHC diet..
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Chapter 7 General discussion
The overall aim of this thesis addressed dietary strategies for the treatment of an 
ALP/metabolic syndrome. There were three major dietary themes: the effects of 
the ratio of n-6/n-3 fatty acids; the effect of low and high glycaemic index low- 
fat diets; and weight-reducing diets including high-protein, high-fat and low-fat, 
high-CHO diets. Due to the large sample numbers in the dietary interventions a 
high throughput method for the identification of LDL subclasses was warranted. 
Previous methods for the separation of LDL subclasses are time consuming and 
technically demanding (Griffin et al, 1990; Krauss & Burke, 1982) and can take 
up to 24 hours. Chapter 3 describes a new method for the identification of LDL 
subclasses which distinguishes atherogenic phenotypes into pattern A, B or the 
intermediate pattern I. Adaptation of this method to a 16-place rotor decreased 
centrifugation time and increased sample throughput. Furthermore, the 
procedure requires very little preparation, and analysis is aided with easy to use 
software; this method has recently been published (Davies et al, 2003) and is 
shown in appendix I.
The major outcomes of the OPTILIP study were beneficial changes in markers of 
an ALP including reductions in plasma TAG, TAG:HDL-C, sdLDL (%AUCB), 
postprandial lipaemia and increases in HDL2 that were confined to the two diets 
containing LC n-3 and the lowest ratios of n-6/n-3 fatty acids (Section 4.4). 
There were no significant effects on traditional markers of CVD, plasma TC, 
LDL-C, and HDL-C. The lowering of plasma TAG (-9.1% and -6.3% for n-3 
LCP 3:1 and n-3 LCP/ALNA 3:1 respectively) was shown to be comparable with 
other similar studies (Brady et al, 2004; Minihane et al, 2000) albeit to a lesser 
magnitude. Only a study by Finnegan et al (2003) showed a similar plasma TAG 
lowering (-7.7%) with a supplemented fish-oil group (high n-3 LCP dietary 
group). The OPTILIP study used the manipulation of whole foods (with fish 
consumption advice) and avoided the use of supplementation to achieve the 
ratios of n-6/n-3 fatty acids opposed to the studies mentioned above, that varied 
doses of fish-oil in supplement form. Very few studies to date have investigated 
the ratio of n-6/n-3 fatty acids and therefore comparisons are mainly confined to 
separate studies on n-3 fatty acids from fish-oil and dietary interventions. Indeed
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a meta-analysis of 72 human trials given 7 g/d or less of n-3 fatty acids (from 
fish-oil) showed a plasma TAG lowering effect of ~ 26% (Harris, 1996). In 
comparison, fish consumption in the Lyon Diet Heart study (de Lorgeril et al,
1999) produced a 9.3% reduction in plasma TAG comparable to the OPTILIP 
study.
The OPTILIP study also showed the high n-3 LCP diets shifted both smaller 
LDL and HDL particles to less atherogenic larger species. This result was in 
agreement with studies employing fish-oil capsules (Petersen et al, 2002; 
Minihane et al, 2000; Suzukawa et al, 1995). Whereas fish consumption has 
shown a variable response with respect to lipoprotein size with Beauchesne- 
Rondeau et al (2003) showing an increase in LDL size and Li et al (2004) found 
no effect on LDL size but an increase in HDL size and a decrease in medium and 
small VLDL.
The effects of n-3 fatty acids and fish consumption on mortality and CHD have 
been analysed recently in two meta-analyses (He et al, 2004; Bucher et al, 2003). 
The He et al (2004) meta-analysis showed that consumption of fish was inversely 
associated with fatal CHD with multivariate relative risks from 0.85 -  0.62 with 
fish consumption from 1 to 3 times per month up to 5 times per week 
respectively. The relative risk for fish consumption 2 to 4 times per week (in line 
with current recommended intake) was 0.77. The study by Bucher et al (2003) 
investigated both supplementary and dietary intake of n-3 fatty acids; the 
findings of this meta-analysis showed a reduction in all cause mortality and 
mortality due to MI and sudden death. Furthermore, there was an overall 
reduction in plasma TAG (-20%). The effects of dietary or supplemented LCP n- 
3 consumption on plasma TAG have been shown to be as affective or close to 
certain lipid-lowering drug therapy. The meta-analysis of Harris (1996) showed 
a reduction in plasma TAG of 26% which is comparable to that of NIASPAN 
(nicotinic acid based therapy, Capuzzi et al, 1998). Whereas Bucher et al (2003) 
showed reductions in plasma TAG of 20% that were comparable to the combined 
drug therapy of Colestipol-niacin (Blankenhom et al, 1987). Furthermore, the 
consumption of fish has been shown to reduce total mortality to a similar extent 
as the statin drugs. Statin drug therapy reduces the risk of all-cause mortality by
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approximately 30% (see Table 1.1, Section 1.1) the same results have been 
achieved by the consumption of fish in the diet and reinfarction trial (DART) 
with total mortality reduced by 29% (Burr et al, 1989). The plasma TAG- 
lowering effect of fish or LCP n-3 supplementation provides a potential 
mechanism for its cardio-protective effects, other possible mechanisms are 
shown in Table 7.1. Thus, fish consumption or LCP n-3 supplementation 
provides a more natural and perhaps safer option to lipid-lowering drug therapy.
Mechanism
Reduce susceptibility o f the heart to ventricular arrthymia 
Antithrombogenic
Hypotriacylglycerolaemic (fasting & postprandial, discussed in Section 4.5) 
Retard growth o f atherosclerotic plaque 
Reduced adhesion molecule expression 
Reduced plate-derived growth factor 
Antiinflammatory 
Promote nitric oxide-induced endothelial relaxation 
Mildly hypotensive
Table 7.1 Potential mechanisms by which n-3 fatty acids reduce risk for CVD. Taken from
Kris-Etherton et al, 2003.
The study presented in Chapter 5 investigated low-fat diets with a low and high 
GI. The study design was confounded by an order effect. However, when the 
data was analysed as a parallel design comparing 14 subjects equally assigned to 
a low or high GI diet then the results of the LGI diet were more dramatic 
compared to the HGI diet. Plasma TAG (-29%), TAG:HDL-C (-24%), TC (- 
6 %), LDL-C (-11.6%), HDL-C (-6.3%), sdLDL (%AUCB, -9.9%), insulin (- 
35%), and HOMA (-42%) were all decreased to a much greater extent on the 
LGI diet. These reductions were similar to those in previous studies (Table 1.8). 
Although the favourable changes seen in the above biomarkers are a reflection of 
the molecular changes within the body that may lead to a decreased risk in CVD, 
they cannot substitute for hard endpoint measures of disease, i.e. CVD and all 
cause mortality. However, there are no randomised dietary interventions that 
have investigated the effect of glycaemic index on the outcome of CVD or all
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cause mortality. Therefore, one can only extrapolate from previous retrospective 
epidemiological studies that have linked GI to changes in plasma lipids and 
CVD. Liu et al (2000) analysed a cohort of the Nurses Health Study and found 
after a 10 year follow-up there was a direct and positive association with risk of 
CHD and GI and GL and this remained after adjustment for other risk factors 
such as smoking and total energy intake. In contrast to Lui et al (2000), the 
Zutphen Elderly Study examined an elderly cohort of men and found no 
association with GI or GL with CHD after a 10 year follow-up (van Dam et al,
2000). However, there was a non-significant increase in risk ratio compared to 
the low and high tertiles of energy-adjusted glycaemic index. Possible 
explanations why the Zutphen Elderly study showed no associations with GI/GL 
and CHD maybe due to the age of the population i.e., larger numbers of the 
original cohort had already died and the remaining survivors were therefore a 
pre-selected group who were less susceptible to CVD.
While the association with GI/GL and CVD is controversial largely because of a 
limited amount of retrospective studies and a void in prospective randomised 
controlled interventions, the GI has been associated with other disease states such 
as obesity and diabetes, both of which are risk factors for CVD (Bell & Sears, 
2003; Brand-Miller, 2004). In addition, the negative correlation with HDL-C 
seen in the retrospective study by Frost et al (1999) has been proposed to be 
linked to a 29% reduction in CHD mortality (Leeds, 2002). The results in 
Chapter 5 show a reducing effect on HDL-C within the LGI arm. However, this 
was the only deleterious effect of the diet and the decrease in plasma TAG was 
comparable in magnitude to drug therapy with fibrates and nicotinic acid (Table 
1.2). Therefore, even though the studies of the effect of GI/GL on CVD and 
markers of CVD are limited, in terms of sample size and design, there was still 
evidence to suggest beneficial effects of a LGI diet. Furthermore, the 
manipulation of the diet to provide a lower GI is relatively easy and is unlikely to 
present any harmful effects.
As in the two studies mentioned above, the weight-reducing diets described in 
Chapter 6  showed impressive reductions in plasma TAG, especially the HPHF 
diet. The results of this study were positive for both low and high CHO dietary
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approaches, with the former showing more favourable effects on markers of an 
ALP/metabolic syndrome and the latter significant decreases in plasma TC and 
LDL-C. HPHF diets have been criticised for increasing the risk of CVD through 
the raising of plasma TC and LDL-C. The data in Chapter 6  did not support this 
notion. Indeed the risk of CVD through the lowering of plasma TAG and the 
remodelling of sdLDL to its larger species potentially decreases the risk of CVD 
(Griffin, 1999) and is comparable, in this effect, to drug therapy. As with the 
glycaemic index, no long-term prospective studies have shown a direct link with 
HPHF diets and CVD (either positive or negative). Only an uncontrolled study 
by Fleming (2000) showed blood flow to the heart was worsened on a high 
protein diet. Therefore, it is still contentious as to which is the better diet. While 
the results in Chapter 6  and that of others do show beneficial effects of HPHF 
diets, side effects have been reported such as headache, bad-breath, and nausea 
(Ornish, 2004).
7.1 Future work
The results of the three dietary interventions described in this thesis all show, to 
varying degrees, favourable effects on markers of an ALP/metabolic syndrome 
and on traditional markers of CVD, plasma TC and LDL-C. Thus it would be 
intuitive to investigate the combined effects of a diet low in the ratio of n-6/n-3 
fatty acids, high in protein with the source of CHO derived from low GI foods. 
The precise proportions of macronutrients would need further work and may 
even depend on genotype and or phenotype and therefore warrant an individual 
approach to nutrition with prospective selection of subjects. For example, 
individuals with the phenotypic characteristics of an ALP/metabolic syndrome 
may respond to diets lower in overall CHO, due to the potential HTG effect of 
high-CHO diets. Considering the plasma TC and LDL-C are not necessarily 
elevated in this condition, ALP/metabolic syndrome subjects are more at risk 
from high plasma TAG, small dense LDL and low HDL-C and therefore 
reductions in total fat may not be necessary. Although advice on the type of fat 
may be necessary, replacing saturated fat with n-3 especially LC n-3 and MUFA 
maybe beneficial; as saturated fat can increase insulin resistance and therefore 
may exacerbate the metabolic syndrome (Riccardi et al, 2004). On the other
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hand, individuals characterised with hypercholesterolaemia but plasma TAG and 
LDL size within reference ranges may benefit from diets lower in total fat.
Diets high in protein, moderate in fats and CHO with a low GI are emerging as 
potential strategies for weight loss and the amelioration of insulin resistance and 
lipid abnormalities (Noakes & Clifton, 2004; Brinkworth et al, 2004; McMillan- 
Price & Brand-Miller, 2004; Halton & Hu, 2004). Increasing the protein content 
of the diet represents a method of lowering the GL and, like the addition of 
dietary fibre, may attenuate the adverse effects of low-fat diets. Yet the potential 
long-term side effects of HPHF diets are unknown and may have deleterious 
effects due to high-fat intake as described previously (Ornish, 2004; Blackburn,
2001). However, critics of high-protein diets tend to categorise high-protein and 
HPHF diets as one (Ornish, 2004), yet this does not have to be the case. High- 
protein, low-fat, high-CHO and high-protein, moderate-fat, moderate-CHO diets 
(Wolfe et al, 1991; Wolfe et al, 1999) have both been shown to lower plasma TC, 
TAG, LDL-C, and increase HDL-C. In addition, the work of Dumesnil et al 
(2001) showed increases in LDL size, and decreases in plasma TAG and insulin 
with a low-fat, low GI, high-protein diet with increases in satiety and 
spontaneous reduction in energy intake that is congruent with the recent work of 
Johnston et al (2004). Furthermore, two recent long-term high-protein diet 
studies (> 1 year) have shown greater reductions in abdominal fat (Due et al, 
2004) and hypertension (Brinkworth et al, 2004). Although high protein diets 
have been implicated with the aetiology of bone and renal disease (Reddy et al,
2 0 0 2 ) there are no long-term studies providing conclusive evidence to support 
such an association. To date there are no studies that have investigated the CV 
benefits of the combination of high-protein, LGI, high n-3 diets. Volek et al 
(2000) combined high-protein, high-fat with the fat source high in n-3 and 
MUFA but with low-CHO and no advice on glycaemic index. Whereas 
Dumensil (2001) combined high-protein, low GI and low-fat and omitted the use 
of n-3; with both strategies showing favourable effects on the lipid profile. 
Therefore, the potential of combination dietary therapy may induce an additive or 
synergistic effect. Further work could investigate the above dietary combination 
in long-term randomised, controlled, dietary interventions. The interventions 
could be targeted towards different subgroups of the population including: ALP,
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metabolic syndrome, subtypes of obesity, hypercholesterolaemic, diabetes. Even 
within these phenotypes of disease there will be individual variation due to 
genetic heterogeneity and therefore further knowledge of the interaction of genes 
and nutrients would provide more evidence for the more precise prescription of 
macronutrient intakes. Indeed, a review by Tai & Tan (2004) on polymorphisms 
of lipoprotein metabolism have suggested tailoring the intake of dietary fat for 
different types of polymorphisms.
The majority of dietary research to date is based on the understanding that 
changes in the concentration of selected biomarkers will be informative with 
respect to CVD. Recent technological advances in genomics, proteomics, and 
metabonomics have made it possible to measure thousands of metabolites in a 
single step (German et al, 2003). Current technology to analyse DNA, 
employing microarrays, allows for the simultaneous expression of up to 40 000 
genes (Bryant et al, 2004); proteomics is advancing its attempts to characterise a 
complete set of proteins of a tissue using 2-D gel electrophoresis and various 
advanced LC-MS applications (Aldred et al, 2004); and the most recent of the 
“omics”, metabonomics and metabolomics are emerging as powerful platforms 
for the analysis of low molecular weight compounds (Goodacre et al, 2004; 
Whitfield et al, 2004). The diagnostic and prospective application of these new 
technologies will provide the potential to describe metabolic biomarkers of 
disease; mechanistic discoveries; and gene-nutrient interactions (van Ommen, 
2004). Therefore, future research should focus on these informative platforms 
and analyse the effects of nutrients employing a systems biology approach.
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Appendix II
Table A II.l. Plasma fatty acids. Significant effect o f time. 2 significant effect o f treatment 
(diet).3 significant interaction o f time and treatment.. P < 0.05..
Plasma FA
OLO1,2,3,4
Control SEM LCP 3:1 SEM ALNA
3:1
SEM LCP/ALNA
3:1
SEM ALNA
5:1
SEM
0 mo 20.97 0.36 21.15 0.38 21.60 0.41 20.98 0.36 21.42 0.44
3 mo 20.36 0.41 20.57 0.34 21.01 0.38 19.87 0.41 21.96 0.43
6 mo 
LA1’3
20.19 0.35 20.99 0.36 21.40 0.43 20.60 0.33 22.51 0.41
0 mo 25.70 0.58 26.01 0.50 26.20 0.49 26.13 0.45 26.38 0.49
3 mo 28.46 0.62 26.46 0.44 27.40 0.50 26.59 0.41 26.98 0.47
6 mo
ALA1’2'3
28.23 0.52 25.79 0.42 26.46 0.52 25.80 0.47 26.01 0.47
0 mo 0.64 0.03 0.63 0.03 0.68 0.02 0.61 0.03 0.62 0.02
3 mo 0.59 0.04 0.69 0.03 0.79 0.03 0.80 0.04 0.67 0.03
6 mo
DHLA1’2’3
0.56 0.03 0.70 0.02 0.77 0.03 0.79 0.03 0.68 0.02
0 mo 1.53 0.05 1.49 0.04 1.58 0.05 1.63 0.05 1.64 0.04
3 mo 1.53 0.04 1.32 0.04 1.57 0.05 1.44 0.04 1.61 0.04
6 mo
AA1’2’3
1.55 0.04 1.39 0.04 1.57 0.05 1.38 0.05 1.57 0.05
0 mo 6.65 0.16 6.31 0.21 6.24 0.16 6.72 0.19 6.34 0.22
3 mo 6.63 0.17 5.76 0.18 6.14 0.16 6.00 0.17 6.14 0.21
6 mo
EPA1’2’3
6.86 0.17 5.93 0.17 6.28 0.15 6.00 0.14 6.12 0.20
0 mo 1.42 0.09 1.70 0.14 1.40 0.08 1.40 0.09 1.26 0.07
3 mo 1.24 0.09 2.73 0.19 1.44 0.09 2.55 0.17 1.26 0.07
6 mo 
DPA1,2,3
1.30 0.12 2.50 0.17 1.51 0.10 2.59 0.18 1.35 0.09
0 mo 0.69 0.03 0.69 0.02 0.66 0.02 0.68 0.03 0.66 0.02
3 mo 0.55 0.02 0.67 0.02 0.60 0.02 0.68 0.03 0.58 0.02
6 mo 
DHA1,2,3
0.60 0.02 0.70 0.02 0.64 0.02 0.73 0.02 0.61 0.02
Omo 2.88 0.12 3.17 0.14 2.89 0.14 2.85 0.12 2.70 0.11
3 mo 2.58 0.10 3.79 0.14 2.69 0.12 3.72 0.15 2.56 0.12
6 mo
n-6 total2,3
2.84 0.11 3.89 0.15 2.88 0.16 3.87 0.16 2.68 0.13
0 mo 33.89 0.64 33.80 0.58 34.02 0.50 34.45 0.46 34.41 0.49
3 mo 36.62 0.67 33.54 0.50 33.78 1.06 33.41 0.80 34.68 0.48
6 mo
n-3 total1,2,3.
36.64 0.48 33.11 0.47 34.31 0.55 33.27 0.48 33.58 0.49
0 mo 5.64 0.21 6.20 0.27 5.63 0.21 5.57 0.20 5.20 0.18
3 mo 4.96 0.19 7.89 0.33 5.30 0.24 7.72 0.36 5.01 0.20
6 mo
n-6:n-31,2,3
5.29 0.22 7.80 0.31 5.80 0.26 8.02 0.35 5.26 0.22
Omo 6.38 0.27 6.35 0.46 6.45 0.24 6.59 0.25 6.96 0.25
3 mo 7.81 0.31 5.05 0.44 6.77 0.26 4.78 0.24 7.40 0.29
6 mo 7.39 0.30 4.81 0.29 6.41 0.25 4.53 0.20 6.83 0.25
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Table A II.l. Plasma fatty acids. Significant effect o f tim e.2 significant effect o f treatment 
(diet).3 significant interaction o f time and treatment.. P < 0.05..
Control
MEAN SE
LCP 3:1 
MEAN SE
ALNA 3:1 
MEAN SE
LCP/ALNA 3:1 
MEAN SE
ALNA 5:1 
MEAN SE
OLO1
0 mo 14.4 0.24 14.2 0.17 14.3 .0.20 13.7 0.21 14.3 0.20
3 mo 14.2 0.26 14.2 0.18 14.4 0.17 13.9 0.18 14.8 0.18
6 mo 14.5 0.22 14.4 0.19 14.3 0.19 14.1 0.20 14.9 0.19
l a 1A3
Omo 10.0 0.23 10.3 0.19 10.4 0.16 10.0 0.18 10.2 0.18
3 mo 10.6 0.25 9.8 0.19 10.5 0.17 9.8 0.16 10.3 0.14
6 mo 10.8 0.18 9.6 0.21 10.4 0.17 9.4 0.19 10.1 0.17
ALNA1 
0 mo 0.2 0.02 0.2 0.01 0.2 0.01 0.2 0.02 0.2 0.01
3 mo 0.2 0.01 0.2 0.01 0.2 0.01 0.2 0.01 0.2 0.01
6 mo 0.2 0.02 0.2 0.01 0.2 0.01 0.2 0.01 0.2 0.01
DHLA123
0 mo 1.7 0.05 1.8 0.04 1.8 0.06 1.8 0.07 1.8 0.05
3 mo 1.7 0.04 1.6 0.04 1!8 0.05 1.7 0.05 1.9 0.06
6 mo 1.8 0.04 1.6 0.04 1.8 0.06 1.6 0.05 1.8 0.05
AA1’2”3 
0 mo 15.2 0.25 14.4 0.25 14.7 0.33 15.5 0.23 14.7 0.26
3 mo 15.2 0.27 13.3 0.31 14.9 0.28 14.4 0.24 14.9 0.23
6 mo 15.5 0.28 13.4 0.30 15.1 0.23 13.8 0.24 14.6 0.26
EPA1’2’’3
0 mo 1.6 0.10 1.7 0.09 1.5 0.07 1.6 0.09 1.4 0.07
3 mo 1.5 0.08 2.4 0.11 1.4 0.07 2.4 0.12 1.4 0.06
6 mo 1.5 0.08 2.6 0.13 1.5 0.07 2.7 0.15 1.5 0.08
ADR1-2-3
Omo 2.7 0.08 2.4 0.10 2.5 0.09 2.7 0.09 2.6 0.08
3 mo 2.8 0.11 2.0 0.09 2.5 0.09 2.3 0.08 2.7 0.09
6 mo 2.9 0.12 2.0 0.10 2.6 0.08 2.0 0.09 2.5 0.09
DPA2
0 mo 3.2 0.07 3.1 0.07 3.1 0.09 3.2 0.08 3.1 0.08
3 mo 3.0 0.08 3.2 0.07 3.0 0.08 3.3 0.07 3.0 0.07
6 mo 3.0 0.09 3.2 0.08 3.1 0.07 3.3 0.07 3.0 0.08
DHA1’2’3 
0 mo 6.8 0.24 7.1 0.25 6.5 0.28 7.0 0.23 6.3 0.22
3 mo 6.7 0.24 7.8 0.25 6.5 0.24 7.8 0.19 6.4 0.20
6 mo 6.8 0.24 8.0 0.23 6.6 0.22 8.1 0.22 6.8 0.26
N-6 Tot1’2’3 
Omo 29.54 0.41 ’ 28.93 0.44 29.39 0.44 30.02 0.31 29.30 0.33
3 mo 30.29 0.36 26.68 0.49 29.74 0.38 28.06 0.36 29.79 0.32
6 mo 30.83 0.37 26.56 0.47 29.84 0.35 26.95 0.39 29.11 0.35
N-3 Tot1’2’3 
0 mo 11.87 0.38 12.13 0.37 11.27 0.40 12.02 0.33 11.01 0.32
3 mo 11.38 0.36 13.57 0.40 11.18 0.36 13.66 0.33 11.00 0.29
6 mo 11.50 0.34 14.02 0.38 11.45 0.35 14.24 0.40 11.49 0.39
n-6:n-31’2’3 
0 mo 2.49 0.11 2.38 0.12 2.61 0.12 2.50 0.08 2.66 0.10
3 mo 2.66 0.11 1.97 0.09 2.66 0.11 2.05 0.07 2.71 0.08
6 mo 2.68 0.10 1.89 0.08 2.61 0.09 1.89 0.07 2.53 0.09
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Table AII.3 Associations o f dietary fatty acids withRBC fatty acids
Correlations RBC
% energy LA ALNA AA
LA Pearson Correlation 0.19 -0.06 0.19
Sig. (2-tailed) 0.00 0.37 0.00
ALNA Pearson Correlation -0.05 0.12 -0.04
Sig. (2-tailed) 0.48 0.06 0.59
EPA Pearson Correlation -0.23 0.03 -0.34
Sig. (2-tailed) 0.00 0.65 0.00
DHA Pearson Correlation -0.19 0.04 -0.33
Sig. (2-tailed) 0.00 0.57 0.00
n-6 Pearson Correlation 0.19 -0.06 0.19
Sig. (2-tailed) 0.00 0.38 0.00
n-3 Pearson Correlation -0.15 0.10 -0.21
Sig. (2-tailed) 0.02 0.12 0.00
n-3 LCP Pearson Correlation -0.21 0.04 -0.34
Sig. (2-tailed) 0.00 0.59 0.00
n-6:n-3 Pearson Correlation 0.21 -0.10 0.26
Sig. (2-tailed) 0.00 0.12 0.00
EPA ADR DPA DHA n-6 tot n-3 tot n-6:n-3
-0.28 0.28 -0.09 -0.22 0.27 -0.24 0.29
0.00 0.00 0.19 0.00 0.00 0.00 0.00
0.13 -0.13 0.01 0.00 -0.08 0.04 -0.08
0.05 0.05 0.93 0.99 0.25 0.50 0.22
0.45 -0.43 0.09 0.33 -0.43 0.36 -0.46
0.00 0.00 0.18 0.00 0.00 0.00 0.00
0.44 -0.43 0.07 0.33 -0.40 0.35 -0.44
0.00 0.00 0.28 0.00 0.00 0.00 0.00
-0.28 0.28 -0.09 -0.22 0.27 -0.24 0.29
0.00 0.00 0.20 0.00 0.00 0.00 0.00
0.33 -0.33 0.05 0.18 -0.28 0.23 -0.31
0.00 0.00 0.48 0.01 0.00 0.00 0.00
0.45 -0.44 0.08 0.34 -0.42 0.36 -0.46
0.00 0.00 0.23 0.00 0.00 0.00 0.00
-0.38 0.44 -0.07 -0.24 0.36 -0.29 0.39
0.00 0.00 0.26 0.00 0.00 0.00 0.00
Table AII.4. Associations o f dietary fatty acids with plasma fatty acids
% energy
Plasma fatty acids 
LA ALNA DHLA AA EPA DPA DHA n-6 tot n-3 tot n-6:n-3
LA Pearson Correlation 0.21 -0.19 0.13 0.16 -0.23 -0.16 -0.19 0.23 -0.21 0.24
Sig. (2-tailed) 0.00 0.00 0.05 0.01 0.00 0.02 0.00 0.00 0.00 0.00
ALNA Pearson Correlation -0.04 0.19 0.01 0.00 0.13 0.10 0.11 0.02 0.22 -0.24
Sig. (2-tailed) 0.59 0.00 0.83 1.00 0.05 0.11 0.11 0.77 0.00 0.00
EPA Pearson Correlation -0.04 0.15 -0.16 -0.18 0.41 0.28 0.44 -0.10 0.47 -0.48
Sig. (2-tailed) 0.50 0.02 0.02 0.01 0.00 0.00 0.00 0.12 0.00 0.00
DHA Pearson Correlation 0.01 0.11 -0.10 -0.13 0.37 0.25 0.43 -0.05 0.42 -0.43
Sig. (2-tailed) 0.90 0.09 0.11 0.04 0.00 0.00 0.00 0.47 0.00 0.00
n-6 Pearson Correlation 0.21 -0.19 0.13 0.16 -0.23 -0.16 -0.18 0.23 -0.21 0.24
Sig. (2-tailed) 0.00 0.00 0.05 0.01 0.00 0.02 0.00 0.00 0.00 0.00
n-3 Pearson Correlation -0.03 0.20 -0.06 -0.09 0.31 0.22 0.31 -0.03 0.40 -0.42
Sig. (2-tailed) 0.60 0.00 0.37 0.19 0.00 0.00 0.00 0.69 0.00 0.00
n-3 LCP Pearson Correlation -0.02 0.13 -0.13 -0.15 0.40 0.27 0.44 -0.07 0.45 -0.46
Sig. (2-tailed) 0.81 0.05 0.05 0.02 0.00 0.00 0.00 0.27 0.00 0.00
n-6:n-3 Pearson Correlation 0.17 -0.30 0.15 0.16 -0.38 -0.29 -0.35 0.18 -0.41 0.48
Sig. (2-tailed) 0.01 0.00 0.02 0.02 0.00 0.00 0.00 0.01 0.00 0.00
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Appendix III
Questionnaire for Chapter 5.0
Thank you for your interest in our study; we have certain selection criteria for 
participants. Therefore, we would like to ask you a few questions. Any 
information you give us will be kept confidential.
Please complete the following questions:
1. Have you been diagnosed, by a GP, diabetic? Yes/No.
2. Are you or have you ever taken medication for a heart disease related 
condition Yes/No.
If you have answered yes to either question then we are sorry, but we are unable 
to use you in our study -  thank you for your interest.
If you have answered no to the questions then we would like you to participate in 
our study.
We will be in contact with you in the near future.
Thank you
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GI Values Assigned to Foods Consumed During the Study Periods
Low GI Foods GI High GI Foods GI
Fruit Fruit
Kiwi 53 Ripe bananat 74
Apple 38 Watermelon 72
Orange 42 Dried dates 103
Plums 39 Raisins 64
Pear 38 Processed fruit bars 90
Dried apricots 31
Grapes 46 Snacks
Mango 51 Pretzels 83
Skittles 70
Snacks PopTart 70
Peanuts 14 Water biscuits 71
M&Ms peanut 33 Wafer biscuits 77
Chocolate 43 Crumpet 69
Oatcakes 57 Bagel 72
Oatmeal biscuits 55 Morning Coffee biscuits 79
Muesli bar 61 Sweet waffle 76
Jelly beans 78
Cakes & Buns
Blueberry Muffin 59 Cakes & Buns
Banana cake 51 Doughnut 76
Rice cakes 78
Bread
Fruit bread 44 Bread
Granary bread 55 White bread 70
Pitta bread 57 French baguette 95
Puddings Puddings
Low fat yoghurt 27 Tapioca 81
Rice pudding 56 Chocolate ice cream 6 8
Low fat ice-cream 43 Lychees 79
Tinned fruit cocktail 55 Tinned apricots in light 
syrup
64
Tinned peaches in natural 
juice
38
Breakfast Cereals Breakfast Cereals
All Bran 42 Branflakes 74
Porridge 58 Cornflakes 81
Unsweetened muesli 55 Cocopops 77
Vegetables Vegetables
Carrots 47 Parsnips 97
Broccoli/spinach 0 Broccoli/spinach 0
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Low GI Foods GI High GI Foods GI
Evening Meals Evening Meals
Spaghetti bolognaise 43 Shepherds Pie 85
Fish with spicy beans 27 Chicken and vegetable 
stir fry
73
Sweet potato fritters 56 73
Tabbouleh salad 48 Carbohydrates
Carbohydrates Mashed potato 74
Yam 37 Oven chips 75
Noodles 47 Boiled old potatoes 75
New potatoes 57 Jacket potato 85
Sweet potato 61 Instant rice| 65
Basmati rice 58 Instant mashed potato 85
Foods Common To Both Diets
Sausages 28 Apple juice 40
Skimmed milk 32 Orange juice 50
Semi-skimmed milk* 30 Chilli con carne (mince 
only)
28
All meat/fish 0 Cheese 0
Spread/butter 0 Alcohol 0
Foods Consumed During Intervention Period Not Included in Menu Booklet
Baked beans 48 Ovaltine 45
Broad beans 48 Sugar 68
Cantaloupe melon 64 Croissant 69
Chocolate muffin 53 Crispbread 64
Clementine 42 Sultana Bran cereal 73
Crisps 54 Coca cola 58
Grapefruit juice 46 Hot cross bun 44
Minestrone soup 39 Strawberry jam 51
Peas 48 Sandwich biscuits 64
Pineapple chunks 59 Cherry cake 46
Pineapple juice 46 Iced bun 73
Roast potatoes 75 Fermented milk drink 46
Sweetcom 54 Digestive biscuits 59
Unripe banana 52 Special K cereal 69
Wholemeal bread 71 Squash 66
Vegetable curry with 
rice
60
All values taken from the International table of glycemic index and glycemic load values (Foster-
Powell, 2002) using glucose as the standard
*value taken as a mean of GI values for skimmed and full fat milk 
t  as published by Hermansen et al (1992)
Jtaken as a mean of items # 278-289 (Foster-Powell, 2002)
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RECIPES FOR DIET A 
Creamed Rice With Sliced Pears (Diet A)
Serves 4
Ingredients
500ml water
200g Basmati rice
185ml evaporated skimmed milk
55g brown sugar
5ml (ltsp) vanilla essence
1 large tin (420g) pear slices
Method
1. Bring the water to the boil, add the rice and boil for 15 minutes; drain.
2. Return the rice to the saucepan with the milk.
3. Stir over low heat until all the milk is absorbed.
4. Stir in the sugar and vanilla essence; cool.
5. Serve the rice with the pear slices.
Fish With Spicy Beans And Tomato (Diet A)
Serves 4 
Ingredients
10ml (2 tbsp) oil (oil provided)
1 stick celery, finely diced 
1 medium onion, finely chopped 
1 clove garlic, crushed 
1 large tin (400g) chopped tomatoes 
1 300g tin butter beans, drained
1 tsp minced chilli 
125 ml dry white wine
4 boneless white fish fillets (about 500g), cut into cubes
2 tbsp chopped fresh parsley 
Freshly ground black pepper
Method
1. Fry celery, onion and garlic in oil for about 5 minutes or until softened.
2. Add tomatoes, beans and chilli.
3. Simmer, uncovered, for 10 minutes.
4. Meanwhile, heat the wine in a medium saucepan over moderate heat.
5. Add the fish and poach gently for about 3 to 4 minutes or until just cooked 
through.
6 . Combine the undrained fish with the tomato and bean mixture.
7. Add the parsley with pepper to taste.
Serve with basmati rice (Diet A).
Chicken and Vegetable Stir Fry (Diet A)
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Serves 4 
Ingredients
4 lean chicken breasts, remove skin and chop 
1 red pepper, seeded and chopped 
1 onion, peeled and chopped
1 tub bean sprouts
Supermarket selection of stir fry vegetables e.g. mange tout, baby com and baby carrots, 
chopped
2 tbsp oil (oil provided)
2 tbsp soy sauce 
Black pepper
Salt
Method
1. Heat the oil in a large frying pan or wok and fiy the onion for about 3 to 4 
minutes.
2. Add the chicken and fiy until cooked.
3. Add the remaining vegetables, soy sauce and seasoning and cook until just 
tender, sprinkling in a little water if necessary.
Serve with egg noodles (Diet A).
Chilli Con Came (Diet A)
Serves 4
Ingredients
2 tbsp oil (oil provided)
3 tsp chilli powder
500g (lib) lean mince beef
1 large onion, peeled and chopped
2 garlic cloves, peeled and finely chopped 
125ml (Va pint) beef stock
1 large tin (400g) chopped tomatoes
1 large tin (400g) kidney beans, drained
1 tsp oregano
1 tbsp tomato puree
Salt
Pepper
Method
1. Fry onion, chilli powder and garlic in oil for 5 minutes.
2. Add mince and cook for 10 minutes, stirring continuously.
3. Add all of the other ingredients except the kidney beans.
4. Season to taste.
5. Bring to the boil and simmer for about 20 minutes.
6 . 5 minutes before serving add the kidney beans.
Serve with basmati rice (Diet A).
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Sweet Potato and Corn Fritters (Diet A)
Makes 8 fritters 
Ingredients
1 medium orange sweet potato, peeled and roughly chopped
2 new potatoes, peeled and roughly chopped
1 medium onion, finely chopped 1 egg, lightly beaten
1 tin 270g com kernels 
Freshly ground black pepper 
45g rolled oats
2 tbsp self-raising flour 
Extra flour
5 ml (1 tbsp) oil (oil provided)
Method
1. Combine the potatoes and onion and steam or microwave together until the
potatoes are tender.
2 . Mash the potatoes and onion with the egg.
3. Add the com, pepper to taste, rolled oats and self-raising flour; mix until well
combined.
4. Refrigerate the mixture for 30 minutes or until completely cooled (this makes it
much easier to shape).
5. Shape the mixture into 8 rounds, coating gently with extra flour.
6 . Heat the oil and add the rounds in a single layer.
7. Cook over moderate heat, about 4 minutes each side or until browned.
Tabouleh (Diet A)
Serves 4
Ingredients
11 Og bulghur wheat 
250ml water
50g flat-leaf parsley, finely chopped 
1 small onion, finely chopped 
1 medium tomato, finely chopped 
Vz cucumber, chopped
Dressing:
30ml (2tbsp) lemon juice 
30ml (2tbsp) oil (oil provided)
Pinch salt
Freshly ground black pepper 
Method
1. Soak the bulghur wheat in water for 1 hour, or longer if a softer texture is 
preferred; drain well.
2. Combine the bulghur, parsley, onion, tomato and cucumber in a bowl.
3. For the dressing, combine all of the ingredients in a screw-top jar; shake well. 
Add the dressing to the bulghur mixture and toss lightly to combine.
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Spaghetti Bolognese (Diet A)
Serves 4 
Ingredients
15 ml (1 tbsp) oil (oil provided)
1 very small onion, finely chopped 
1 carrot, grated 
1 stick celery, sliced
1 rasher bacon, fat removed, finely chopped
2 cloves garlic, crushed 
300g lean minced beef 
2 tbsp tomato puree
1 large tin (400g) chopped tomatoes 
120ml beef stock 
% tsp dried oregano 
Freshly ground black pepper
1 bay leaf
2 pinches ground nutmeg 
375g spaghetti
Chopped fresh parsley, to serve (optional)
Grated Parmesan cheese
Method
1. Fry onion, celery, carrot, bacon and garlic for about 10 minutes or until the 
onion is very soft, stirring frequently.
2 . Increase the heat and add the beef.
3. Cook for about 5 minutes, stirring continuously until the beef is crumbly and 
browned.
4. Add the tomato puree, tomatoes, wine and stock and bring to the boil.
5. Add the oregano, pepper, bay leaf and nutmeg and stir thoroughly.
6 . Cover and simmer for 1 hour, stirring frequently to prevent sticking.
7. Remove the bay leaf.
8 . Meanwhile, cook the spaghetti until just tender; drain.
9. Serve the beef sauce over the spaghetti.
10. Sprinkle with parsley and serve with Parmesan cheese, if liked.
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RECIPES FOR D IET S
Chilli Con Came (Diet B)
Serves 4
Ingredients
2 tbsp oil (oil provided)
3 tsp chilli powder
500g (lib) lean mince beef
1 large onion, peeled and chopped
2 garlic cloves, peeled and finely chopped 
125ml QA pint) beef stock
1 large tin (400g) chopped tomatoes
1 large tin (400g) kidney beans, drained
1 tsp oregano
1 tbsp tomato puree
Salt
Pepper
Method
7. Fry onion, chilli powder and garlic in oil for 5 minutes.
8 . Add mince and cook for 10 minutes, stirring continuously.
9. Add all of the other ingredients except the kidney beans.
10. Season to taste.
11. Bring to the boil and simmer for about 20 minutes.
12. 5 minutes before serving add the kidney beans.
Serve with instant white rice (Diet B).
Chicken and Vegetable Stir Fry (Diet B)
Serves 4 
Ingredients
4 lean chicken breasts, remove skin and chop 
1 red pepper, seeded and chopped 
1 onion, peeled and chopped
1 tub bean sprouts
Supermarket selection of stir fry vegetables e.g. mange tout, baby com and baby carrots, 
chopped
2 tbsp oil (oil provided)
2 tbsp soy sauce 
Black pepper
Salt
Method
4. Heat the oil in a large frying pan or wok and fiy the onion for about 3 to 4 
minutes.
5. Add the chicken and fry until cooked.
6 . Add the remaining vegetables, soy sauce and seasoning and cook until just 
tender, sprinkling in a little water if necessary.
Serve with instant white rice (Diet B).
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Fish With Spicy Beans And Tomato (Diet B)
Serves 4 
Ingredients
10ml (2 tbsp) oil (oil provided)
1 stick celery, finely diced 
1 medium onion, finely chopped 
1 clove garlic, crushed 
1 large tin (400g) chopped tomatoes 
1 300g tin butter beans, drained
1 tsp minced chilli 
125 ml dry white wine
4 boneless white fish fillets (about 500g), cut into cubes
2 tbsp chopped fresh parsley 
Freshly ground black pepper
Method
8 . Fry celery, onion and garlic in oil for about 5 minutes or until softened.
9. Add tomatoes, beans and chilli.
10. Simmer, uncovered, for 10 minutes.
11. Meanwhile, heat the wine in a medium saucepan over moderate heat.
12. Add the fish and poach gently for about 3 to 4 minutes or until just cooked 
through.
13. Combine the undrained fish with the tomato and bean mixture.
14. Add the parsley with pepper to taste.
Serve with mashed potato (Diet B).
Shepherd’s Pie (Diet B)
Serves 2 
Ingredients
15ml oil (oil provided)
1 onion, finely chopped
2 carrot, finely chopped 
25Og extra-lean mince 
10ml tomato puree
A dash of Worcestershire sauce
40ml gravy granules, made up with 500ml boiling water
lOOg frozen peas
93g instant mashed potato, made up with 400ml boiling water and 30g spread (provided)
A little extra spread (provided) for the top
Salt
Pepper
Method
1. Heat the oil in a fiying pan and saute the onion and carrot until soft.
2. Add the mince and brown quickly.
3. Add the tomato puree, Worcestershire sauce, gravy and peas.
4. Cover and simmer for 20 minutes.
5. Preheat the grill while making up the mashed potato.
6 . Season the mince and place in a small greased pie dish and cover with the 
potato.
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7. Rough up the surface w ith a fork, and dot w ith spread.
8 . G rill for 5-10 m inutes, or until golden brown.
Diet diaries
FOR EACH ITEM THAT YOU EAT OR DRINK PLEASE 
READ THE FOLLOWING FOR DETAILS REQUIRED:
Always state what sort of oil or fat was used for baking, frying 
etc.
Give brand and full name of products where possible
For meals/snacks eaten away from home, please note 
where these items were eaten, giving name and/or type of 
restaurant, cafe, pub etc., where appropriate
Please could you answer the questions at the back (pages 
40-43) after you have completed the seven days of the diary
Please remember to provide us with as much detail as 
you possibly can
WHERE POSSIBLE, ALWAYS STATE WHAT SORT OF OIL 
OR FAT WAS USED FOR BAKING, FRYING ETC.
Food/Drink Description & Preparation Amount
Home-made d ishes P lease  say what the dish is called and 
give recipe or ingredients, including 
amounts, if possible
tablespoons, or 
one of the  pictures
Ready-made meals what sort: e.g. pizzas, microwave dishes, 
slimmers' m eals etc. Please  give main 
ingredients a nd nutrition information on 
packet, and enclose label and bar code if 
possiole
weight from packet
i Meals eaten  away 
| from home
what sort: e.g. pizzas, Chinese, Indian 
dishes, fish and chips, hamburgers, hot 
dogs etc. P iease  say whet the dish is cal.-ed 
and give ingredients w here possible.
Give the nam e of the restaurant if it is a  
well known chain
tablespoons, 
number or 
one of the  p ictures
WHERE POSSIBLE, ALWAYS STATE WHAT SORT OF OIL 
OR FAT WAS USED FOR BAKING, FRYING ETC.
Food/Drink Description & Preparation Amount
Sausage rolis large or small, type of pastry number
Scones what sod: with currants, sw eet or plain: 
cheese
number
Snacks - in packet what sort: e.g. cheese  straws, Twiglets. 
pretzels (give brand name)
packet weight or 
number
Soft drinks squash, undiluted or diluted; fizzy drinks; 
low calorie; give brand name
glasses or cans
Soup whal sort; canned, packet, instant or vending 
machine, home-made; give brand name
tablespoons, 
bowl or mug
Soya. Quorn TVP. mince, burgers or tofu number or 
pictures 4 or 5
Spaghetti, other pasta canned, boiled; white, wholemeal; in sauce 
give name and brand where applicable
tablespoons or 
picture 9
Spices type V? or '/« teaspoons
Spreads on oread, what sort and brand Vj or 7« teaspoons; 
tnick, average or 
thin spread
Spinls what sort, e  g. whisky, gin, vodka, rum; 
at home or in pub
single m easures 
a s  in pub
Sugar added to cerea ls tea. cotfee, fruit etc.; 
what sort: e.g. white, brown, demerara
heaped or level 
teaspoons
Sweets what sort: e.g. toffees o r boiled sweets; 
diabetic; give nam e and brand i‘ possib;e
number or packet 
size
Tea with or w;thout milk; what sort: herb, fruit, 
decaffeirtated/caffeinated: tea  bag or 
leaves; strong, average or weak
cups or mugs
Vegetables whal sort and variety with butter, other 
fat or sauce; fresh, frozen or canned; how 
cooked e.g fried, boiled, microwaved, or raw
tablespoons or 
pictures 12 13 or 
14
Water state w hether tap, filtered, or bottled; give 
nam e and brand w here applicable
glasses or bottle
Wine, sherry-, port white, red; sw eet, medium, dry; low alcohol glasses
Yogurt, Homage frais what son : e.g. w th fruit, natural, plain; 
flavour: low fat, Greek, creamy, soya; give 
full nam e and  brand if possible
carton weight/size 
or taolespoons
Use the pictures to help you to indicate the size ot the portion you have 
eaten. Write down the picture number and size nearest to your own 
helping eg. 2a. 3b, 1c etc.
The pictures could also be used for 'oods not snown, e.g. fru t crumbie 
might be a sim ilar portion to shepherd's pie. fruit cake sim ilar to veal 
and ham pie, and baked beans similar to peas.
Remember that the picture sizes are much smaller than life size. The 
shaded circle ir  the background shows the size of the dinner plates 
used. Please note that items sucn as cake are photographed on a tea 
plate which is placed on top of a dinner plate.
1 a 1 b 1 c
4
*>. . :>v ,.:.C
*
k ' "  .
2a 2b 2c
• > . .  - - v . :
3a 3b 3 c
;;T \l ■
it: , y r ^ .  & ^  ¥
k v
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Bread 
Butter■
Biscuits
Choose
Tomatoes
Cake
  / '
12b 12 c
17 c
1 0 . A X E
Description and Preparation
Campbell's condensed cream o? 
mushroom, dilutes half and half 
with water
White, large bat Sunrcst 
Anchor salted
Jacob's Cream Cracker#
Tesco matured eheddar
Home-made Victoria sponge wth 
jam f n i  rg (see recipe)
Tetley5 tea bag. weak 
Silver top, full cream 
White granulated
2 medium slices 
Thick spread on each 
j  slice 
’ 4 
2a
2 medium 
15b
2 cups
1 tablespoon in each cup
2 heaped teaspoons j
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WHERE POSSIBLE. ALWAYS STATE WHAT SORT OF OIL 
OR FAT WAS USED FOR BAKING FRYING ETC.
Foodrtfcinfc Ottertptfon & preparation Amcwm
C-v met. dry. wttag*. low •tow  afcettot (>rt& and Nay pwa | 
ftonfetrelean* 
bones, ndudng wo j
Co wWvv*eaoue rtfk. «f*t *<•«. MS mivhaff 
*•&*>. Ari m*. gtourtc.. ^ stant. 
eat“e*vv»<w. averse <x weak
Ci^ eorriHiga
| Ccodrwtts pepp*. w* or «mt»r.«use 7g or V4 letup oow. jr 
p*nerio*c
1 Coekrftgotf typo brand name toajpox’j
j Crmm h*f tow wTfcccm-j <fcxo« 
dowd ow tat. Iroan cr sutoosMto 
sweotaoed <y
UOiespoons
Cfept brand name; tow ta:„ low #a* pocket
j now 4 oookod Doted trod- seramefod. poacnod. omoWSe,, ek
rsimber
1 ^ •«M*>c»tfcoc.coa<«. g*s« ©cached netnmst^  pewod.. vr-c**) or **iec with 6*ne* o' 
twatoirW. t xvsed o4 or tomato &w# 
stM. grve brand rsame wr*re
be$<ng, nurttoer or j ] 
p<ture6
j FahoftMor tag** wfut sort torje, meefctm or *ma* *iz«. 
fried or gr«s#o. fliv® br*"xj name 4
nwnt**
wriat sort ana vanity e 9 Co* W * cored 
wm or wtthatf vor.
numCse#
j Fn*t - stewed o* 
earned
wna* sort and variety e 9 Sramtoy agpto. 
*** <JF wtiiQUt *0 frut Of tyrtjp taeeespoons 00 Ian we
uw* what sort; or gfoasea or Ca«4 (
Cfewy or trwv ooiani or pocket, mode 
& wthcM dnppmg. mH Mc«* e*c
tafreapocne
type f-pshordned y(C< .tOASDCCTS
Honey, jam type, specify 4 tow sups* tevapoona
; dairy er non-doty, flavour or variety UWespoons
. lw c*q. ton* 0* fned or stewoc pctvre 4 Of 5
I Maryann* hard, ecrt, potyunsaSu^ ated ovr hit. wwy
Jew fat. pvr) <wn» and or end -f
mck Or j 
th*n spread
W H E RE P O S S IB L E . A L W A Y S ST A T E  W HA T S O R T  O F  OIL 
O R  FAT W A S  U S E D  F O R  BA K IN G . FR Y IN G  ETC.
FcxxtOrmk D escription & Preparation A mount
Mam’* * * * tyca and brard, speaty tf tow su^ar teascocre tree*. J 
average or yaripre*^
U s ,w - 4 isfi grve name and prand. state rf Vow fat feespoor's
j Meat p-e casbe. pastry ?& t inavrtu*! c< **>0 * 9  s^ e  tat used 
for pdsty , 5*ver brand nam e w r^ e  po«*b>e
number or 
pictures
1 MC4tS wnat sort, ksen o r fatty; **ed. mityowemed. 
gm ea zomi. txirteojec wei dcrx» or r*» etc; 
«Htf» or wst*put gravy, cut o*W  pcMed. 
smoked or saRed
s e e s  netortQor
pdtures 4  Or 5
j fJkIk ■ *<* drtr.iorg on 
j ** Own or for OW«.tH
fal cream. s*.ver wp, «<*»-iM:ri-^ed swrrmed 
favowmd. pow dered soya
pint*, glasses or 
cups
1 U n c e d tm f on a  own. w th  vegetables tahy or lean tatfcMpOOr.s or 
pcturoS
jP a a ru a dry noassed or d f M r y  saScd pecitef w«»^t
; Pcrrxdge •m sy^ar or honey * 9* mrk, oetm  or *e*«r b e e *
; Potatoes £^'-•<5 bo#ed: a ?n or w-.tNxr? a«r  
meshed, creamed m e d cn o s . mOant. 
tom*, OurtOf. m a ^ r n e  e*c
t*bK*p©on». or 
psctures tocr
Pu tfrtQ wbat sort and e  g te a m e d  spor^e, 
*wm frufc s»e iwrijt sort;, tmwmarQe 
mcxAse; nsts-T* desserts m *  pockJrtg*
ffve recspe
ta^ospeorvs, t t c w  
orpc?ure«3. i 5 cv i
IT
' R c e brown or wrist* 5»e<J C* tried; pgdd^g tactejpocvi cx 
p e M e 6
: Salad describe -ngros-ents. fiSriW-sng; 
wriat sort o? te  3  erf and vtregar, 
sa^ad cream, mayonrvMe}
or
prttii'O 14
j Sandwicne* *na ma* wrwSeme^, v r tr^  or brown broad; type ol 
* *rg budof or m a^enne. largo or 
em al V»*; m eoum  <y vm  ( K m
nurb«r ©f rcfe  ©r j 
e«oee of breed
ij Sauce • hot (for vegetables m eal o< fe n  p ^ o rn g s i 
who* sort; aavcury 0* sweet c*
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!} Sauce • c od Arisi sort e g  tcnasa >MJtehup, brown sewce. 
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tow »at targe or smas. new oookea
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WHERE
OR
POSSIBLE, ALWAYS STATE WHAT SORT OF OIL 
FAT WAS USED FOR BAKING, FRYING ETC.
Cooking oil 
Cream
Crisps
E99
Fish cakes or fi 
Fruit - fresh
Fruit - juice 
Gravy
Herbs 
Honey, jam 
Ice-cream 
Liver kidney 
Margarine
pinch etc
tablespoons
Description & Preparation
sweet, dry, vintage, low alcohol; % alcohol pints and half pints;
number of cans/ 
oottles, including size 
with/without milk, what sort; half milk/nalf cups or m ugs 
water; all milk, ground, instant, decaffeinated/ 
caffeinated; strong, average or weak 
pepper, salt or substitute
type; brand nam e
half, single, sour, whipping, double, 
clotted; low fat; fresh or substitute; 
sw eetened or unsw eetened
brand nam9; low fat; low salt packet weight
how was it cooked: boiled, fried, number
scrambled, poached, omelette, etc.
what sort; fried, boiled, grilled, poached, microwaved; helping, number or
pickled, smoked cr salted; with batter or picture 6
breadcrumbs; tinned with oil or tomato sauce;
size: give brand name where applicable
what sort: large, medium or small size; number
fried or grilled; give brand nam e if possible
what sort and variety e.g. Cox apple; cored; number
with or without skin
what sorl and variety e.g. Bramley apple; tablespoons or
with or without sugar: in fruit juice or syrup tin size
what sort; sw eetened or unsw eetened g lasses or cups
thick or thin, instant or packet, made with tablespoons
or without dripping, m eat juices etc.
type, fresh or dried : V2 or V, teaspoons
type, specify if low sugar teaspoons
dairy or non-dairy; flavour or variety tablespoons
pig, lamb, ox; fried or stew ed picture 4 or 5
hard, soft, polyunsaturated, low fat. very thick, average or 
low fat. give name and brand if possible thin spread
WHERE POSSIBLE, ALWAYS STATE WHAT SORT OF OIL 
OR FAT WAS USED FOR BAKING, FRYING ETC.
Food/Drink Description & Preparation Amount
Marmalade type and brand; specify if low sugar teaspoons; thick, 
average or thin spread
Mayonnaise give nam e and brand; sta te  if low fat teaspoons
Meat pie. pastie, pastry what sort; individual or helping, Size; fat used 
for pastry; give brand nam e where possible
number or 
picture 3
Meats what sort: e an  or fatty; fried, microwaved, 
grilled, roasl. barbecued; well done or rare etc 
with or without gravy, cut used; pickled, 
smoked or salted
slices, nelping or 
pictures 4 or 5
Milk - for drinking on 
its own or for cereals
full cream, silver top, semi-skimmed, skimmed, 
sterilized, UHT, flavoured, powdered, soya
Dirts, g la sses or 
cups
Minced beef on its own, with vegetables, fatty or lean tablespoons or 
picture 5
Peanuts dry roasted or ordinary salted packet weight
Porridge with sugar or honey; with milk, cream or water bowls
Potatoes baked, boiled; with or without skin; 
m ashed, cream ed, fried/chips, instant, 
roast; with butter, margarine etc,
tablespoons, or 
pictures 10 or 11
Pudding what sort and brand: e.g. steam ed sponge: 
with fruit: pie (what sort); jelly; blancmange; 
mousse; instant desserts; milk puddings, 
give recipe
tablespoons, slices 
or pictures 3 ,1 5  or 
17
Rice brown or white; boiled or fried; rice pudding tablespoons or 
picture 8
Salad describe ingredients, with dressing; 
what sort of d ressing (e.g oil and vinegar, 
saiad cream , m ayonnaise)
tablespoons or 
picture 14
Sandw iches and rolls wholemeal, white or brown bread; type of 
filling; butter or margarine; large or 
small loaf; thick, med-um or thin s lices
num ber of rolls or 
slices of bread
Sauce * hot (for vegetables, m eat or fish; puddings) 
what sort; savoury or sweet; '.hick cr thin, 
give recipe if possible
tablespoons or 
picture 12
Sauce  - cold what sort: e.g. tomato ketchup, brown sauce, 
scy sauce; salad cream; sw eet or savoury
tablespoons or 
picture 12
Sausages what sort: e.g. pork, beef, pork and  beef; 
low fat; large or small; how cooked
number
256
Appendix IV 
Exclusion criteria
Participants were excluded if they had a prior history of:
• CHD; known Type 1 or Type 2 diabetes;
• Renal failure;
• Liver disease;
• Gout;
• Respiratory disease (except stable asthma);
• History of, or currently being treated for, a malignancy;
• History of, or are being currently treated for clinical depression,
• Those on antidepressant medication and other psychological disorders;
• Are pregnant, breast-feeding or considering becoming pregnant over the 
time that the study will run;
• History of eating disorders including anorexia or bulimia nervosa;
• History of obesity of known cause e.g Cushings disease;
• Are using any weight loss drug/ preparation within 30 days prior to 
enrolment, including orlistat (Xenical) or sibutramine (Reductil);
• Previous gastric/obesity surgery;
• History of gluten induced enteropathy;
• Are lactose intolerant;
• History of drug or alcohol abuse within the last 2 years;
• Uncontrolled thyroid disease or an abnormal TSH level based on GP 
opinion.
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Oneway ANOVA, sdLDL
Female
Descriptives
95% Confidence 
Interval for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound
Upper
Bound Minimum Maximum
Percentage 
d ifference%AU CB
HFHP 26 17.4754 47.61446 9.33796 36.7073 1.7564 -70.00 123.53
LFHC 33 29.8132 34.38243 5.98521 42.0047 17.6218 -85.19 87.50
Control 28 24.0061 26.75707 5.05661 34.3814 13.6308 -78.57 15.38
Total 87 24.2571 36.73505 3.93841 32.0864 16.4278 -85.19 123.53
Percentage HFHP 26 -.1977 .18873 .03701 -.2740 -.1215 -.58 .29
difference peak 
density
LFHC 33 -.1617 .15443 .02688 -.2165 -.1070 -.58 .19
Control 28 -.1317 .17938 .03390 -.2012 -.0621 -.58 .19
Total 87 -.1628 .17325 .01857 -.1997 -.1259 -.58 .29
a gender = 0
ANOVA(a)
Sum of
Squares df Mean Square F Sig.
%age
difference
%AUCB
Between 
Groups 
Within Groups
Total
2216.257
113837.66
9
116053.92
6
2
84
86
1108.128
1355.210
.818 .445
%age
difference
Between
Groups .059 2 .029 .980 .379
peak density Within Groups 
Total
2.522
2.581
CO 
CO 
CO
.030
a gender = 0
258
Males
Descriptives
95% Confidence 
Interval for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound
Upper
Bound Minimum Maximum
%age
difference% AU C B
HFHP 12 57.7091 12.82536 3.70236 65.8579 49.5602 -79.25 -41.67
LFHC 14 48.3258 22.40927 5.98913 61.2645 35.3870 -76.47 15.38
Control 8 30.3225 25.67980 9.07918 51.7913 -8.8536 -70.59 3.57
%age difference 
peak density
Total
HFHP
LFHC
34
12
14
47.4015
-.4351
-.3177
22.41096
.21932
.18660
3.84345
.06331
.04987
55.2210
-.5745
-.4255
39.5819
-.2958
-.2100
-79.25
-.87
-.68
15.38
-.10
-.10
Control 8 -.1693 .17730 .06269 -.3175 -.0210 -.48 .00
Total 34 -.3242 .21617 .03707 -.3997 -.2488 -.87 .00
a gender = 1
ANOVA(a)
%age
difference%A
UCB
%age 
difference 
peak density
Between 
Groups 
Within Groups
Total
Between 
Groups 
Within Groups
Total
Sum of 
Squares df Mean Square F Sig.
3620.457 2 1810.228 4.332 .022
12953.833 31 417.866
16574.290 33
.340 2 .170 4.389 .021
1.202 31 .039
1.542 33
a gender = 1
Post Hoc Tests
Multiple Comparisons
95% Confidence
Mean Interval
Dependent (I) (J) Difference Std. Lower Upper
Variable dietcode dietcode (l-J) Error Sig. Bound Bound
per_aucb Tukey
HSD
HFHP LFHC -9.38330 8.04175 .481 29.1756 10.4090
Control
27.38660(*) 9.33034 .017 50.3503 -4.4229
LFHC HFHP 9.38330 8.04175 .481 10.4090 29.1756
Control -18.00330 9.05984 .132 40.3013 4.2947
Control HFHP 27.386600 9.33034 .017 4.4229 50.3503
LFHC 18.00330 9.05984 .132 -4.2947 40.3013
Dunnett HFHP Control
t (2- - 9.33034 .011 - -5.9443
27.386600 48.8289
sided)(a)
LFHC Control -18.00330 9.05984 .096 38.8239
per_den Tukey
HSD
HFHP LFHC -.11740 .07746 .298 -.3080
Control -.265860 .08987 .016 -.4870
LFHC HFHP .11740 .07746 .298 -.0732
Control -.14846 .08726 .221 -.3632
Control HFHP .265860 .08987 .016 .0447
LFHC .14846 .08726 .221 -.0663
Dunnett HFHP Control
t (2- -.265860 .08987 .011 -.4724
sided)(a)
LFHC Control -.14846 .08726 .165 -.3490
* The mean difference is significant at the .05 level.
a Dunnett t-tests treat one group as a control, and compare all other groups against it. 
b gender = 1
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2.8173
.0732
-.0447
.3080
.0663
.4870
.3632
-.0593
.0521
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Associations with markers of an ALP
Correlations
A change %AUCB Peak density HDL-C TAG TC:HDL-C TAG:HDL-C
%AUCB Pearson Correlation 1.00 0.82 -0.14 0.63 -0.05 0.62
Sig. (2-tailed) 0.00 0.13 0.00 0.63 0.00
Peak density Pearson Correlation 0.82 1.00 -0.26 0.61 0.13 0.58
Sig. (2-tailed) 0.00 0.00 0.00 0.18 0.00
HDL-C Pearson Correlation -0.14 -0.26 1.00 -0.23 -0.47 -0.43
Sig. (2-tailed) 0.13 0.00 0.01 0.00 0.00
TAG Pearson Correlation 0.63 0.61 -0.23 1.00 0.13 0.94
Sig. (2-tailed) 0.00 0.00 0.01 0.19 0.00
TC:HDL-C Pearson Correlation -0.05 0.13 -0.47 0.13 1.00 0.30
Sig. (2-tailed) 0.63 0.18 0.00 0.19 0.00
TAG:HDL-C Pearson Correlation 0.62 0.58 -0.43 0.94 0.30 1.00
Sig. (2-tailed) 0.00 0.00 0.00 0.00 0.00
Correlations
A change Body fat Fat mass Lean mass Waist BMI Body mass
Peak density Pearson Correlation -0.22 -0.13 0.47 0.52 0.42 0.47
Sig. (2-tailed) 0.30 0.53 0.02 0.00 0.01 0.00
%AUCB Pearson Correlation -0.06 0.02 0.25 0.44 0.35 0.43
Sig. (2-tailed) 0.79 0.93 0.22 0.01 0.03 0.01
Glucose Pearson Correlation -0.15 -0.07 0.27 0.09 0.32 0.31
Sig. (2-tailed) 0.48 0.75 0.21 0.62 0.06 0.07
Insulin Pearson Correlation 0.02 0.14 0.21 0.21 0.31 0.31
Sig. (2-tailed) 0.92 0.55 0.36 0.23 0.07 0.07
TC Pearson Correlation -0.22 -0.23 0.13 0.06 -0.06 -0.08
Sig. (2-tailed) 0.30 0.30 0.56 0.74 0.72 0.66
HDL-C Pearson Correlation 0.00 -0.18 -0.33 -0.29 -0.37 -0.37
Sig. (2-tailed) 1.00 0.40 0.13 0.09 0.03 0.03
LDL-C Pearson Correlation -0.06 -0.06 -0.03 0.05 0.00 -0.03
Sig. (2-tailed) 0.79 0.80 0.91 0.77 1.00 0.88
TAG Pearson Correlation 0.07 0.25 0.33 0.34 0.48 0.52
Sig. (2-tailed) 0.77 0.27 0.14 0.06 0.00 0.00
HOMA Pearson Correlation 0.02 0.15 0.21 0.25 0.36 0.36
Sig. (2-tailed) 0.94 0.52 0.38 0.18 0.04 0.04
TC:HDL-C Pearson Correlation -0.22 0.02 0.57 0.46 0.42 0.44
Sig. (2-tailed) 0.32 0.91 0.00 0.01 0.01 0.01
TAG:HDL-C Pearson Correlation 0.09 0.24 0.27 0.31 0.48 0.53
Sig. (2-tailed) 0.71 0.29 0.24 0.09 0.00 0.00
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